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1
1. HISTORICAL OVERVIEW
1.1 History of Clinical Transplantation
Organ transplantation is a life-saving treatment for end-stage liver, heart and lung 
disease. Although end-stage renal disease (ESRD) patients can be treated with dialysis, 
renal transplantation is the best treatment for the majority of patients with ESRD both 
in terms of patient survival, quality of life and cost effectiveness. Many of the important 
developments in the field of organ transplantation have taken place within the past 60 
years. The road to successful organ grafting has been long and fraught with problems.
The first experimental transplantation of a kidney between dogs was performed by 
Emerich Ullmann in Vienna in 1902.1 A few years later, in 1906, the Frenchman Mathieu 
Jaboulay connected the renal vessels of a sheep and a pig kidney, respectively, to the 
brachial vessels of two patients with renal failure.1,2 Both transplants failed and both 
patients died. The first use of a human deceased donor kidney for transplantation 
took place in 1933 when Yu Yu Voronoy, a Ukrainian surgeon, performed the first of a 
series of six transplantations to treat patients suffering from acute renal failure result-
ing from mercury poisoning. All the allografts failed, in large part as a consequence of 
the 6-hours lapse between the donor’s death and organ procurement.2,3 The first “suc-
cessful” deceased donor kidney transplantation was performed by Richard Lawler and 
his colleagues, and took place on June 17, 1950 in the United States. A kidney from 
a woman of approximately the same age, blood group and Rhesus type as the patient 
was transplanted orthotopically after the removal of her left polycystic kidney.4 Some 
10 months after transplantation, however, the graft was lost as a result of rejection.5 
In 1951, French surgeons Rene Kuss, Charles Dubost and Marceau Servelle performed 
a series of renal transplantations with kidneys that were recovered from prisoners im-
mediately after their execution by guillotine.6 Some of these kidney allografts functioned 
for a limited period of time (days or weeks) but most of the transplanted kidneys were 
acutely rejected.1 In 1953, the French surgeon Jean Hamburger performed the first living 
donor kidney transplantation (from a mother to her son). The kidney functioned well for 
3 weeks before being rejected.6
Immune responses to alloantigens in the graft, which are proteins that vary from 
individual to individual, and are thus perceived as foreign by the recipient’s immune 
system, were the major barrier to the success of transplantation. The first modern-day 
studies in transplantation began at the beginning of the twentieth century, when skin 
grafting between animals initiated the first series of experiments that eventually led to a 
scientific understanding of graft rejection. Medawar’s work during and after the Second 
World War studying the rejection of skin grafts had demonstrated the potency of the 
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immune system.7 This opened the door to the modern era of human transplantation with 
the first successful kidney transplant between two identical siblings in 1954 at the Peter 
Bent Brigham Hospital by Joseph Murray (Nobel laureate in 1990).1,8 There then followed 
a series of identical twin transplants. Most of these recipients had a return of normal 
kidney function and survived for a considerable time.9,10
1.2 Pharmacological Immunosuppression
After Medawar’s suggestion that rejection was an immunological event, a logical ques-
tion arose:7,11 Why not protect the allograft from rejection by suppression of the immune 
system? The first methods used to achieve immunosuppression included total body irra-
diation and glucocorticoids.12 After successes in the field of bone marrow transplantation 
between siblings, where total body irradiation was used, this was also pursued in renal 
transplantation but with little success, although three recipients of kidneys from a non-
identical twin did achieve relatively long-term function.13,14 As a result of the profound 
bone marrow depression, total body irradiation led to patients’ deaths from overwhelm-
ing infections. Therefore, by the early 1960s it became clear that total body irradiation 
was not the solution and less toxic methods for immunosuppression were needed.15 
Glucocorticoids alone were then used, also with limited success. The breakthrough came 
in the late 1950s with the discovery of the immunosuppressive effect of 6-mercapto-
purine, which was already in clinical use as an anti-cancer agent.16,17 6-mercaptopurine 
prolonged the survival of kidney allografts in dogs although the survival of the animals 
remained poor.18,19 Shortly thereafter (in the early 1960s), 6-mercaptopurine was re-
placed by its pro-drug azathioprine, a purine analogue which was less toxic. After the 
first successful series of renal transplantations performed in Denver by Thomas E. Starzl, 
the combination of azathioprine and prednisone (a synthetic adrenal glucocorticoid) 
came into widespread use for the next 20 years. Immunosuppression with azathioprine 
in combination with prednisone was a significant achievement in a time period when di-
alysis was still in its infancy and renal failure was usually a death sentence, as it enabled 
transplantation of deceased donor kidneys with a 1-year graft survival of about 60%.1
Until the early 1980s, azathioprine in combination with prednisolone was the only im-
munosuppressive therapy for the prevention of acute rejection after solid organ trans-
plantation. The transplantation field was again revolutionized by the immunosuppressive 
power of the calcineurin inhibitor (CNI) cyclosporine A (CsA) first described by Borel et 
al.20 Shortly thereafter, the first clinical study was performed with CsA as a single immu-
nosuppressant, in Cambridge, UK by Calne et al.21 In this early study, it became evident 
that there was also a downside to CsA, namely its nephrotoxicity. Thomas E. Starzl then 
decided to decrease the dose of CsA and use it in combination with prednisone in a 
successful series of 22 kidney recipients.22 Several trials, comparing the efficacy of CsA 
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with conventional immunosuppressive treatment consisting of azathioprine and pred-
nisolone, demonstrated that treatment with CsA led to a considerable improvement of 
transplantation outcomes. CsA-based immunosuppression markedly decreased both the 
incidence and the severity of acute rejection and increased 1-graft survival to 80%.23,24 
In addition, CsA had advantages over conventional immunosuppression as it decreased 
the incidence of infections and allowed for reduced doses of prednisolone.25,26 The 
impact of CsA on the field of non-renal organ transplantation was even larger and with 
its introduction heart, lung, and liver transplantation first became realistic therapeutic 
options.2 As experience with the new drug increased, it became evident that it did have 
several important side effects in addition to its nephrotoxicity. These include glucose 
intolerance, hypertension, gout and hyperlipidemia. This fostered the search for and dis-
covery of other immunosuppressive agents. In the last decade of the twentieth century, 
such immunosuppressive drugs became available, including tacrolimus, mycophenolate 
mofetil (MMF), interleukin (IL)-2 receptor antagonists, and the mammalian target of rapa-
mycin inhibitors sirolimus and everolimus, all with different safety and efficacy profiles.
Tacrolimus (Tac) is a CNI that nowadays has replaced CsA as the CNI of first choice for 
the prevention of graft rejection. Several studies were conducted to compare the ef-
ficacy and safety profile of Tac with that of CsA.27-31 A meta-analysis incorporating 30 
trials concluded that Tac is superior to CsA in preventing acute rejection after kidney 
transplantation. Moreover, Tac-treated recipients had an improved short-term graft 
survival. However, this comes at the expense of a higher risk to develop post-transplant 
diabetes mellitus.32 At present, in most centers, immunosuppressive therapy after renal 
transplantation consists of the combination of Tac, MMF and glucocorticoids with or 
without induction therapy with an IL-2 receptor antagonist or a T-lymphocyte depleting 
agent. With Tac-based immunosuppressive therapy, acute rejection rates during the first 
post-transplant year have fallen below 20% and 1-year graft survival has risen to above 
90%.33-35
Despite the considerable improvement of the short-term transplantation outcomes, the 
availability of modern immunosuppressive drug therapy has not resulted in a compa-
rable improvement in the long-term outcomes. In fact, some studies suggest that long-
term graft survival (censored for death of the recipient) may even have decreased in 
recent years despite an almost halving of the acute rejection incidence during the same 
time period.36 Late renal allograft loss is most frequently caused by either the death of a 
patient with a functioning allograft or due to progressive renal dysfunction. The latter has 
multiple causes but the nephrotoxicity associated with prolonged treatment with Tac is 
still considered an important cause of late kidney allograft dysfunction.
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2. TACROLIMUS PHARMACODyNAMICS
2.1 Mechanisms of Tacrolimus-mediated immunosuppression
Tacrolimus is a macrolide which was isolated from the fermentation broth of a strain of 
Streptomyces. Like CsA, this agent belongs to the class of CNIs and exerts its immunosup-
pressive effect mainly by inhibiting the activation of T-lymphocytes, although Tac also 
has inhibitory effects on B-lymphocytes, natural killer cells and dendritic cells.37,38 The 
immunosuppressive properties of Tac result from inhibition of calcineurin, a calcium- and 
calmodulin-dependent phosphatase. The receptor of Tac is an intracellular immunophilin 
called FK-binding protein (FKBP)-12.39 The Tac-FKBP-12 complex inhibits the activity of 
the enzyme calcineurin, which in turn prevents the dephosphorylation and subsequent 
activation of the nuclear factor of activated T-cell (NFAT). As a result, by blocking the 
activation of NFAT, Tac prevents the transcription of several genes, including IL-2 and 
interferon gamma, that are essential for T-lymphocyte activation and proliferation, and 
thus for the development of acute rejection.40,41
Apart from its effect on the calcineurin-NFAT pathway, Tac also affects the activation of the 
mitogen-activated protein kinase (MAPK) signaling pathway by inhibiting p38MAPK.42-44 
MAPK signaling is key in T-cell development and activation45 and acts as an activator of 
NFAT.46,47 The phosphorylation status of p38MAPK was recently found to be inversely cor-
related with Tac whole-blood predose concentrations (C0) of kidney transplant patients. 
Furthermore, increased phosphorylated p38MAPK concentrations were associated with 
a higher T-lymphocyte activation status, which was inhibited by Tac in a dose dependent 
manner in vitro.48
2.2 Efficacy
The incidence of acute rejection among kidney transplant recipients has been reduced 
dramatically since the introduction of CNIs. As a result, 1-year kidney transplant survival 
has improved considerably. Positive effects of tacrolimus, such as prevention of acute 
rejection, were found to be related to drug exposure levels.49-52 In a dose-ranging study 
conducted in de novo renal transplant recipients (n = 120), patients were randomized 
to one of three tacrolimus (0.2, 0.3, and 0.4 mg/kg per day) based-regimens designed 
to achieve a low (5-14 ng/mL), medium (15-25 ng/mL) or high (26-40 ng/mL) C0. In the 
group of patients with the highest tacrolimus C0 range (n = 29), a 62% incidence of 
toxicity was observed whereas only 10% of the patients developed an acute rejection. 
In the lowest target C0 target range group (n = 33), the reverse was observed with 33% of 
the patients experiencing toxicity but having an acute rejection incidence of 21%. Based 
on these results, a tacrolimus C0 range of 5-15 ng/mL was advised to achieve optimal 
efficacy with minimal toxicity.53
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2.3 Toxicity
The clinical introduction of Tac has not resulted in the desired improvement of the long-
term transplantation outcomes. The disappointing long-term kidney transplant survival 
can be partly attributed to the considerable toxicity of Tac and other immunosuppressive 
drugs. Toxicity associated with Tac therapy can occur at drug exposure levels similar to 
that required for a beneficial effect.50 Optimal long-term immunosuppression without ad-
verse effects is difficult to achieve and is often complicated by nephrotoxicity, infections, 
neurotoxicity, cardiovascular disease, and malignancy. The considerable side effects of 
Tac hamper long-term renal graft and patient survival, and result in additional morbidity. 
Other studies have reported that higher Tac exposure is associated with an increased risk 
of nephrotoxicity, neurotoxicity or development of infections.54-56
Tac-induced acute and chronic nephrotoxicity are a well-known adverse effects and 
a serious concern, often leading to irreversible histological renal damage to all renal 
compartments, including glomeruli, arterioles, and the tubulo-interstitium.57,58 The acute 
nephrotoxic effect of Tac manifests clinically as acute oligo-anuria and / or as a rise in 
serum creatinine. Constriction of the afferent glomerular arteriole and direct tubular 
toxicity are considered the main mechanisms. The proposed mechanism of chronic 
Tac-induced nephrotoxicity is chronic ischaemia of the nephron caused by narrowing 
of the vascular lumen through accumulation of hyaline deposits in the arteriolar wall 
and prolonged afferent arteriolar vasoconstriction.57 Although the risk of chronic renal 
failure in Tac-treated patients is considerable, not all patients develop renal transplant 
failure because of this phenomenon. Limited evidence suggested that variations in 
genes involved in the pharmacokinetics (ABCB1 and CYP3A5) and pharmacodynamics 
(TGF-β, CYP2C8, ACE, CCR5) of Tac may influence a patients’ risk to develop Tac-induced 
nephrotoxicity.59,60
3. TACROLIMUS PHARMACOKINETICS
Tacrolimus has highly variable and unpredictable pharmacokinetics. In recent years it 
has become clear that an important part of these between-patient differences in the 
pharmacokinetics of Tac result from variability in the activity of the Tac metabolizing 
enzymes (CYP3A4 and CYP3A5) and the drug-transporting protein ABCB1. These me-
tabolizing enzymes and ABCB1 are characterized by considerable variation in their activ-
ity and expression, either caused by genetics or by induction and/or inhibition by other 
substances such as drugs. CYP3A enzymes comprise 30-60% of total CYP content and 
are responsible for the oxidative metabolism of over 50% of the drugs in use.61 CYP3A4 
and CYP3A5 have largely overlapping substrate specificities. Functional CYP3A4 protein 
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is expressed in liver, jejunum, colon, and pancreas. Immunohistochemistry analyses show 
limited expression of this enzyme in the kidney. All individuals synthesize functional 
CYP3A4 but with up to a 40-fold variation in protein expression and a substantial vari-
ability in enzyme activity.62 Recently, a new mutation, namely CYP3A4*26, was found 
to be associated with CYP3A4 deficiency.63,64 The expression of CYP3A5 is even more 
variable, as only some individuals express significantly high levels of functional CYP3A5 
protein. CYP3A5 is also expressed in the liver and small intestine but at levels of 10% 
to 30% of CYP3A4. In the kidney, however, CYP3A5 is the predominant form of CYP3A.65
The rate of Tac absorption and its bioavailability vary largely between individuals and 
is related to first pass metabolism. Its oral bioavailability averages around 25%, but 
can range from 5% to 90%.66,67 Peak Tac whole-blood concentrations (Cmax) are usually 
achieved within 2 hours, although the time to Cmax (tmax) varies widely.67 The absorption 
of Tac occurs mainly in the small intestine and is affected by several factors. Ingestion of 
food with a moderate fat content may delay the absorption of Tac and reduce its bioavail-
ability. CYP3A5 initially came to light as a contributor to the large inter-individual varia-
tion in Tac exposure due to the well-known phenomenon that the Tac dose requirement 
of patients of African ancestry is about two-fold higher than that of white individuals. 
Increased first pass metabolism and consequently reduced oral bioavailability, is respon-
sible for this difference rather than a protracted elimination as the half-life of Tac is the 
same in African and Caucasian patients when the drug is administered intravenously.68 
The poor bioavailability of Tac may also be attributed to the fact that Tac is a substrate of 
the multidrug-efflux pump ABCB1, previously known as P-glycoprotein (P-gp). ABCB1 is an 
ATP-driven efflux pump which exports xenobiotics from the cytoplasm or cell membrane 
to the exterior of the cell, reducing thereby the accumulation of drugs and metabolites 
within cells. Physiologically, ABCB1 is expressed in the liver (at the canalicular surface 
of hepatocytes), pancreas, and at the apical surface of mature enterocytes in the small 
intestine and colon. In the normal human kidney, ABCB1 is expressed in the brush border 
of proximal tubular epithelial cells, in epithelial cells of Bowman’s capsule, glomerular 
mesangial cells, on the apical membrane of the thick ascending limb of Henle’s loop, 
intracellularly in distal tubules, and on the apical membrane of the collecting duct.69-71 
ABCB1 expression in endothelial cells of renal arteries, arterioles, and glomerular and 
peritubular capillaries was found to be absent or low.71,72 In addition, ABCB1 is also 
expressed in testes, placenta (trophoblasts), on the luminal surface of capillaries in the 
brain and at the choroid plexus.73 Finally, ABCB1 is found on various leukocytes, includ-
ing T and B lymphocytes, and dendritic cells.74,75 The specific tissue expression of ABCB1 
suggests that the protein functions as a protective barrier. Its expression in the intestine 
is thought to limit the absorption of Tac, whereas its expression in the biliary tract and 
kidney may facilitate the elimination of Tac and its metabolites.
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In blood, Tac binds extensively to erythrocytes, which have a high content of FKBP-12. 
Whole-blood Tac concentrations are significantly higher (average 15 times, range 4-114 
times) than those measured in plasma. Approximately 99% of Tac in plasma is bound to 
plasma proteins, mainly albumin and α1-acid glycoprotein. Distribution of Tac between 
erythrocytes and plasma is dependent on factors such as hematocrit, plasma protein 
concentrations, and Tac concentration. The volume of distribution of Tac is about 1.4 L/
kg.67 Tac distributes widely into most tissues, including kidney, liver, heart, lungs, spleen, 
brain, and muscles. This drug crosses the placenta and passes into the breast milk.76
Tacrolimus is more rapidly metabolized by CYP3A5 than CYP3A4. The catalytic activity 
of CYP3A5 (in vitro) towards Tac is 1.6-fold higher than that of CYP3A4.77 More than 15 
Tac metabolites are formed through CYP3A-mediated metabolism. 13-O-demethyl-Tac 
is the main breakdown product. This metabolite has an immunosuppressive activity that 
is one-tenth of that of Tac. The reported elimination half-life of Tac is variable, ranging 
between 12 and 35 hours.67 More than 95% of Tac metabolites are eliminated biliary 
with about 5% being excreted in the urine. Less than 1% of the absorbed amount of Tac 
is excreted in the urine as unchanged drug.66,67,78
In addition to the well-described inter-patient pharmacokinetic variability, the clinical use 
of Tac is also complicated by considerable intra-patient variability (IPV) in Tac exposure. 
Several factors can contribute to IPV in Tac exposure, among which medication adherence 
may be one of the most important determinants. Recipients of a kidney, in comparison to 
recipients of other organs, demonstrate the highest level of immunosuppressive medica-
tion nonadherence,79 which in turn is related to poorer clinical outcomes.80 A high Tac IPV 
may result in a Tac exposure which is outside the therapeutic window. These patients 
may be at risk for under-exposure and rejection, or Tac toxicity in case of over-exposure.
4. TACROLIMUS PHARMACOGENETICS
It is well recognized that different patients respond differently to the same medication. 
As described above, the clinical use of Tac is complicated by high inter-patient variability 
in its pharmacokinetics. In general it has been estimated that genetics can account for 
20-95% of variability in drug disposition and effect.81 Genetic polymorphisms in drug 
metabolizing enzymes and efflux pumps are potential targets for developing a pharma-
cogenetic strategy to individualize immunosuppressant therapy. The encoding genes of 
CYP3A4, CYP3A5, and ABCB1 contain numerous single-nucleotide polymorphisms (SNPs) 
and these polymorphisms have been the subject of a considerable number of studies as 
they may explain the differences in Tac pharmacokinetics between patients.
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4.1 CyP3A
At least 28 SNPs have been identified in the CYP3A4 gene. The 392A>G SNP (rs2740574), 
also known as CYP3A4*1B, is the most extensively studied CYP3A4 SNP. The CYP3A4*1B 
polymorphism has been associated with an increased CYP3A4 transcriptional activity.82 
However, the clinical relevance of this polymorphism is not clarified.83 The frequency of 
CYP3A4*1B polymorphism depends on ethnicity. It is present in approximately 2-9.6% 
of Caucasians, 35-67% of Africans, 9.3-11% of Hispanics and 0% of Asians.84 No 
reproducible association has been found between the CYP3A4*1B variant and the Tac 
pharmacokinetics. The controversy regarding the functional effect of CYP3A4*1B, is most 
likely explained by the fact that this SNP is in linkage disequilibrium with the CYP3A5 
6986A>G SNP (see below).83,85,86
The polymorphic expression of CYP3A5 was identified as early as 1990.87 Its genetic 
basis was elucidated by Paulussen et al. who first identified genetic variants predictive of 
CYP3A5 expression in liver samples.88 Kuehl et al. described the CYP3A5*3 variant allele 
in intron 3 (CYP3A5 6986A>G; rs776746), which disrupts the correct splicing of CYP3A5 
transcripts.89 Individuals who are homozygous for the CYP3A5*3 allele lack CYP3A5 pro-
tein activity, whereas individuals carrying at least one CYP3A5*1 allele (considered to be 
the wild-type) were found to express large amounts of CYP3A5 protein. The frequency of 
these alleles differs between individuals of different ethnicities with approximately 15% 
of Caucasians expressing functional CYP3A5, whereas as much as 85% of individuals of 
African descent (sub-Saharan genetic origin) are CYP3A5-expressers. Asian populations 
fall between these two groups with about 50% carrying the CYP3A5*1 allele.89-91
The identification of SNPs in CYP3A5 was the first evidence that genetic factors may 
determine the inter-individual variability in Tac pharmacokinetics. It has been consis-
tently demonstrated that CYP3A5 expressers require approximately two-fold higher Tac 
doses to reach the same steady-state C0 than CYP3A5 non-expressers.57,83,85,92-94 Avail-
able data describe a gene-dose effect with lower dose-corrected Tac C0 in CYP3A5*1/*1 
homozygotes than in CYP3A5*1/*3 heterozygotes.95 As a consequence of the higher 
Tac dose requirement of CYP3A5 expressers, in some investigations there was a delay 
in achieving the target Tac concentration after standard, bodyweight-based dosing.95-97 
CYP3A5 expressers may therefore be at an increased risk for under-immunosuppression, 
particularly in the early phase after transplantation, and the development of acute rejec-
tion.92 Several researchers suggested that the Tac starting dose in CYP3A5 expressers 
should be about two-fold higher than that of CYP3A5 non-expressers.98 Despite a strong 
association between the CYP3A5 6986A>G SNP and Tac pharmacokinetics, there is no 
consistent evidence of organ rejection as a consequence of genotype-related under-
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immunosuppression.60 In fact, there’s little evidence from randomized-controlled clinical 
trials that a pharmacogenetic-based approach to Tac treatment will benefit patients.
4.2 ABCB1
Over the last 10 years more than 50 single-nucleotide polymorphisms (SNPs) have been 
identified in ABCB1 (previously known as MDR-1). The SNPs that have been studied most 
widely are the C to T transition at position 1236 within exon 12 (rs1128503), the G to 
T/A transition at position 2677 within exon 21 (rs2032582) and the C to T transition at 
position 3435 within exon 26 (rs1045642).99,100 These three SNPs are in strong linkage 
disequilibrium and their allelic frequency varies between different ethnic groups.101 
Only the 2677G>T/A SNP results in an amino acid substitution (Ala893Ser or Ala893Thr, 
respectively), whereas ABCB1 3435C>T and 1236C>T are synonymous SNPs. The 
functional impact of these three SNPs is not clear in vivo although in vitro the ABCB1 
3435C>T SNP has been associated with reduced mRNA expression102 and stability,103 and 
more recently, with changes in substrate specificity.104 With regard to the latter, evidence 
suggests that the 3435C>T transition affects the timing of co-translational folding and 
insertion of ABCB1 into the plasma membrane, thereby altering the structure of substrate 
and inhibitor interaction sites.104 However, these findings have not been confirmed by 
other investigators and at present, the consequences of the silent 3435C>T SNP for 
mRNA expression and stability, as well as protein function, are subject to debate.105 The 
functional impact of the 1236C>T and 2677G>T/A, and other ABCB1 SNPs on ABCB1 
expression and function also remains controversial and has been the topic of several 
review articles.106,107
Polymorphisms in ABCB1 could also contribute to alterations in Tac pharmacokinetics. The 
ABCB1 3435C>T, 1236C>T, and 2677G>T/A SNPs, have been extensively investigated in 
relation to Tac pharmacokinetics. Taken together, the results of these studies have been 
negative as they have demonstrated only a limited (if any) effect of ABCB1 SNPs on Tac 
disposition.83,108
Perhaps even more important than its relation to pharmacokinetics is the influence of 
genetic variation on Tac pharmacodynamics and consequently transplantation outcome. 
Several studies investigated the effect of SNPs in ABCB1 on Tac pharmacodynamics. Simi-
larly, the ABCB1 SNPs exert no obvious impact on Tac pharmacodynamics, with studies 
demonstrating conflicting results in regard to the main parameters of acute rejection 
and nephrotoxicity.60 However, recently have been found that kidneys from donors with 
T allele at ABCB1 rs1045642 are associated with shorter renal allograft survival.109 It 
has been hypothesized that a high degree of ABCB1 expression or activity may lead, as 
a consequence of an increased efflux of Tac out the lymphocytes, to rejection episodes 
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in transplant recipients. One recent study has shown that recipients ABCB1 genotype is 
related to intracellular Tac concentrations in their peripheral blood mononuclear cells.110 
Since increased Tac intracellular concentrations might in turn improved immunosuppres-
sive status and prevention of rejection, ABCB1 recipient genotyping might be useful to 
better individualize the Tac therapy after solid organ transplantation.
5. THERAPEUTIC DRUG MONITORING
Optimal immunosuppression is essential to maintain a viable allograft. The well-known 
large inter- and intra-individual variability of the pharmacokinetics of Tac, as well as its 
narrow therapeutic window are a challenge to clinicians, who need to select the best 
treatment and the best dosage for a given patient. Tac is therefore considered to be a 
critical dose drug. In most transplant centers, monitoring of Tac therapy by use of pre-
dose concentrations, a practice known as therapeutic drug monitoring (TDM), is standard 
of care of (renal)-transplant recipients. In the early years after the clinical introduction 
of Tac there was debate regarding the appropriate matrix for the determination of Tac 
concentrations. Because the concentration of Tac is high within the erythrocytes, it 
proved impractical to measure the drug in plasma or serum, and all our current data on 
the application of Tac concentrations as a guide to therapy are based on whole blood 
measurements.111
Because Tac dose does not correlate with Tac exposure TDM remains mandatory to 
optimize clinical outcomes and reduce toxicities. A few multicenter, prospective, ran-
domized-controlled trials have been published to enable the establishment of target 
Tac whole blood levels in relation to clinical outcome. In renal transplant recipients, 
Laskow et al. found a significant trend for increasing toxicity with increasing maximum 
Tac C0  recorded within 7 days after transplantation and for decreasing rates of rejection 
with increasing minimum Tac C0.53 A significant relationship was found between low area 
under the concentration-time curve (AUC < 200 ng · h/mL) and acute rejection on day 
2, but no correlation was demonstrated between rejection and low AUC at 2 weeks or 3 
months after kidney transplantation.52 The AUC0-12 value of 200 ng ∙ h/mL was found to 
correspond to a Tac C0 of approximately 10 ng/mL. It was, therefore, suggested that in 
order to reduce the risk of rejection the minimum Tac C0 of 10 ng/mL should be achieved 
by day 2 to 3 post-transplantation.52 In a prospective 12-momths pharmacokinetic study 
of Tac in 100 de novo renal allograft recipients these results were confirmed. Kuypers et 
al. demonstrated that on day 7 after transplantation Tac AUC0-12 greater that 150 ng ∙ h/
mL was associated with a lower incidence of acute rejection.56
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The AUC, which is calculated on the basis of a full pharmacokinetic profile, is in general 
considered as the best marker of drug exposure, but it is difficult to justify for financial 
and practical reasons. Despite that the correlation between C0 and AUC0-12h for Tac is a 
matter of debate, with generally a better relationship during early phase after transplan-
tation (first month) than later on, most centers still rely on the Tac C0.112 Tac 2 hours after 
dose ingestion (C2 ) do not seem to correlate better with AUC than C0.111 A more reliable 
estimation of the total exposure can be obtained by a limited sampling strategy (LSS). 
This means sampling at limited or optimal sampling times, still allowing for an accurate 
and precise estimation of the AUC. However, although this LSS adequately predicted Tac 
exposure, a LSS does not really overcome the logistical and financial disadvantages of 
a full pharmacokinetic profile. Moreover, it is unlikely to rapidly gain widespread clini-
cal acceptance of LSS because of the lack of any data demonstrating improved clinical 
outcomes over C0 monitoring.113
Careful interpretation of clinical data allows us to roughly position current effective target 
Tac C0 between 5-15 ng/mL, at least in the first year post-transplantation provided that 
Tac is incorporated in an immunosuppressive regimen with mycophenolate, glucocorti-
coids, and anti-IL-2 induction. These target ranges are not based on validated guidelines 
but an observation of what has been evaluated in today’s clinical studies.111,114
The routine measurement of Tac C0 has until recently mostly been performed by use 
of immunoassays, especially the microparticle enzyme immunoassay (MEIA, Abbott 
Diagnostics, Chicago, IL). In more recent years other immunoassays have been become 
available, such as the enzyme multiplied immunoassay technique (Dade Behring, now 
Siemens), the antibody conjugated magnetic immunoassay (ACMIA, Siemens) and the 
cloned enzyme donor immunoassay (CEDIA, Microgenics). These immunoassays are to 
some degree biased by cross-reactivity with Tac metabolites, and changes in haematocrit 
lead to additional bias in the MEIA assay.115,116 With the recent progress in analytical 
techniques regarding robustness of measurement, reproducibility, dynamic range (3-4 
orders of magnitude) and measurement time (seconds), traditional methods for Tac TDM 
have been reconsidered. High-performance liquid chromatography (HPLC) based meth-
ods have been developed, either with single mass-spectrometric detection (HPLC-MS), or 
linked to tandem mass spectrometry (HPLC-MS/MS).111 Some hospital laboratories have 
already implemented HPLC-MS(/MS) for measurement of samples for patient care, while 
others still rely on immunoassays.
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6. AIMS Of THE THESIS
Although Tac has been in widespread use since the 1990s, there are still a number 
of unanswered questions related to its clinical use. For example, the optimal starting 
dose of Tac and the optimal target concentration in both the early and late phase after 
transplantation, are unknown. At present, the main challenge to transplant physicians is 
to improve the long-term outcomes of solid organ transplantation while maintaining the 
good short-term outcomes that have already been achieved. The aim of this disserta-
tion was to try and answer some of these questions and to find strategies to optimize 
Tac treatment with the ultimate aim to improve the long-term outcomes of solid organ 
transplantation. More specially, we investigated the following:
1. Is there a relationship between the currently used, empirically defined, Tac target concen-
trations and the incidence of acute rejection in kidney transplant recipients?
TDM of Tac is universally applied. However, contrary to the expectations of most phy-
sicians, the concentration-effect relationship for Tac is poorly defined. To justify the 
widespread implementation of TDM for Tac a concentration-effect relationship should be 
present. Several studies have attempted to define the optimal Tac concentration range, 
where both a low incidence of rejection and good tolerability to Tac is achieved. Since 
the findings of these reports are contradictory, we investigated in a large study popula-
tion whether the currently applied Tac target C0 are indeed associated with a lower risk 
for developing an acute rejection (Chapter 2.1).
2. Does conversion from twice-daily Tac formulation (Prograft®) to a once-daily Tac for-
mulation (Advagraf®) have an effect on p38MAPK phosphorylation in kidney transplant 
recipients?
Tac suppresses the phosphorylation of the MAPK pathway by inhibiting p38MAPK. The 
amount of phosphorylation of this signaling molecule was found to be inversely cor-
related with Tac whole blood C0 of kidney transplant recipients. Increased p38MAPK 
phosphorylation was also associated with a higher T-lymphocyte activation status, which 
was inhibited by Tac.42,48 Despite the fact that Tac therapy is routinely monitored by mea-
suring whole blood C0, some patients who have Tac C0 that are considered therapeutic, 
still suffer from acute rejection or toxicities. We speculated that measurement of drug’s 
pharmacodynamics effects may be a better way to perform TDM of Tac. Phospho-specific 
flow cytometry was used to study the biological effects of conversion from twice-daily 
to a once-daily Tac formulation on p38MAPK phosphorylation (Chapter 2.2). Potentially, 
pharmacodynamic monitoring of Tac treatment may offer an attractive new method to 
individualize Tac therapy.
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3. Does the pre-transplant Tac dose requirement predict the post-transplantation dose 
requirement?
Tac is a drug with high between-patient variability in its pharmacokinetics. In the early 
phase after transplantation, following initiation of treatment with a standard Tac dose, 
many patients have Tac concentrations outside the target range, putting them at risk for 
rejection or toxicity. Knowledge of the pharmacokinetics of Tac in a patient obtained be-
fore transplantation may be helpful in personalizing Tac therapy and achieving therapeu-
tic Tac concentrations early after transplantation. In the study presented in Chapter 3.1 
we investigated whether the pre-transplant Tac dose requirement in patients scheduled 
to undergo living donor kidney transplantation correlates with early post-transplantation 
dose requirement.
4. Does pharmacogenetic adaptation of Tac starting dose increase the number of patients 
having therapeutic Tac exposure early after transplantation and consequently lead to 
improved clinical outcomes?
In the area of transplantation it is well known that CYP3A5 genotype is a strong predictor 
for the Tac dose needed to reach target concentrations. CYP3A5 expressers need an ap-
proximately 2-fold higher Tac dose than non-expressers, and have lower Tac exposure in 
the first week after transplantation, which puts them at risk for acute rejection. Our ran-
domized controlled trial was specifically designed to prospectively investigate whether 
dosing of Tac according to CYP3A5 genotype leads to earlier achievement of target Tac 
C0 and consequently to a better clinical outcome than the standard body-weight based 
dosing approach (Chapter 3.2).
5. Does high IPV in Tac exposure influence long-term kidney transplant outcomes?
Tac is known to have a considerable IPV in its pharmacokinetics, which is defined as the 
fluctuation in Tac concentrations within an individual over a certain period of time during 
which the Tac dose is unchanged. A high Tac IPV might put patients at risk for episodes 
of under-immunosuppression, and consequently rejection, as well as toxicity in case of 
over-exposure. In a large cohort of renal transplant recipients we investigated (during 
a relatively long follow-up period) whether Tac IPV predicts adverse kidney transplant 
outcomes (Chapter 4.2).
6. Does high Tac IPV correlate with progression of graft vascular disease in heart transplant 
recipients?
In renal transplant recipients a higher IPV for Tac pharmacokinetics was shown to be 
associated with impaired long term transplant outcomes. Several other studies have now 
confirmed our findings in cohorts of kidney transplant patients. There are far less data 
available on the importance of IPV for long term outcome after other solid organ trans-
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plants. In Chapter 4.3 we investigated whether a high IPV in Tac exposure is associated 
with progression of cardiac allograft vasculopathy as a determinant of long-term survival 
of heart transplant recipients.
7. Does conversion from twice-daily Tac formulation (Prograft®) to a once-daily Tac formu-
lation (Advagraf®) lead to a lower intra-patient variability in Tac exposure?
Non-adherence to the immunosuppressive drug regimen is common and reported to av-
erage 23%.79 Medication non-adherence is considered an important risk factor for poor 
long-term transplantation outcome. Non-adherence to the immunosuppressive drugs 
among renal transplant recipients is associated with an increased risk for graft failure.117 
To improve adherence in transplant recipients, a modified-release, oral dosage form of 
Tac (Advagraf®, Astellas Pharma) has been developed to provide a once-daily dosing 
alternative. As medication adherence may be an important determinant of IPV in drug 
exposure, we decided to investigate whether conversion from twice-daily to once-daily 
Tac formulation leads to a lower IPV in a large cohort of stable renal transplant recipients 
(Chapter 4.4).
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ABSTRACT
TDM for tacrolimus (Tac) is universally applied. However, the concentration-effect rela-
tionship for Tac is poorly defined. This study investigated whether Tac concentrations 
are associated with acute rejection in kidney transplant recipients. Data from three large 
trials were pooled. We used univariate and multivariate analysis to investigate the rela-
tionship between BPAR and Tac predose concentration at 5 time points (day 3, 10, and 
14, and month 1 and 6 after transplantation). A total of 136/1304 patients experienced 
BPAR, giving an overall incidence of 10.4%. We did not find any significant correlations 
between Tac predose concentrations and the incidence of BPAR at the different time 
points. In the multivariate analysis, only Delayed Graft Function (DGF) and the use of 
induction therapy were independently correlated with BPAR, with an odds ratio of 2.7 
[95% CI: 1.8 - 4.0; p < 0.001] for DGF and 0.66 [95% CI: 0.44 - 0.99; p = 0.049] for induc-
tion therapy. The other variables, including the Tac predose concentrations, were not 
statistically significantly associated with BPAR. We did not find an association between 
the Tac predose concentrations measured at 5 time points after kidney transplantation 
and the incidence of acute rejection occurring thereafter. Based on this study it is not 
possible to define the optimal target concentrations for Tac.
Tacrolimus concentration and acute rejection 37
2
INTRODUCTION
Tacrolimus (Tac) has almost replaced cyclosporine A (CsA) as the drug of first choice for the 
prevention of graft rejection after kidney transplantation.1 Therapeutic Drug Monitoring 
(TDM) for Tac is universally applied. Requirements for a drug to implement TDM in clinical 
practice include a high between-patient variability in pharmacokinetics, a relatively low 
within-patient variability, and a concentration-effect relationship. In order to do TDM, 
assays to measure drug concentrations also need to be available and ideally, randomized 
trials should show an improvement in clinical outcome when a drug is dosed based on 
measured drug concentrations compared to a fixed-dose approach. For Tac several assays 
are available, but randomized trials showing a benefit of TDM are not available. However, 
it is not realistic to expect that for Tac such a trial will ever be performed.
Contrary to the belief of many physicians and surgeons, the concentration-effect rela-
tionship for Tac is poorly defined. As the most important reason to prescribe Tac to a 
transplant recipient is the prevention of acute rejection, it is surprising that there are so 
few data on the concentration-effect relationship of Tac. Based on the current literature 
there is little support to promote the use of a specific therapeutic window and aim for 
certain target concentrations.
Several investigators have attempted to identify the optimal Tac concentration range, i.e. 
the one which is associated with the lowest incidence of rejection and with acceptable 
toxicity, as shown in Table 1. The findings of many of these reports are conflicting and 
limited by the fact that they were of a retrospective design, included limited numbers of 
patients, and that the co-immunosuppressive medication used was different from that 
which is currently considered the gold standard. For the interpretation of the studies that 
are available an important additional problem is the fact that not all investigators studied 
Tac concentrations at the same time point after transplantation.
Rodriguez et al.2 recently performed a meta-analysis of 64 studies investigating the cor-
relation between the Tac predose concentration and the incidence of rejection in liver 
transplant recipients. They concluded that the mean Tac predose concentration during 
the first month was not correlated with acute rejection. Nevertheless, they suggested 
that lower Tac predose levels would be more appropriate after liver transplantation to 
prevent Tac toxicity.
Despite limited evidence for performing TDM for Tac and the exact predose concentra-
tions to aim for, in most transplant centers considerable time and effort is spent on the 
precise dosing of Tac in order to reach the predefined Tac target concentrations rapidly. 
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Once on target, maintaining patients within the target concentration range also requires 
careful monitoring.
The aim of the present study therefore was to investigate whether the currently used 
and empirically-defined Tac target predose concentrations are indeed associated with 
the risk of developing acute rejection in kidney transplant recipients. We pooled the data 
of three large randomized-controlled trials (RCTs) and studied the relation between Tac 
exposure and the incidence of biopsy-proven acute rejection (BPAR).
PATIENTS AND METHODS
Patients and clinical trials
For the present analysis we combined the data of three large, randomized-controlled 
clinical trials in kidney transplant recipients, the FDCC,3 Symphony4 and OptiCept5 trials. 
In brief, the main common elements of the three studies were the randomized, open-
label, parallel-arm, multicenter design, and the fact that they included a broad spectrum 
of patients. In general, these patients had a low-to-medium immunological risk and were 
treated under the respective protocols for at least one year after kidney transplantation. 
In addition to adults, the FDCC and OptiCept studies enrolled paediatric patients, who 
were, however, not included in our analysis.
Tac target concentrations
For the present analysis we included only the patients from these three RCTs who 
received Tac as part of their immunosuppressive regimen from the day of transplanta-
Table 1. Literature
Author, year Number of patients Conclusion
Borobia et al, 200915 57 kidney The Tac predose concentrations within the first post-operative week are an 
important predictor of acute rejection
Staatz t al, 200116 29 kidney Significant relationship between acute rejection and median Tac predose 
concentrations in the first month.
Bottiger et al, 199917 14 kidney Concentrations below 10 ng/mL seem to be beneficial with respect to side effects
Kershner et al, 199618 92 kidney Significant relationship between the Tac concentrations and toxicity
Undre et al, 199919 56 kidney Mean 12-hour Tac area-under the concentration vs. time-curve (AUC0-12) on day 2 
after transplantation was significantly lower in 17 patients who experienced acute 
rejection than in the 39 patients who remained rejection-free
Kershner et al, 199618 721 liver No relationship between the Tac concentrations and toxicity
Laskow et al, 199621 92 kidney No significant difference among three different Tac-ranges (5-14 ng/mL, 15-25 ng/
mL, and 26-40 ng/mL) with respect to the incidence of rejection
Nashan et al, 200921 60 liver Tac predose concentrations of 5-8 ng/mL in the first month of transplantation 
resulted in the same rejection rates as Tac concentrations of 10-15 ng/mL.
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tion and had a minimum of 1 known Tac level. The Tac levels were targeted differently 
between the studies. For the FDCC study, Tac dosing was according to each center’s 
protocol, and on average was between 10 and 14 ng/mL in the first month, with gradual 
tapering thereafter. In the Symphony study, Tac levels were targeted at 3-7 ng/mL for 
the study period. In the OptiCept trial, the Tac predose concentrations were 8-12 ng/mL 
within the first month, 4-6 or 8-10 ng/mL in the second and third months (depending on 
the randomization group), and 3-5 or 6-8 ng/mL from the fourth month onwards. Data 
on Tac dose and predose concentrations, as well as other demographic and clinical char-
acteristics were collected from the databases of the three RCTs and pooled. Tac predose 
concentrations were studied at day 3 (± 2 days), day 10 (± 2 days), day 14 (± 3 days), 
month 1 (± 7 days), month 6 (± 4 weeks). We changed the Tac levels that were higher than 
30 ng/mL (24 measuring points in total) into missing values, to prevent that non-predose 
Tac concentrations would be included in the analysis. However, we also performed the 
analysis with all the Tac levels (including the ones that were higher than 30 ng/mL).
Acute rejection
BPAR was defined as any histologically-confirmed episode for which a Banff score of 
1 (mild, grades IA and IIA), 2 (moderate, grades IB and IIB), or 3 (severe, grade III) was 
recorded. In all three trials, all biopsy samples were assessed by a local pathologist, and 
rejection was classified according to the revised Banff grading system.6 For the present 
analysis, only the first episode of BPAR was investigated. Ongoing or recurrent rejections 
were not studied.
Statistical analyses
The correlations between Tac concentrations and BPAR were done for BPARs occurring 
after the time of the Tac concentration measurement, within the remainder of the first 
post-transplant year tested with the non-parametric Mann Whitney U test at the five 
different time points. We also did the same analysis for BPARs occurring within the 
month following the Tac concentration measurement, again for all five time points. We 
also performed a similar analysis categorizing the patients as high-risk if they had one 
or more of the following characteristics: delayed graft function (DGF), second or third 
transplantation, panel reactive antibodies (PRA) of more than 15%, four or more human 
leukocyte antigen (HLA) mismatches, or were of African descent (black). All other patients 
were considered as low-risk. We have previously used the same definition for high and 
low risk.7 The significance level was stated at 5%. Induction therapy (yes/no)(either ATG 
of anti ILR monoclonal antibody induction), HLA mismatches (<4 / ≥4), DGF (yes/no), PRA 
(<15 / ≥15) and number of transplant (first / ≥second transplant) were correlated with 
the occurrence of BPAR within one month and one year after transplantation by using 
the Chi Square test. To identify independent risk factors for the development of BPAR, a 
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binary logistic regression was performed, including all the above mentioned variables, 
plus median levels of Tac predose concentrations. Statistical analysis was carried out 
using SPSS version 19 (SPSS / IBM Inc., Chicago, Illinois, USA).
RESULTS
Patient characteristics
In the three clinical trials a total of 1363 renal transplant patients were treated with Tac 
after transplantation. Of these patients, 1304 met the inclusion criteria and were used 
for further analysis (Fig. 1). Of these 1304 patients, 358 (27%) participated in the FDCC 
study, 385 (30%) in the Symphony study, and 561 (43%) in the Opticept study. The 
patient characteristics are listed in Table 2. A total of 4953 Tac predose concentrations 
of 1304 patients were available for the analysis (Total predose concentrations of 818 on 
day 3; 1127 on day 10; 804 on day 14; 1167 on month 1 and 1019 on month 6). The Tac 
predose concentrations show a substantial range and are depicted in Figure 2A. Twenty-
four Tac concentrations were >30 ng/mL (n =13 on day 3; n =4 on day 14, n = 4 on month 
1 and n = 3 on month 6). As we were unable to check whether these concentrations 
were truly predose concentrations or in fact post-dose concentrations, these values were 
classified as “missing values” and excluded from the primary analysis.
Relationship between Tac and BPAR
In this cohort the overall incidence of BPAR was 10.4% (n = 136) within one year after 
transplantation. The vast majority of BPARs occurred within the first month after trans-
plantation (91/136 = 7%). We univariately tested the relationship between median 
Patients in the database 
n = 1363 
Included in the analysis 
n = 1304 (95.7%)
FDCC study 
n = 358 (27.5%) 
Symphony study 
 n = 385 (29.5%) 
OptiCept study 
n = 561 (43.0%) 
Excluded n = 59 (4.3%) 
- Age unknown (n = 5)  
- Age < 18 years (n = 9) 
- Tac concentrations unknown (n = 45) 
  
figure 1. Included patients from the three clinical trials and reasons for exclusion from the study.
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Tac predose concentrations and the occurrence of BPAR within the first post-transplant 
year at 5 different time points, as shown in Table 3A and Figure 2B. We did not find 
any significant relationship between the Tac concentration and the incidence of BPAR. 
The results for BPAR within the first month after the Tac measurements did show similar 
results: again patients that developed a BPAR had Tac predose concentrations that were 
not different compared to patients without a BPAR, as shown in Table 3B. As for only 61% 
of the patients a Tac predose concentration was available for day 3 (Table 3A), we have 
studied the mean Tac predose concentration for each patient, based on samples drawn 
between day 3 and day 14 and correlated this to BPAR. Again, these Tac concentrations 
were not significantly different between patients with BPAR and patients without BPAR 
(10.02 vs. 9.97; p = 0.90).
The data were further analyzed by stratification into two groups: patients with a predose 
concentration < 5 ng/mL vs. patients with a predose concentration > 5 ng/mL, and pa-
tients with a predose concentration < 10 ng/mL vs. patients with a predose concentration 
> 10 ng/mL. The results are shown in Table 4. There were no statistically significant asso-
ciations between the Tac predose concentrations and the occurrence of BPAR within one 
month after the measurement or throughout the rest of the first year after transplantation.
To analyse the risk of BPAR further, we divided the group into high and low immuno-
logical risk patients according to the definition described above. The total number of 
patients defined as being low-risk was 499 (39%) whereas 786 (61%) patients were 
considered to be high-risk. Nineteen patients were not included in this analysis, because 
one or more of the variables needed to define their immunological risk were not known. 
The incidence of BPAR was higher in patients in the high-risk group (100/786 = 12.7%) 
compared to the low-risk group (36/499 = 7.2%), with an odds ratio of 1.9 for patients 
Table 2. Patient Characteristics
Gender (female / male) 450 (34%) / 854 (66%)
Age (yr; mean (SD) 48 (13.8)
Ethnicity (%):
 - Black 161 (12%)
 - Non- Black 1143 (88%)
Transplantation (1st / ≥2) 1219 (94%) / 84 (6%)€
Delayed Graft Function: Yes / No 238 (18%) / 1066 (82%)
Panel reactive antibodies (< 15% / ≥ 15%) 1124 (91.5%) / 105 (8.5%)€
HLA-mismatches (< 4 / ≥4) 709 (54%) / 595 (46%)
Living related / living unrelated / deceased donor 338 (26%) / 183 (14%) / 783 (60%)
Induction therapy: Yes / No 890 (68%) / 414 (32%)
€: For transplantation and PRA there were missing values in 1 and 6 patients, respectively.
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A 
B 
figure 2. A. Boxplots depicting the Tac predose concentrations of all patients at the five different 
time points after transplantation.
B. Boxplots depicting the Tac predose concentrations of patients experiencing BPAR (black boxes) 
and patients without BPAR (white boxes) at the five different time points after transplantation.
Bottom, middle, and top lines of each box correspond to the 25th percentile, the 50th percentile 
(median), and the 75th percentile, respectively. The caps show the 5th and 95th percentiles. The 
points represent the outliers and the asterisks represent the extreme outliers (more than three times 
the height of the boxes).
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in the high-risk group vs. the low-risk patients [95% CI: 1.3 - 2.8; p < 0.05]. First we 
analysed the Tac concentrations at the different time points for the high-risk group vs. 
the low-risk group. At all the time points the median Tac predose concentrations were 
not statistically significantly different between the high and low risk groups. We further 
analysed the Tac concentrations at the different time points within the high and low risk 
group separately, as shown in Table 5. Again no significantly differences could be found 
Table 3A. Median Tac predose concentrations and their association with BPAR occurring within the 
remainder of the first post-transplant year after the Tac concentration measurement.
Post-transplant Time 
point
Median predose Tac concentration (ng/mL) in 
patients with BPAR
Median predose Tac concentration (ng/mL) in 
patients without BPAR
Day 3 Tac: 10.3 [6.5; 17.1; 27.6]Ω
n = 135 (61%)¥
Tac: 9.5 [6.0; 14.5; 29.5]Ω
n = 1168 (63%)¥
Day 10 Tac: 9.0 [7.0; 11.8; 25.8]Ω
n = 92 (85%)¥
Tac: 9.1 [6.6; 12.2; 28.2]Ω
n = 1013 (87%)¥
Day 14 Tac: 7.8 [5.6; 10.4; 26.2]Ω
n = 65 (72%)¥
Tac: 8.1 [6.2; 11.4; 29.7]Ω
n = 722 (62%)¥
Month 1 Tac: 8.7 [5.8; 12.7; 20.2]Ω
n = 45 (84%)¥
Tac: 9.7 [7.0; 12.5; 27.6]Ω
n = 1050 (90%)¥
Month 6 Tac: 7.5 [6.3; 10.5; 11.0]Ω
n = 15 (80%)¥
Tac: 6.8 [5.3; 8.6; 23.6]Ω
n = 924 (79%)¥
¥ The percentage of patients of whom the Tac levels were available for analysis at this post-trans-
plant time point. Tac concentrations were related to BPAR occurring after the date of the Tac con-
centration measurement.
Ω The numbers show the 25th percentile, 75th percentile and the range respectively. For all com-
parisons no statistically significant differences were found, all p-values were > 0.05.
Table 3B. Median Tac predose concentrations and their association with BPAR occurring within 1 
month after the Tac concentration measurement.
Post-transplant Time 
point
Median predose Tac concentration (ng/mL) in 
patients with BPAR
Median predose Tac concentration (ng/mL) in 
patients without BPAR
Day 3 Tac: 11.1 [6.3; 10.5; 11.0]Ω
N = 60 (66%)¥
Tac: 9.5 [6.3; 10.5; 11.0]Ω
N = 1212 (62%)¥
Day 10 Tac: 9.0 [6.3; 10.5; 11.0]Ω
N = 51 (86%)¥
Tac: 9.1 [6.3; 10.5; 11.0]Ω
N = 1047 (87%)¥
Day 14 Tac: 8.5 [6.3; 10.5; 11.0]Ω
N = 24 (71%)¥
Tac: 8.1 [6.3; 10.5; 11.0]Ω
N = 1209 (62%)¥
Month 1 Tac: 8.0 [6.3; 10.5; 11.0]Ω
N = 7 (71%)¥
Tac: 9.7 [6.3; 10.5; 11.0]Ω
N = 1206 (90%)¥
Month 6 Tac: 7.4 [6.3; 10.5; 11.0]Ω
N = 5 (100%)¥
Tac: 6.8 [6.3; 10.5; 11.0]Ω
N = 1178 (79%)¥
¥ The percentage of patients of whom the Tac levels were available for analysis at this post-trans-
plant time point. Tac concentrations were related to BPAR occurring after the date of the Tac con-
centration measurement.
Ω The numbers show the 25th percentile, 75th percentile and the range respectively. For all com-
parisons no statistically significant differences were found, all p-values were > 0.05.
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between the patients that developed BPAR and patients without BPAR for the low (Table 
5A) as well as for the high risk patients (5B).
We have changed the Tac levels that were higher than 30 ng/mL (24 measuring points 
in total) into missing values, to prevent that non predose Tac concentrations would be 
included in the analysis. However, we have also performed the analysis with all the Tac 
levels (including the ones that were higher than 30 ng/mL), but the results did not change 
(data not shown).
Explaining BPAR
Next to the Tac predose concentrations, in the univariate analysis, induction therapy, 
HLA mismatches, DGF, PRA and number of transplants were tested with the occurrence 
of BPAR within one year after transplantation. Of all 1304 patients 68% used induction 
therapy, and 9.6% of these patients suffered from a BPAR whereas this percentage was 
12.3% in patients who did not use induction therapy after transplantation (p = 0.13). We 
also correlated the incidence of BPAR and the mean Tac concentration of day 3 to day 
14 only within patients that did not use induction therapy. The Tac concentration in this 
group was not statistically different between patients with BPAR and patients without 
BPAR (p = 0.53). To test the influence of HLA mismatching we divided the group into 
patients that had 0-3 HLA mismatches vs. patients that had more than 3 HLA mismatches. 
There was a significant correlation between the number of HLA mismatches and the oc-
Table 4. Numbers of patients with Tac concentrations below or above 5 ng/mL (Table 4A) and num-
bers of patients with Tac concentrations below or above 10 ng/mL (Table 4B) at 5 post-transplant 
time points, and incidence of BPAR in these patients following that time point.
4A. Tac predose concentrations < / > 5 ng/mL.
Time point Tac < 5ng/mL BPAR Tac > 5ng/mL BPAR P -value
Day 3 146 10 (6.8%) 671 73 (10.9%) 0.14
Day 10 129 7 (5.7%) 962 71 (7.4%) 0.42
Day 14 92 8 (8.7%) 677 39 (5.8%) 0.27
Month 1 86 2 (2.3%) 1002 36 (3.6%) 0.54
Month 6 185 2 (1.1%) 751 10 (1.3%) 0.79
4B. Tac predose concentrations < / > 10 ng/mL.
Time point Tac < 10ng/mL BPAR Tac > 10ng/mL BPAR P -value
Day 3 426 40 (9.4%) 391 43 (11%) 0.48
Day 10 619 49 (7.9%) 472 29 (6.7%) 0.26
Day 14 495 32 (6.5%) 274 15 (5.5%) 0.58
Month 1 573 22 (3.8%) 515 16 (3.1) 0.58
Month 6 797 9 (1.1%) 139 3 (2.2%) 0.32
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currence of BPAR. In patients with more than 3 HLA mismatches 12.3% had BPAR vs. 8.9% 
in patients that had 0-3 HLA mismatches (p = 0.046). Also for DGF we found a significant 
correlation with the occurrence of BPAR (19.7% in patients with DGF vs. 8.3 % in those 
without DGF), p < 0.001). The PRA status was not significantly related to the development 
of BPAR. PRA was separated into patients that had a PRA < 15% and patients with a PRA 
Table 5. Median Tac predose concentrations at different time points after transplantation in patients 
with BPAR and in patients without BPAR divided into low (5A) and high risk patients (5B).
5A. Low Risk patients.
LOW-RISK PATIENTS (n = 499)
(Total BPAR incidence: 36/499 (7,2%))
Post-transplant Time 
point
Median predose Tac concentration (ng/mL) in 
patients with BPAR
Median predose Tac concentration 
(ng/mL) in patients without BPAR
P-value
Day 3 Tac: 10.3 [6.3; 10.5; 11.0]Ω
n = 17¥
Tac: 10.1 [6.3; 10.5; 11.0]Ω
n = 269¥
0.46
Day 10 Tac: 9.5 [6.3; 10.5; 11.0]Ω
n = 20¥
Tac: 9.0 [6.3; 10.5; 11.0]Ω
n = 394¥
0.68
Day 14 Tac: 8.9 [6.3; 10.5; 11.0]Ω
n = 11¥
Tac: 7.9 [6.3; 10.5; 11.0]Ω
n = 302¥
0.73
Day 3- day 14 Tac: 9.2 [6.3; 10.5; 11.0]Ω
n = 36¥
Tac: 9.2 [6.3; 10.5; 11.0]Ω
n = 454¥
0.63
Month 1 Tac: 10.1 [6.3; 10.5; 11.0]Ω
n = 10¥
Tac: 9.3 [6.3; 10.5; 11.0]Ω
n = 421¥
0.64
¥: The patients from whom the Tac levels were available for analysis at this post-transplant time 
point. For month 6 after transplantation the number of patients was too low to perform the analysis 
and this time point is therefore excluded from the analysis. ΩThe numbers show the 25th percentile, 
75th percentile and the range respectively.
5B. High Risk patients.
HIGH-RISK PATIENTS (n = 786)
(Total incidence of BPAR: 100/786 (12,7%))
Post-transplant Time 
point
Median predose Tac concentration (ng/mL) in 
patients with BPAR
Median predose Tac concentration (ng/
mL) in patients without BPAR
P-value
Day 3 Tac: 10.6
n = 66¥
Tac: 9.4
n = 454¥
0.26
Day 10 Tac: 8.7
n = 58¥
Tac: 9.1
n = 600¥
0.98
Day 14 Tac: 7.8
n = 36¥
Tac: 8.1
n = 402¥
0.28
Day 3- day 14 Tac: 9.1
n = 99¥
Tac: 9.3
n = 673¥
0.63
Month 1 Tac: 8.7
n = 28¥
Tac: 9.9
n = 614¥
0.24
¥: The patients from whom the Tac levels were available for analysis at this post-transplant time 
point. For month 6 after transplantation the number of patients was too low to perform the analysis 
and this time point is therefore excluded from the analysis. ΩThe numbers show the 25th percentile, 
75th percentile and the range respectively.
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> 15%, in the first group 10.5% developed BPAR and in the last group 8.6% (p = 0.54). 
We have also studied the development of BPAR within patients that had a first kidney 
transplantation and compared this to patients that had one or more transplants before. 
Patients who had been transplanted before had a higher risk of developing BPAR (17.9%) 
compared with patients who received their first kidney allograft (9.9%; p = 0.021). The 
variables are listed in Table 6A. Because of the different designs of the studies we have 
also tested the incidence of BPAR within the different studies (Symphony, Opticept and 
FDCC). The patients in the Opticept trial suffered significantly less from a BPAR than in 
the other studies (7.5% vs. 12.2% (Symphony) and 13.1% (FDCC); p = 0.01.
In order to exclude the possibility that some of the other factors associated with the 
incidence of BPAR have confounded the relationship between Tac concentrations and 
BPAR we have adjusted for observed confounders and we performed a multivariate 
analysis which included these variables, as well as the Tac concentrations. Multivariate 
analysis demonstrated that only DGF and the use of induction therapy were indepen-
dently correlated to BPAR, with an odds ratio of 2.7 [95%-CI: 1.8 - 4.0; p < 0.001] for DGF, 
and 0.66 [95%-CI: 0.44 - 0.99; p = 0.049] for the use of induction therapy. The other 
Table 6A. Other variables related to BPAR (univariate analysis).
Patients (%) Patients with BPAR (%) P-value
DGF 18.3 19.7 < 0.001
No DGF 81.7 8.3
HLA mismatches > 4 46 12.3
HLA mismatches < 4 54 8.9 0.046
Number transplantation > 1 6.4 17.9 0.021
Number transplantation = 1 93.6 9.9
PRA > 15% 13.8 8.6 0.54
PRA < 15% 86.2 10.5
Induction therapy 68 9.6 0.13
No Induction therapy 32 12.3
DGF = Delayed graft function; PRA = panel reactive antibody
Table 6B. Multivariate analysis.
OR (95% CI) P-value
DGF 2.7 (1.8 – 4.0) 0.0001
Induction 0.66 (0.44 – 0.99) 0.049
Mean Tac concentration day 3 – day 14 0.98 (0.94 – 1.03) 0.48
HLA mismatches < 4 1.47 (1.02 – 2.13) 0.07
Number transplantation > 1 1.71 (0.91 – 3.23) 0.09
PRA > 15% 0.51 (0.17 – 1.53) 0.23
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variables, including the Tac predose levels, were not significantly associated with the risk 
of developing BPAR as shown in Table 6B.
DISCUSSION
We did not find a correlation between the Tac predose concentration measured at 5 
time points after transplantation and the occurrence of acute rejection in the period 
thereafter, within the first post-transplant year. The same was true for BPARs within the 
first month following the Tac measurement. We investigated a large and heterogeneous 
study population, and the Tac concentrations measured showed a substantial range, 
despite rather tight target concentrations defined in the protocols.
The situation for Tac seems to be quite different from mycophenolic acid (MPA). For MPA, 
a concentration-effect relationship has been shown repetitively8-9 and for MPA it was 
also shown that in contrast to patients at low-risk for BPAR for high-risk patients there 
was a significant difference in the incidence of BPAR depending on the MPA concentra-
tions reached.7 In the present study, in neither the high-risk nor in the low-risk patients 
the incidence of acute rejection was dependent on the Tac concentrations. A bit to our 
surprise the mean Tac concentrations in high risk patients were not different from the 
Tac concentrations found in the low risk population. We had expected that physicians re-
sponsible for dosing Tac would aim for higher Tac concentrations in patients considered 
to be at presumed higher risk for BPAR, and that they would allow for lower concentra-
tions in patients with a lower risk of rejection. Also in the multivariate analysis the Tac 
concentrations did not surface as predictor for BPAR.
TDM is generally considered to be required for managing Tac therapy. Often transplant 
centers have specified the target concentrations for Tac, depending on time post-
transplant, on co-medication and presumed risk of rejection. One would think that for 
a drug so extensively used the evidence for the optimal Tac concentration would be 
compelling. We show that this is not the case. In the past 15 years we have seen a sub-
stantial change in the target Tac concentrations, with targets as high as 20 ng/mL in the 
early years, and with targets as low as 3-7 ng/mL in the Symphony study. This change in 
target concentrations was largely reached empirically, and there is only limited evidence 
for the different targets. This does not imply that TDM for Tac is useless. Without TDM 
the large between-patient variability in Tac pharmacokinetics would go unnoticed, and 
extremes in Tac exposure would occur, exposing some patients to toxic levels and others 
to very low levels. Based on our analysis however it is not possible to conclude that 
the Tac target concentrations should be above for example 5 or 10 ng/mL. Possibly the 
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threshold for efficacy is at a concentration that is even lower than the currently applied 
targets, and it is possible that only when concentrations reach values as low as 1 or 2 
ng/mL the incidence of BPAR starts to increase. The same was suggested by Rodriguez2 
who proposed to further lower the Tac concentration in liver transplantation. They even 
recommended the regulatory authorities and pharmaceutical industry to change the 
regulatory drug information for lowering the target levels.
This study is a combined analysis of three large clinical trials, and a large number of kid-
ney transplant recipients was included. In spite of the considerable number of patients 
studied, we could not show an association between the development of acute rejection 
in 1 month or 1 year after transplantation and the Tac whole blood concentrations. Also 
adjusting for confounders in a multivariate analysis the results stayed negative. Recently 
Capron et al.10 also showed that there is no correlation between Tac whole blood concen-
trations and rejection after liver transplantation. However, they did find a strong correla-
tion between Tac concentrations within peripheral blood mononuclear cells (PBMCs), the 
site of action of Tac, and the staging of rejection in liver transplant recipients. However, 
as indicated above, the currently clinically employed assays measure the Tac concentra-
tion in whole blood, which is determined to a large extent by the Tac concentration in 
the erythrocyte fraction. Tac concentrations in PBMCs are not 1:1 correlated with whole 
blood (or erythrocyte) concentrations, for example due to the presence of drug transport-
ing enzymes in the cell membranes of PBMCs. Therefore Tac concentration within PBMCs 
might be a better marker of immunosuppressive efficacy than the whole blood predose 
concentration. Future studies should study the relationship between intracellular Tac 
concentrations and rejection risk in kidney transplant recipients in more detail.
A limitation to this study is that donor specific anti-HLA antibodies were not routinely 
measured, and therefore we have no data on correlations between tacrolimus exposure 
and DSA. Next to this, we had only access to Tac concentrations drawn at predefined time 
points. These Tac concentrations might not be the last measured concentration prior to 
diagnosing BPAR and we cannot exclude the possibility that a similar analysis with the 
last levels drawn would show an association. However, intrapatient variability of Tac is 
limited and we do not think that we would have achieved another outcome by using 
the last levels drawn. Another limitation is that the pre-dose concentrations that were 
investigated in this study do not adequately reflect the exposure to Tac. Kuypers et al. 
in 2004 showed that in contrast to Tac predose concentrations the Tac area under the 
concentration curve from 0 to 12 hours [AUC(0-12)] was correlated with clinical efficacy, 
at different time points after transplantation.11 However, a good correlation between Tac 
predose concentrations and AUC has been demonstrated. In clinical practice predose 
concentrations are the preferred method to monitor Tac treatment.12 In a multivariate 
Tacrolimus concentration and acute rejection 49
2
analysis also Australian investigators13 did not find a correlation between Tac pre-dose 
concentrations or Tac AUC and incidence of acute rejection, whereas in their study MPA-
AUC was correlated to BPAR.
Another explanation might be that other mechanisms, such as innate immunity, which 
are not calcineurin driven might play a role in the development of acute rejections. These 
rejections could not be prevent by the use of calcineurin inhibitors, such as Tac and for 
these type of rejections it is therefore not useful to aim for a specific Tac target. Although 
T-cells, inhibited by Tac, have a critical role in acute rejection it is known that there is an 
upregulation of proinflammatory mediators in the allograft before the T cell response, 
this is due to innate immunity and it is independent of the adaptive immune system.14
In this study we have focused only on efficacy, as the incidence of nephrotoxicity was not 
prospectively collected. Therefore it is not possible form this study to define the upper 
threshold for Tac treatment.
In conclusion, we did not find an association between the Tac predose concentrations and 
the incidence of acute rejection after kidney transplantation. Even though it is generally 
accepted that TDM is essential to maintain the efficacy of Tac, the analysis in this study 
does not show that TDM, at the used whole blood target ranges, adds to lowering the risk 
of acute rejection. We do not want to suggest that TDM for Tac can be abolished, but a 
more critical perception on the relevance of the presumed optimal target concentrations 
is recommended.
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ABSTRACT
Background: The once-daily formulation of tacrolimus (TACOD) has been developed to 
overcome adherence problems. Conversion from the twice-daily TAC (TACBID) formulation 
to TACOD on a 1:1 basis, however, often leads to a decrease of TAC pre-dose concentra-
tions which averages ~15%. Switching between the two TAC formulations may thus influ-
ence drug efficacy and necessitates therapeutic drug monitoring. As an additional tool 
in transplantation diagnostics, phospho-specific flow cytometry was used to study the 
biological effects of conversion on p38MAPK phosphorylation levels, a kinase involved 
in T-lymphocyte activation.
Methods: Stable renal transplant recipients (n=12), at least one year after their trans-
plantation, were converted from TACBID to TACOD on 1:1 mg for mg base. Co-medication 
consisted of mycophenolate mofetil (n=10) and prednisolone (n=3). TAC whole-blood 
pre-dose concentrations were determined by immunoassay before and 3 months after 
conversion. P38MAPK phosphorylation levels were measured in T-lymphocytes by 
whole-blood phospho-specific flow cytometry.
Results: Three months after conversion, no significant decreases in TAC pre-dose con-
centrations (C0) were found (p= 0.674), while p38MAPK phosphorylation increased with 
11.4% (p<0.05) in CD4+ and with 15.6% (p<0.05) in CD8+ T-lymphocytes. The TACBID C0 
inversely correlated with p38MAPK levels in T-lymphocytes (rs= -0.638, p <0.05).
Conclusions: The results demonstrate that p38MAPK phosphorylation levels can be used 
as a method to determine the biological effects of conversion from TACBID to TACOD. This 
method can be used as a new tool for detailed TAC drug monitoring.
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INTRODUCTION
Therapy with the immunosuppressant tacrolimus (TAC) is routinely monitored by measur-
ing whole-blood pre-dose concentrations (C0). However, lack of efficacy (i.e. the occurrence 
of acute rejection) or toxicity does occur in solid organ transplant recipients who have 
TAC concentrations that are considered therapeutic. A better way to perform therapeutic 
drug monitoring (TDM) of TAC may be to measure the drug’s pharmacodynamic effects.
TAC inhibits the calcineurin pathway of activated T-lymphocytes resulting in decreased 
levels of de-phosphorylated Nuclear Factor of Activated T-lymphocytes (NFAT), less 
production of the cytokine IL-2, and ultimately, inhibition of T-lymphocyte proliferation. 
Earlier studies demonstrated that the expression of IL-2 in cell samples can be used as 
a pharmacodynamic tool for TDM of TAC. However, this assay measures the effects of 
other immunosuppressive drugs as well, and therefore is not specific for TAC. In addition, 
this assay is time-consuming, costly and may not reflect to TAC toxicity.1,2 Thus there is 
an unmet need of better pharmacodynamic assays to monitor TAC treatment, leading to 
more customized immunosuppressive therapy.3
Apart from its effects on the NFAT pathway, TAC also suppress the phosphorylation of 
the mitogen activated protein kinase (MAPK) pathway.4 Phosphorylation concentrations 
of this signaling molecule were recently found to be inversely correlate with TAC whole-
blood C0 of kidney transplant patients. Furthermore, increased phosphorylated p38MAPK 
concentrations were associated with a higher T-lymphocyte activation status, which was 
inhibited by TAC in a dose dependent manner in vitro.4,5
Here, the effect of conversion from the standard, twice-daily TAC formulation (TACBID) to 
the once-daily, prolonged-release TAC formulation (TACOD) on p38MAPK concentrations 
in kidney transplant recipients is reported. The novel TACOD formulation was developed 
to overcome adherence problems. However, whole-blood TAC C0 may decrease by 
9-15% following 1:1 conversion on a mg for mg basis.6,7 This may lead to sub-therapeutic 
TAC exposure and may put certain patients at risk for rejection. We speculated that the 
present assay may be more sensitive than conventional PK monitoring and may discover 
subtle changes in drug effects.
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PATIENTS AND METHODS
Study design and determination of tacrolimus blood concentrations
All twelve patients reported here (for their characteristics see Table 1) participated in a 
substudy of a larger clinical trial that was reported previously.7 The aim of the clinical 
trial was to study the safety of conversion from TACBID (Prograf®, Astellas Pharma, Leiden, 
the Netherlands) to TACOD (Advagraf®, Astellas Pharma, Leiden, the Netherlands) on a 1:1 
(mg:mg) basis. The aim of the substudy, which is presented here, was to investigate the 
effects of this conversion on P38MAPK phosphorylation status. Heparin blood samples 
for p38MAPK phosphorylation status were collected 1 day before (visit 1) and 3 months 
after conversion to TACOD (visit 2). TAC whole-blood C0 were determined in whole EDTA 
blood by using the antibody-conjugated magnetic immunoassay (ACMIA) on a Dimen-
sion Xpand analyzer (Siemens HealthCare Diagnostics Inc., Newark, DE) according to the 
manufacturer’s instructions. The lower and upper limits of detection were 1.5 ng/mL 
and 30 ng/mL, respectively. For calculation purposes, TAC C0 below the detection limit 
were set at half the detection limit (0.75 ng/mL). Proficiency samples were obtained from 
the United Kingdom Quality Assessment Scheme (Dr. Holt, St George’s Hospital Medical 
School, London, UK). The laboratory successfully participates in international proficiency 
testing schemes.
Whole-blood phospho-specific flowcytometry
P38MAPK phosphorylation was measured according to the manufacturer’s instructions 
and as described previously.4 In brief, 200 μl of heparinized blood was activated with 
PMA/Ionomycin (1.6 μM/ 10 μg/mL, Sigma-Aldrich, Steinheim, Germany) and stained with 
APC-labelled mouse anti-human CD3, Pacific Blue mouse anti-human CD4 and PE-Cy7 
mouse anti-human CD8 (BD Biosciences, San Jose, CA) for 30 minutes at 37˚C. Then cells 
were fixed for 10 minutes with Lyse/fix buffer and treated with permeabilization buffer 
III (both from BD biosciences) at -20˚C. Samples were stained with the fluorochrome-
conjugated mAb PE mouse anti-p38MAPK (clone pT180/pY182, BD Biosciences) for 30 
Table 1. Patient characteristics (n = 12)
Summary measure
Gender (male/female) 2 (16.7%) / 10 (83.6%)
Age (years) 54.7 (19.6 – 69.7)*
Time from transplantation to conversion (years) 4.92 (1 – 12)*
Number of subjects with concomitant MMF therapy 10 (83.3%)
Number of subjects with concomitant steroid therapy 3 (17.6%)
Tac dose (mg/day) 4.3 (1.5 – 10)*
Tac C0 before conversion (ng/mL) 5.6 (0.75 – 9.8)*
*mean (range)
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minutes at room temperature and analysed on a FACS Canto II flow cytometer (BD Biosci-
ences). Isotype control IgG1-PE (clone X40, BD Biosciences) and FMO control tubes were 
included. Interday-variability of the flowcytometer was corrected by using Quantibrite PE 
beads (BD Biosciences) according to the manufacturer’s instructions.
Data analysis and statistics
P38MAPK phosphorylation concentrations were calculated as the Median Fluorescence 
Intensity (MFI) and normalized using Quantibrite-PE beads. Data and statistical analysis 
was performed with diva-version 6.0 software (BD Biosciences) and Graph Pad Prism 5.0 
(Graph Pad Software Inc., La Jolla, CA) by using paired T test (for p38MAPK phosphoryla-
tion after performing log transformation). Spearman tests were used to calculate the 
correlation between TAC C0 and p38MAPK phosphorylation. A two-sided p-value <0.05 
was considered statistically significant.
RESULTS
Conversion from TACBID to TACOD resulted in a decrease in C0 of 4.18% (Figure 1A), which 
was not statistically significant (p= 0.674). Before conversion the median TAC C0 was 6.0 
ng/ml (range: 0.75 - 9.8 ng/ml); after conversion the median TAC C0 was 5.4 ng/ml (range: 
3.0 – 7.1 ng/ml).
A typical example of induced p38MAPK phosphorylation in CD3+, CD3+CD4+ and 
CD3+CD8+ T-lymphocytes, respectively is shown in Figure 1B. The MFI levels of p38MAPK 
increased after stimulation with PMA/Ionomycin.
After conversion to TACOD p38MAPK phosphorylation concentrations increased sig-
nificantly, both in CD3+CD4+ (11.4% increase, p =0.034) and CD3+CD8+ T-lymphocytes 
(15.6% increase, p =0.038, figure 1C).
Next, phosphorylation concentrations were correlated to the TAC C0. A significant inverse 
correlation between TAC C0 and p38MAPK phosphorylation in CD3+ T-lymphocytes was 
found for TACBID (rs = -0.638, p <0.05, Figure 1D), but not for TACOD (rs = -0.375, p=0.230, 
Figure 1D).
DISCUSSION
P38MAPK phosphorylation potential increases significantly after 1:1 conversion from 
TACBID to TACOD, despite an unchanged TAC whole-blood C0. This observation suggests 
that measuring p38MAPK phosphorylation is a more sensitive method to measure TAC 
therapy compared with conventional pharmacokinetic TDM.
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figure 1. Decreased Tac blood C0 after conversion from TACBID to TACOD lead to increased concen-
trations of p38 phosphorylation.
A) Tac C0 in kidney transplant patients before and 3 months after conversion from TACBID to TACOD B) 
Dot plots demonstrating the selection of lymphocytes and the CD3+CD4+ and CD3+CD8+ lympho-
cytes subsets from whole blood samples. The histograms show the p38 phosphorylation for each 
subset after PMA/Ionomycin stimulation of whole blood for 30 min. C) P38 phosphorylation per cell 
before and 3 months after conversion from TACBID to TACOD in CD3+CD4+ (left panel) and CD3+CD8+ 
(right panel) T-lymphocytes. D) Correlation between p38 phosphorylation per cell and TACBID C0 (left 
panel) or TACOD C0 (right panel) in CD3+ T-lymphocytes. FSC, forward scatter; SSC, side scatter (n=12).
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In this study whole-blood single-cell phospho-specific flowcytometry was used to mea-
sure p38MAPK phosphorylation at the single cell level. This technique was earlier used 
by Nolan et al. who investigated the consequences of growth factor treatment on the pro-
files of cancer cell signaling networks of T-lymphocytes in tumor immunology.8 Measuring 
the p38MAPK phosphorylation is an advantage over the classical pharmacodynamical 
parameter IL-2 as the phosphorylation concentration in contrast to cytokine concentra-
tions shows the upstream effects in the signaling cascade and consequently may be 
better linked to clinical outcomes specific for TAC therapy. In addition, phosphorylation 
of molecules is a rapid process and can be measured with single-cell phospho-specific 
flow cytometry in whole-blood T-lymphocyte subsets within hours.4,9
It has been reported that TACOD has the same safety and efficacy profile as TACBID.10-13 
However, these observations were made in a group of patients whereby the clinical 
outcome for an individual person can be different. Furthermore, the use of TACOD has 
been associated with clinical benefit, including improved adherence, a flatter PK profile 
and better glycemic control.14 Nonetheless, C0 may drop considerably after conversion 
from TACBID on a 1:1 basis in individual patients and close monitoring of TAC exposure 
after switching is recommended.14-16 In the conversion trial, of which the present study 
was a sub-study, one patient did indeed experience a late acute cellular rejection that 
was associated with a marked drop in TAC exposure: TAC C0 decreased from 6,9 ng/ml 
immediately before conversion to 3,6 ng/ml shortly after conversion.7
Increased concentrations of p38MAPK phosphorylation have been associated with more 
T-lymphocyte activation17 and consequently may in theory result in a higher risk of acute 
cellular rejection for kidney transplant patients.18 Despite this non-significant change in 
TAC exposure, a significant 11.8% increase in p38MAPK phosphorylation expression was 
observed demonstrating the high sensitivity of this assay. The present finding suggests 
that conversion to TACOD alters exposure to the drug and that this may translate into 
a change in biologic effect which is not detected by routine C0 monitoring. Although 
it could be better to measure the AUC instead of C0, this will also not show the direct 
biological effects of a drug.
In addition, these results suggest that both CD4+ and CD8+ T-lymphocytes are less sup-
pressed in their activation potential after conversion. This could indicate that patients 
have a higher risk for rejection after conversion. In order to test the usefulness of the 
current phospho-specific flow cytometry assay in the assessment of rejection risk, 
phosphorylation concentrations of peripheral blood samples from patients with biopsy 
proven rejection should be compared to samples from patients without rejection.
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A limitation of this study is that TAC C0 was measured with an immunoassay, which not 
only measures the parent compound but also cross-reacts with several TAC metabolites. 
Nonetheless, although measurement of TAC concentrations by LC-MS has increased, 
many transplant centers throughout the world still rely on immunoassays. Second, we 
tested only a limited number of patients. Therefore, the present findings should be 
interpreted with caution and be considered as hypothesis-generating.
In the future, it can be interesting to determine the risk of rejection during TAC therapy in 
kidney transplant patients with the help of phospho-specific flow cytometry. This phar-
macodynamical approach could detect the risk of rejection in a more sensitive way than 
the standard pharmacokinetic method. Furthermore, the assessment of the p38MAPK 
phosphorylation concentrations is a fast method for therapeutic drug monitoring of 
TAC and can be used to consider dose adjustment during therapy, although there is no 
significant difference observed in C0. This will lead to a more personalized TAC therapy 
for kidney transplant patients.
Other signaling proteins that are members of the MAPK pathway, such as ERK, can be 
included in the analysis to find the optimal biological marker for patient monitoring after 
TAC conversion. Furthermore, it will be essential to start a longitudinal study to investi-
gate the long-term effects of TAC conversion on p38MAPK phosphorylation to assess the 
phosphorylation concentrations change over time and to define if this change is related 
to a higher risk for rejection.12
CONCLUSION
Conversion from TACBID to TACOD is associated with a significant increase in p38MAPK 
phosphorylation concentrations which was not reflected by TAC whole-blood exposure 
as determined by C0. Measurement of p38MAPK phosphorylation status may be a more 
sensitive way to assess the biological effects of TAC.
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ABSTRACT
Background: The aim of this study was to investigate whether pre-transplant tacrolimus 
(Tac) dose requirements of patients scheduled to undergo living donor kidney transplan-
tation correlate with post-transplantation dose requirements.
Method: The predictive value of Tac dose requirements (defined as the ratio of the Tac 
predose concentration, C0, divided by the total daily Tac dose, D) pre-transplantation on 
this same parameter post-transplantation was assessed retrospectively in a cohort of 57 
AB0-incompatible kidney transplant recipients. These patients started immunosuppres-
sive therapy 14 days before transplant surgery. All patients were using a stable dose of 
glucocorticoids and were at steady-state Tac exposure before transplantation.
Results: Tac dose requirements immediately before transplantation (C0/Dbefore) explained 
63% of the Tac dose requirements on day 3 post-transplantation: r2 = 0.633 (F (1, 44) = 
75.97, p <0.01). No other clinical and demographic variables predicted Tac dose require-
ments early after transplantation.
Conclusion: Steady-state Tac dose requirement before transplantation largely predicted 
post-transplantation Tac dose requirements in AB0-incompatible kidney transplant 
recipients. The importance of this finding is that the post-transplantation Tac dose can 
be individualized based on a patient’s pre-transplantation Tac concentration/dose ratio. 
Pre-transplant Tac phenotyping therefore has the potential to improve transplantation 
outcomes.
Keywords: Dose requirement, kidney transplantation, tacrolimus.
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INTRODUCTION
In many transplant centers, the starting dose of tacrolimus (Tac) is based on a patient’s 
bodyweight. Following the first few dosages, whole-blood Tac concentrations are mea-
sured and followed by dose-adjustments in order to reach and maintain the targeted 
predose concentration (C0).1,2 Therapeutic drug monitoring (TDM) is currently the only 
way to prevent under- or overexposure to Tac. However, this approach is based on `trial 
and error´ and has no predictive value.3 In fact, in the early phase after transplantation, 
many patients have Tac concentrations outside the target range, putting them at risk for 
rejection or toxicity.2
Knowledge of the pharmacokinetics (PK) of Tac in a patient obtained before transplanta-
tion may be helpful in personalizing Tac therapy. Several investigators have attempted 
to predict an individual’s response to calcineurin inhibitor (CNI) treatment after trans-
plantation. Lindholm et al. evaluated ciclosporin (CsA) PK in patients before kidney 
transplantation by giving them a single oral and intravenous dose. In this study, pre-
transplant bioavailability and clearance of CsA correlated poorly with post-transplant CsA 
exposure.4 Likewise, Boots et al. observed that there is a poor correlation between Tac 
exposure after oral administration of a single dose prior to surgery and the required Tac 
dose after transplantation.5 Finally, Campbell et al. found no difference in the proportion 
of patients reaching the target Tac C0 (>10 ng/mL) in the first days post-transplantation 
when dosing was either based on bodyweight or the pre-transplant 2-hour post-dose 
(C2) concentration.6
These poor correlations between pre-transplant and post-transplant CNI exposure may 
be explained by post-operative changes in intestinal motility (e.g. ileus), hepatic me-
tabolism, and diet. They may also be explained by the fact that in all above-mentioned 
studies, PK parameters were assessed after single-dose administration and the patients 
were therefore not in steady-state. Finally, the use of interacting medication such as 
glucocorticoids and antibiotics, may have obscured a correlation between pre- and post-
transplant PK.7
In our transplant program, Tac treatment is not started prior to transplantation except in 
patients scheduled to receive a blood group AB0-incompatible (AB0i) kidney transplant. 
In this population, treatment with Tac, mycophenolate mofetil (MMF), and prednisolone 
is routinely started two weeks before transplant surgery and TDM is performed during 
this time. These patients are thus in steady-state at the time of surgery and the effects of 
glucocorticoids on Tac PK may not change much after transplantation.
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The primary aim of this study was to investigate whether pre-transplant Tac dose require-
ments in AB0i kidney transplant recipients predicts post-transplant dose requirements. 
The secondary aim was to assess the incidence of immunosuppressive drug-related 
adverse events (AEs) prior to transplantation.
PATIENTS AND METHODS
The AB0i kidney transplant program of the Erasmus MC started in 2006. The clinical results 
of this program were reported previously.8 For the present retrospective study, all consecu-
tive patients who received an AB0i kidney transplant up until May 29th, 2013 were included. 
Data were retrospectively collected. Patients needed to be an adult (≥18 yrs.) and to receive 
an AB0i kidney. Patients who used Tac interacting drugs at time of initiation of immunosup-
pressive (14 days before transplantation) therapy were excluded from the study.
Immunosuppressive regimen
Our protocol for AB0i kidney transplantation was published recently.8 In brief, patients 
were treated as follows:
Before transplantation: All patients received a single-dose of rituximab (Mabthera®, 
Roche Pharmaceuticals, Nutley, New Jersey, U.S.A.) intravenously at a dose of 375 mg/
m2 body surface area, four weeks before the scheduled transplant surgery. Two weeks 
before transplantation, treatment with Tac (Prograf; Astellas Pharma, Leiden, The Nether-
lands) with a starting dose of 0.1 mg/kg (based on actual body weight) twice daily with a 
dosing interval of 12 hours, MMF (Cellcept®, Roche Pharmaceuticals; 1000 mg bid), and 
prednisolone 20 mg once daily were started. Tac was targeted to a C0 of 10-20 ng/mL. 
The day before transplantation, after the last immunoabsorption, all patients received 
0.5 g/kg human immunoglobulin intravenously (Nanogam®, Sanquin, Amsterdam, the 
Netherlands).
After transplantation: On days 0, 1, and 2 all patients received prednisolone intravenously 
at a dose of 50 mg twice daily. Thereafter, patients received 20 mg of prednisolone daily 
for the first two weeks, and subsequently prednisolone was tapered to 5 mg at month 3. 
Treatment with Tac was continued aiming for a C0 of 10-20 ng/mL (weeks 1 and 2) and 
5-12 ng/mL, thereafter. MMF was continued at a dose of 1000 mg twice daily for the first 
two weeks post-transplant.
Immunoabsorption: Immunoabsorption was performed using a specific adsorption col-
umn for anti-A or anti-B antibodies (Glycorex Transplantation AB, Lund, Sweden) aiming 
for an anti-donor blood group IgG antibody titer of <1:8 the day before transplantation. 
The number of immunoabsorptions ranged from 0 to 7 depending on the titer of anti-
donor blood group antibodies and the rebound after every session.8
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Pharmacokinetic and Efficacy endpoints
In all patients, Tac dose and Tac C0 at days -7 and -1 (before) and days 3, 7, 10, 14, and 
30 (after transplantation) were retrospectively collected. Dose-corrected Tac C0 (hereafter 
“dose requirement”) was calculated by dividing C0 by the corresponding Tac dose (mg/day).
Immunosuppressive drug-related AEs
Adverse events considered to be related to the use of immunosuppression before trans-
plantation were a) any infection; b) diarrhea or other gastrointestinal side effects not 
otherwise explained; and c) neurologic events including headache and tremor.
Therapeutic drug monitoring
Pre-transplantation Tac C0 was measured starting 4-7 days after the initiation of treat-
ment. Tac C0 was determined after at least 5 unchanged Tac doses (the mean half-life of 
Tac is 12 hrs),9 and were therefore considered to represent steady-state concentrations. 
After transplantation, Tac C0  was routinely measured three times weekly. The attending 
physicians could change the daily Tac dose based on the achieved Tac C0 and/or the 
clinical situation of the individual patient. No Bayesian prediction tools were used.
Tac C0 values were determined throughout the study period in whole-blood by use of 
the ACMIA-Flex assay (Siemens HealthCare Diagnostics, Inc., Newark, DE) on a Dimension 
XPand (Siemens HealthCare Diagnostics, Inc, Newark, DE). The upper and lower detection 
limits of this assay were >30 and <1.5 ng/mL, respectively. When a Tac concentration of 
<1.5 ng/mL was measured, a value of 0.75 ng/mL was imputed (half the lower detection 
limit); Tac concentrations of >30 ng/mL were set at 30 ng/mL for calculation purposes.
Statistical analysis
Statistical analyses were performed using Statistical Program of Social Sciences version 
20 (SPSS Inc., Chicago, Ill., USA). Data distribution was assessed by the Kolmogorov-
Smirnov test. As the distribution was mostly skewed, the log-transformed data were 
used for the statistical analysis. For reasons of clarity, however, the data are presented as 
median (range) in the results section. Comparison of proportions of patients who were 
within the target Tac range before (day -1) and after transplantation was undertaken us-
ing Chi-squared or Fisher’s exact tests, as appropriate. The differences in PK parameters 
between time points were analyzed with one-way repeated measurements ANOVA 
analysis. Correlation between pre- and post-transplant Tac dose requirements was ana-
lyzed by calculating the bivariate Pearson correlation coefficient r. The predictive value 
of pre-transplant Tac dose requirements was then analyzed by multiple linear regression 
analysis in which several other clinical variables were included. Statistical significance 
was defined as a 2-tailed p ≤ 0.05.
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RESULTS
A total of 60 patients received an AB0i renal transplant between March 2006 and May 
2013. For the present analysis, 57 patients were included and 3 were excluded. One 
patient was treated with CsA rather than Tac, and in two patients, no pre-transplantation 
Tac C0 were available. The patient characteristics are presented in Table 1. The patient 
population was predominantly Caucasian (86.0%) and male (61.4%). Their median age 
at the time of transplantation was 57 years.
Table 1. Patient characteristics.
Number of subjects (%)
Gender:
Male / Female 35 (61.4) / 22 (38.6)
Age at the time of transplantation (yr): 57 (19-74)
Ethnicity:
Caucasian 49 (86.0)
Black 4 (7.0)
Asian 3 (5.3)
Other 1 (1.8)
Primary kidney disease:
Polycystic kidney disease 13 (22.8)
Glomerulonephritis 11 (19.3)
Hypertensive nephropathy 11 (19.3)
Reflux disease / Chronic pyelonephritis 4 (7.0)
Diabetic nephropathy 3 (5.3)
Other 12 (21.1)
Unknown 3 (5.3)
Number of kidney transplantation:
1st / 2nd / 3rd 48 (84.2) / 8 (14.0) / 1 (1.8)
Donor type:
Living-Related / Living-Unrelated 22 (38.6) / 35 (61.4)
Blood group acceptor:
A / B / AB / 0 9 (15.8) / 9 (15.8) / 1 (1.8) / 38 (66.7)
Blood group donor:
A / B / AB 33 (57.9) / 14 (24.6) / 10 (17.5)
Renal replacement therapy:
Hemodialysis 22 (38.6)
Peritoneal dialysis 21 (36.8)
Pre-emptive 14 (24.6)
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Tac treatment was started on day -14 ± 2 before transplantation in 54 (94.7%) subjects. 
In two patients (3.5%) immunosuppressive treatment was also started 14 days before 
the scheduled transplantation date but due to medical reasons, surgery was postponed, 
leading to a longer use of immunosuppressive drugs in the period before transplantation 
(26 and 28 days; see below). In one case, immunosuppressive therapy was started 19 
days before transplantation.
A total of 156 C0 were measured between day -14 and 0, of which 119 were steady-
state concentrations. Because most steady-state C0 were measured approximately one 
week and one day before transplantation, only days -7 ± 3 and day -1 were analyzed for 
this study. Steady-state C0 values were available at these two time points for 39 and 53 
patients, respectively.
Table 2 depicts the PK parameters pre- and post-transplantation. Compared with the 
pre-transplant value on day -1, a significant increase in Tac C0 and C0/D at day 3 post-
transplantation was observed: 12.4 vs. 15.4 ng/mL (24.0% change) and 1.17 vs. 1.28 ng/
mL per mg/kg per day (9.4% change), respectively (both p < 0.01). The Tac daily dose 
remained stable between day -1 and day 3. There was a significant decrease in the daily 
dose of Tac, Tac C0, and C0/D by day 30 compared with the early post-transplant phase 
(Table 2). Figure 1 shows the individual changes in Tac C0/D before transplantation and 
on the third day after transplantation. Despite the occurrence of a statistically significant 
increase in the median C0/D, dose requirements did not change to a clinically relevant 
degree. In fact, as can be seen from Figure 1, two patients were outliers (C0/D >1.5 in-
terquartile range (IQR)). When these patients were excluded, the change in the Tac dose 
requirements was no longer significant.
Table 2. Dose and concentration data pre- (days -7 and -1) and post-transplantation. All values are 
expressed as median (range).
Day (-7)
n = 39
Day (-1)
n = 53
Day (3)
n = 50
Day (7)
n = 42
Day (10)
n = 50
Day (14)
n = 49
Day (30)
n = 57
Dose (mg/day) 12.0 
(2.0-28.0)
12.0
(4.0-20.0)
12.0
(3.0-28.0)
12.0
(0.0-30.0)
12.0
(1.5-34.0)
12.0
(2.0-34.0)
10.0
(2.5-36.0)*
C0 (ng/mL) 13.6
(0.8-30.0)
12.4
(5.2-30.0)
15.4
(7.1-30.0)**
11.7
(3.9-30.0)***
14.0
(1.7-28.7)
13.9
(4.6-25.5)
11.8
(4.4-29.4)***
C0/D (ng/mL per mg/
day)
1.10
(0.05-3.40)
1.17
(0.34-3.20)
1.28
(0.44-5.85)¥
1.12
(0.37-6.13)¥ ¥
1.13
(0.28-6.40)
1.08
(0.29-6.45)
1.25
(0.29-4.53)¥
* significant decrease compared with day -1 p < 0.01 and day 3 p < 0.01
** significant increase compared with day -1 p < 0.01
*** significant decrease compared with day 3 p < 0.01
¥ significant increase compared with day -1 p < 0.01
¥ ¥ significant decrease compared with day 3 p < 0.05
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On the day before transplantation, 30 (52.6%) patients were within the target Tac C0 
range of 10-20 ng/mL. Fifty-three percent (n = 16) of these patients remained so at day 
3 after transplantation, whereas 30.0% (n = 9) were above and 3.3% (n = 1) were below 
the Tac target C0 range. For 13.3% (n = 4) of patients Tac C0 values were not available on 
day 3 after transplantation. Overall, there were 34 (59.6%) patients who were on target 
at day 3 after transplantation. The proportion of patients on target before transplantation 
(day -1) was not different from that on day 3 after transplantation (χ2 = 0.081 (n = 46); p 
= 0.77; phi = -0.09).
Correlation between pre- and post-transplantation Tac exposure
Tac dose-corrected C0 on the day before transplantation (C0/Dbefore) had a significant 
influence on the Tac C0/D measured on day 3 after transplantation. The correlation 
between Tac C0/D on days -1 and 3 was substantial (r = 0.80; p <0.01). The coefficient 
of determination (r2) was 0.633 (F (1, 44) = 75.97, p < 0.01). Therefore, 63.3% of the Tac 
dose requirements on day 3 after transplantation was explained by C0/Dbefore (Figure 2). 
Tac C0/D on day -1 also correlated with that on day 7 (r2 = 0.76; p < 0.01). With increasing 
time after transplantation this correlation became less substantial, although it remained 
significant: r2 = 0.45, 0.52, and 0.42 (day -1 vs. days 10, 14, and 30 after transplantation, 
respectively; all p < 0.01). Of the 340 samples analyzed only 5 had a Tac concentration 
>30.
Age, gender, bodyweight, creatinine clearance, hematocrit and albumin concentration 
(measured on the day before transplantation) did not correlate with Tac C0/D post-
transplantation.
Previous research suggested that Tac PK is influenced by hematocrit and albumin concen-
tration.10 Therefore, it was decided to perform multiple regression analysis incorporating 
hematocrit and albumin concentrations despite the fact that correlation analyses showed 
figure 1. The individual changes of Tac C0/D be-
fore and after transplantation. The single aster-
isks represent the outliers (more than 1.5 tomes 
the IQR) and the double asterisks represent the 
extreme outliers (more than 3 times the IQR).
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no significant correlation coefficients for both variables. Sequential multiple regression 
was performed to determine if addition of these variables improved prediction of C0/D 
after transplantation, beyond that afforded by Tac C0/Dbefore. Hematocrit (mean 0.32 ± 
0.05 L/L) and albumin (mean 35 ± 4 g/L) concentrations were found not to predict a sig-
nificant amount of the variance in Tac dose requirements on day 3 post-transplantation 
(data not shown).
Immunosuppressive drug-related AEs
During the pre-transplantation treatment phase, gastrointestinal complaints, particu-
larly diarrhea, were the most frequently reported drug-related AE and occurred in 17 
(29.8%) patients. One elderly patient had severe diarrhea requiring hospitalization 
and intravenous rehydration. The incidence of pre-transplant infections was low (n = 
2, 3.5%). One week before the scheduled transplantation, one patient suffered from 
peritoneal dialysis-associated peritonitis. This required temporary discontinuation of 
immunosuppressive drug treatment (the Tac concentration was >30.0 ng/mL at the time 
of diagnosis) and antibiotic treatment. The second patient had a respiratory tract infec-
tion which necessitated postponement of the transplantation and oral antibiotic therapy. 
Immunosuppressive therapy before transplantation was associated with neurological 
AEs in 9 patients (15.8%). Four patients (7.0%) suffered from headache and 7 patients 
(12.3%) experienced tremor. Tac concentrations exceeded the therapeutic range (>20.0 
ng/mL) in 3 of these 9 patients. Three of these patients had Tac concentrations within the 
therapeutic window and in three patients Tac concentrations were <10 ng/mL.
figure 2. Log-transformed Tac dose-corrected C0 (C 0/D) on day -1 before transplantation vs. log-
transformed Tac C0/D on day 3 after transplantation. The slope of the regression line is not zero (β 
= 0.70; p < 0.01) and therefore, the pre-transplantation Tac C0/D is useful as a predictor of Tac dose 
requirements after transplantation (A). Tac C0/D on day -1 before transplantation vs. Tac C0/D on day 
3 post-transplantation: β = 0.90; p < 0.01(B).
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DISCUSSION
This study demonstrates that Tac dose requirements before transplantation correlate 
strongly with dose requirements early after transplantation and explain 63% of the 
variation in dose requirements on post-operative day 3. These data show that therapy 
with Tac before transplant surgery can provide useful information on what dose of Tac is 
needed to reach the Tac target concentrations in the immediate post-operative period.
These findings contrast with the observations of the only two published reports that 
tried to answer the same question. Boots et al., found a poor correlation between pre-
transplant Tac exposure (abbreviated AUC) after a single oral dose and Tac doses required 
to achieve a C0 of 10 ng/mL after transplantation.5 Contrary to Boots et al., in connection 
with the retrospective design of this study, we chose to evaluate Tac exposure using 
C0 because of reports demonstrating a significant correlation between AUC0-24 and C0 
and because Tac C0 is the TDM parameter that is used most frequently in the clinical 
practice.1,11 Campbell et al., found no difference in the proportion of patients reaching 
the Tac target shortly after transplantation between a group of patients who received a 
standard, bodyweight-based Tac starting dose and a group in which the starting dose was 
based on a pre-transplant C2 obtained after a single test dose. The latter group, however, 
did reach the target Tac concentration significantly faster.6
This discrepancy may be attributed to the fact that the patients in previous studies 
were not in steady-state, whereas in our cohort of AB0i patients, Tac concentrations 
were determined after at least five stable dosages (which corresponds to five times the 
half-life of Tac). In addition, the post-operative inducing effect of glucocorticoids on the 
metabolizing cytochrome P450 enzyme system7 may not have had an important impact 
in our study as our patients had been using a stable and pharmacologically relevant 
prednisolone dose for two weeks prior to transplantation. In the studies by Boots5 and 
Campbell6 that were performed in the pre-transplant setting, no glucocorticoids were co-
administered, whereas their patients did receive glucocorticoids after transplant surgery.
Interestingly, although the Tac starting dose is based on bodyweight is routine practice in 
many transplant centers, including our own, bodyweight was not found to be a covariate 
predicting Tac dose requirements. This is in line with the observations of Press et al. who 
concluded that there is no rationale for bodyweight-based Tac dosing, and that early 
under- and overexposure could be related to low and high bodyweight, respectively.12 
Whether or not initiation of Tac treatment one or two weeks prior to transplantation 
will result in improved outcome compared to starting immunosuppression on the day 
of surgery has not been investigated in randomized-controlled trials. This is remarkable 
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as the potential contribution of reaching the target levels as soon as possible, as well as 
already suppressing the immune system before transplantation, to improved transplan-
tation outcome may be substantial.
Despite the fact that Tac dose requirement is strongly correlated with CYP3A5 geno-
type,13,14 this variable was not studied because recipient DNA was only available for 63% 
of the (largely Caucasian) study population, thereby precluding a meaningful analysis. 
Another limitation of the present study is the fact that an immunoassay was used to mea-
sure Tac concentrations. This assay is known to cross-react with Tac metabolites and this 
may have influenced the results.15,16 However, the same Tac assay was used throughout 
the study as part of standard clinical care and any analytical bias likely influenced the Tac 
concentrations before and after surgery would be expected to occur to the same degree. 
Moreover, a good correlation was observed between pre- and post-transplantation Tac 
concentrations. It is doubtful that this correlation would have been weaker if more ad-
vanced analytical techniques such as mass spectrometry, would have been used.
A strong correlation between pre- and post-transplant Tac dose requirements existed. 
Therefore it may be argued that by basing the Tac starting dose on pre-transplant, steady-
state exposure (obtained after repeated test doses) rather than starting Tac (based on 
bodyweight) at the time of transplant surgery, one may be able to avert supra-therapeutic 
Tac concentrations (and possibly toxicity) and prevent under-exposure (and possibly 
rejection). However, a randomized-controlled clinical trial would be needed to answer 
this question. Such a strategy of pre-transplant Tac dose requirement phenotyping is 
a feasible strategy both for patients scheduled to undergo living donor kidney trans-
plantation, as well as for patients that are waitlisted for a deceased donor transplant. 
In addition, it is a more direct strategy to asses Tac dose requirement as compared with 
pre-transplant CYP3A phenotyping using a probe drug as suggested by others.10
However, the patients described here, were also treated with prednisolone in addition to 
Tac in the two weeks prior to transplantation. It may well be that when a pre-transplant 
immunosuppressive regimen without glucocorticoids is prescribed, the correlation of the 
Tac dose requirements in the pre- and post-transplant (with glucocorticoids) period will 
be less substantial. There is considerable evidence that glucocorticoids influence Tac 
PK.17 Therefore, our results cannot be extrapolated to a setting with a glucocorticoid-free 
pre-transplant immunosuppressive regimen. Another caveat is the fact that only blood 
group AB0i kidney transplant recipients were studied here. We feel however, that the 
results may also apply to blood group AB0 compatible kidney transplant recipients, 
provided they receive a similar pre-transplantation immunosuppressive regimen.
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An alternative strategy could be to start immunosuppression pre-emptively and to 
perform TDM in the 1-2 weeks before transplant surgery, rather than base the Tac 
starting dose (started on the day of surgery) on several pre-transplant test doses. This 
would of course only be feasible in the living kidney donor setting. The present find-
ings suggest that such a strategy may be safe as the number of severe AEs occurring in 
the pre-transplant phase was low, and gastro-intestinal and neurological toxicity are to 
be expected when prescribing Tac and MMF. Nonetheless, two patients suffered from 
serious infections which necessitated temporary discontinuation of immunosuppression 
and led to postponement of transplant surgery. In addition, one elderly patient required 
hospitalization because of severe diarrhea. Of the 57 patients in this study, 14 were 
transplanted pre-emptively. In none of the latter patients, did the initiation of Tac cause 
severe hyperkaliaemia or a deterioration of renal function necessitating dialysis. Again, 
a randomized-controlled clinical trial will be necessary to establish whether the possible 
benefits of such a pre-emptive immunosuppression strategy outweigh the risks.
In conclusion, steady-state, pre-transplant Tac dose requirements strongly correlated 
with post-transplant dose requirements. Using pre-transplant Tac dose and concentration 
data, one may be able to predict Tac exposure after transplantation and limit sub -and 
supratherapeutic exposure. Whether such a strategy will also improve clinical outcomes 
needs to be addressed in a prospective study.
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ABSTRACT
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus 
dose to achieve therapeutic exposure compared with non-expressers. This randomized-
controlled study investigated if adaptation of the tacrolimus starting dose according to 
CYP3A5 genotype increases the proportion of kidney transplant recipients being within 
the target tacrolimus predose concentration range (10-15 ng/mL) at first steady-state. 
Two hundred forty living-donor, renal transplant recipients were assigned to either 
receive a standard, bodyweight-based or a CYP3A5 genotype-based tacrolimus starting 
dose. At day 3, no difference in the proportion of patients having a tacrolimus exposure 
within the target range was observed between the standard-dose and genotype-based 
groups: 37.4% vs. 35.6%, respectively; p = 0.79. The proportion of patients with a sub-
therapeutic (i.e. <10 ng/mL) or a supra-therapeutic (i.e. >15 ng/mL) Tac C0 in the two 
groups was also not significantly different. The incidence of acute rejection was com-
parable between both groups (p = 0.82). Pharmacogenetic adaptation of the tacrolimus 
starting dose does not increase the number of patients having therapeutic tacrolimus 
exposure early after transplantation and does not lead to improved clinical outcome in a 
low immunological risk population.
This study was registered in the Dutch national trial registry (number NTR2226).
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INTRODUCTION
Tacrolimus (Tac) is the cornerstone of immunosuppressive therapy after kidney trans-
plantation.1 The clinical use of Tac is difficult due to its toxicity, narrow therapeutic 
range, and highly variable pharmacokinetics between individuals.2 The exposure to Tac 
correlates with the expression and activity of the Tac-metabolizing enzymes cytochrome 
P450 (CYP) 3A4 and CYP3A5.3,4 These enzymes are polymorphically expressed which 
is in part explained by the presence of single-nucleotide polymorphisms (SNPs) in the 
CYP3A4 and CYP3A5 genes.5-8
A SNP at position 6986 of the CYP3A5 gene (rs776746; 6986A>G) causes a splicing 
defect resulting in the absence of functional CYP3A5 protein. Patients who are homo-
zygous for the 6986 G allele (designated as CYP3A5*3) are therefore expected to lack 
CYP3A5 activity.6 Renal transplant recipients (RTRs) carrying one or two CYP3A5*1 alleles 
(so called CYP3A5 expressers) require a significantly higher Tac dose compared with 
CYP3A5 non-expressers.9,10 In theory, the earlier therapeutic blood concentrations of Tac 
are attained after transplantation, the more effective the drug is likely to be in preventing 
acute rejection.11 The higher dose requirement of patients expressing CYP3A5 may cause 
a delay in reaching the desired Tac target concentrations. Therefore, these patients are at 
an increased risk of sub-therapeutic Tac exposure during the first weeks after transplan-
tation, and may be at higher risk to develop early acute rejection.12
The KDIGO Transplant Work Group stated that dosing of Tac is important but relatively 
under-investigated.11 Despite a statistically significant influence of CYP3A5 genotype on 
Tac dose requirement, patients on the waiting list for a kidney transplantation are not 
routinely genotyped for CYP3A5 in most transplant centers. Rather, patients receive a 
standard dose of Tac based on their bodyweight, and with a “trial and error” approach, 
target concentrations are reached by adjusting the dose based on repetitive concentra-
tion measurements, a practice known as therapeutic drug monitoring (TDM). The question 
is whether the implementation of technological advances such as pre-transplantation 
genotyping will benefit patient management.13
In this randomized-controlled trial, recipients of a living donor kidney transplant were 
randomized to receive a standard starting dose of Tac based solely on their bodyweight 
or to receive a starting dose of Tac based on their CYP3A5 genotype. The goal was to 
study whether CYP3A5 genotype-based Tac dosing leads to earlier achievement of Tac 
target whole-blood exposure and consequently, to a better clinical outcome after kidney 
transplantation.
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PATIENTS AND METHODS
Study design
This was an investigator-initiated, prospective, randomized-controlled, parallel group, 
open-label, single-centre, clinical trial. Adult patients (≥18 years) who were scheduled 
to receive a single-organ, blood group AB0-compatible kidney from a living donor at the 
Erasmus MC, Rotterdam, the Netherlands, were eligible for participation. Patients who 
received immunosuppressive drug treatment within 28 days prior to transplantation 
(except glucocorticoids) and/or used any drugs known to interact with Tac at the time of 
transplantation (see supplementary Table 1 for the list of these drugs) were not included 
in the study.
The study was approved by the institutional review board of the Erasmus MC (Medical 
Ethical Review Board number 2010-080) and was registered in the Dutch national trial 
registry (http://www.trialregister.nl/trialreg/index.asp; number NTR2226, registered 25 
Feb. 2010). Written informed consent was obtained from all patients before inclusion 
and randomization. The study was carried out in compliance with the Good Clinical 
Practice guidelines.
Intervention and randomization procedure
Patients were enrolled and randomly assigned on a 1:1 basis by one of the coordinating 
investigators (R.B., N.S., T.v.G., or D.A.H.) to either receive Tac (Prograf®; Astellas Pharma, 
Leiden, the Netherlands) in a standard, bodyweight-based dose (SDG) of 0.2 mg/kg/day 
according to the package insert14 or to receive a dose determined by their CYP3A5 geno-
type (GBG): CYP3A5 expressers (i.e. carriers of one or two CYP3A5*1 alleles) received 0.30 
mg/kg/day, whereas CYP3A5 non-expressers (CYP3A5*3 homozygotes) received 0.15 
mg/kg/day. The Tac dose was rounded off to the nearest 0.5 mg to enable twice daily oral 
dosing of an equal dose. The first dose of Tac was administered at 22:00 hr on the night 
following transplant surgery. During hospitalization, Tac was taken at 10:00 and 22:00 hrs 
and patients were encouraged to continue doing so after discharge. The randomization 
was performed by use of sealed, opaque, sequentially-numbered envelopes containing 
treatment allocation. The random-allocation sequence was generated by an independent 
statistician by use of a random number generator on a computer. If a patient was assigned 
to the CYP3A5 GBG, the individual’s CYP3A5 genotype was revealed to the treating physi-
cian by an employee of the clinical chemistry department of the Erasmus MC where the 
genotyping was performed (see below). The clinical physicians were not aware of the 
CYP3A5 genotype of patients in the SDG. Data were collected, monitored and entered by 
the coordinating investigators, and stored in a hospital-based electronic study database.
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Additional (immunosuppressive) treatment
The additional immunosuppressive therapy was identical in both groups and consisted of 
basiliximab (Simulect®, Novartis Pharma B.V., the Netherlands) in a dose 20 mg adminis-
tered intravenously on day 0 (immediately before kidney transplant reperfusion) and day 
4 after transplantation. Patients also received a starting dose of 1000 mg mycophenolate 
mofetil (MMF; CellCept®, Roche Pharmaceuticals, the Netherlands) twice daily aiming 
for plasma mycophenolic acid (MPA) pre-dose concentrations (C0) between 1.5 and 3.0 
mg/L. Prednisolone treatment consisted of an intravenous dose of 50 mg twice daily on 
days 0-3, followed by 20 mg orally once daily (on days 4-14), after which the dose was 
tapered to 5 mg at month 3 after transplantation. All patients received trimethoprim/
sulfamethoxazole prophylaxis for pneumocystis jirovecii pneumonia for at least three 
months. All patients receiving a kidney from a cytomegalovirus (CMV) positive donor and 
all patients who were seropositive for CMV received prophylaxis with valganciclovir for 
a duration of six months.
Endpoints
The primary endpoint was the proportion of patients within the desired Tac whole-blood, 
C0 range of 10 – 15 ng/mL at first steady state, i.e. on the morning of day 3 after 5 un-
altered Tac doses. The Tac C0 was defined as the whole-blood concentration 12 ± 2 hrs 
after the previous dose taken the night before at 22:00 hrs. The exact time of Tac intake 
and C0 sampling were not recorded. Before C0 sampling on day 3, no TDM was performed. 
Hereafter, the clinicians could change the Tac dose based on the measured Tac exposure 
and/or the clinical situation of the individual patient in both treatment groups according 
to local protocol. In our transplant unit, the Tac C0 is routinely measured 3-times weekly 
during hospitalization and at every outpatient clinic visit. Clinicians were stimulated to 
use the following formula to calculate the new Tac dose:
New daily Tac dose = (Desired Tac C0 / Current Tac C0) x Current Tac dose
The pre-specified Tac C0 target range was 10.0 – 15.0 ng/mL in week 1-2, 8.0 – 12.0 ng/
mL in week 3-4, and 5.0 – 10.0 ng/mL after week 4 post-transplantation.
Secondary pharmacokinetic endpoints included the average Tac C0 during weeks 1 and 
2 after transplantation, the time required to reach the target C0 range, the number of Tac 
dose modifications needed to reach the target C0 range, and the number of markedly sub-
therapeutic Tac (arbitrarily defined as C0 <5.0 ng/mL) and markedly supra-therapeutic 
(defined as C0 >20.0 ng/mL) C0 measurements.
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Secondary clinical endpoints included the incidence of delayed graft function (DGF; 
defined as the need for dialysis within the first week after transplantation), the incidence 
of biopsy-proven acute rejection (BPAR), the incidence of clinically presumed acute 
rejection, and renal function at month 3 after transplantation. Biopsies were performed 
only for cause, were reviewed in a blinded fashion by two independent pathologists 
after the completion of the trial and were graded according to the most recent Banff clas-
sification of renal allograft rejection .15 Estimated glomerular filtration rate (eGFR) was 
calculated using the abbreviated MDRD study equation.16 Since the MDRD equation does 
not estimate GFR sufficiently accurately at values above 60 mL/min we capped the eGFR 
values at this level. All patients were followed for three months after transplantation or 
until graft loss occurred (defined as death with a functioning transplant, return to dialysis 
or re-transplantation).
Safety
The incidence of (serious) adverse events [(S)AE] was registered and these included (the 
cause of) death, graft loss, cancer, (opportunistic) infections, post-transplant diabetes 
mellitus (PTDM), neurologic events, and acute Tac-induced nephrotoxicity. PTDM was 
defined as the use of glucose-lowering medical therapy up until month 3 after trans-
plantation in a patient not needing such treatment before transplantation. Acute Tac 
nephrotoxicity was defined as any ≥15% increase of serum creatinine with a return to 
baseline after Tac dose reduction and after exclusion of other causes of renal transplant 
function deterioration.
Tacrolimus concentration measurement
Tac C0 was determined in whole-blood in the Nephrology & Transplantation labora-
tory of the Erasmus MC by use of two different immunoassays, the antibody-conjugated 
magnetic immunoassay (ACMIA) on a dimension platform (Siemens Healthcare, N.V., 
the Netherlands) and the enzyme multiplied immunoassay technique (EMIT; Siemens 
Healthcare N.V., the Netherlands). In the first two years (10/11/2010 to 04/12/2012) 
of the trial, Tac concentration measurements were measured exclusively by the ACMIA, 
after which measurements were performed exclusively by use of EMIT. As a result, 76% 
of the day 3 C0 measurements were determined by ACMIA and 24% by EMIT. The reason 
for the forced change in assay was the world-wide shortage of reagents approved by the 
manufacturer with sufficient patient sample recovery.
Comparison of the ACMIA and EMIT immunoassays demonstrated a high correlation (r = 
0.965). The measurements obtained with EMIT were systematically ~15% higher than 
those obtained with ACMIA. The lower limits of detection were 1.5 ng/mL (ACMIA) and 2.0 
ng/mL (EMIT). The upper limit of detection was 30 ng/mL. For calculation purposes, Tac 
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C0 below the detection limit were set at half the detection limit (0.75 and 1.0 ng/mL, for 
ACMIA and EMIT, respectively). Tac C0 above the detection limit were set at 30 ng/mL. The 
laboratory participates successfully in the United Kingdom Quality Assessment Scheme 
(Dr. Holt, St George’s Hospital Medical School, London, UK).
DNA extraction and genotyping
DNA was extracted from peripheral blood leukocytes using the Blood DNA kit (Qiagen, 
Courtaboeuf, France) in accordance with standard protocols. Genotyping of the CYP3A5*3 
allele was performed using TaqMan Assay reagents for allelic discrimination (Applied 
Biosystems, Courtaboeuf, France) with a 7900 Applied Biosystems thermal cycler as 
previously described.9,17 All genotyping was performed in duplo according to quality 
standards of the International Federation of Clinical Chemistry and Laboratory Medicine.
Genotyping was performed during the work-up for transplantation as part of a biobanking 
programme that has been approved by the institutional review board of the Erasmus MC 
(Medical Ethical Review Board number 2010-022; approved June 21, 2010). All patients 
gave written informed consent for participation in this biobanking programme.
Statistical analysis
A study population of 196 patients (98 patients per treatment arm) was considered suf-
ficient to provide a statistical power of 80% to detect a difference between the two 
groups in the proportion of patients within the target Tac C0 on day 3 after transplanta-
tion, on the basis of a two-sided test and a significance level of 5%, assuming a 40% 
incidence of the primary end point in the SDG and a 20% increase of this value in the 
GBG. Taking a 20% drop-out rate into account, a total of 240 patients was included in the 
study. No interim analysis was planned.
For the analysis of efficacy, the intention-to-treat population was used, which included 
all randomized patients who were treated with at least one dose of Tac. Categorical vari-
ables are reported using frequency tables and percentages, and continuous variables 
are expressed as medians with ranges. A Chi-square statistic was used to evaluate the 
null hypothesis of no difference between the SDG and GBG in the proportion of patients 
within the Tac target C0 range on day 3 after transplantation. Continuous variables were 
compared between the groups using the Mann-Whitney U test. The time to reach the 
target Tac C0 range was estimated with Kaplan-Meier survival analysis, and compared 
between the groups using the Log Rank test. To estimate the overall effect of CYP3A5 
genotype on the outcome variables Tac daily dose, Tac C0 and dose-corrected Tac C0 (a 
measure for apparent oral clearance and hence, Tac dose requirement), a mixed between-
within subjects analysis of variance was used. This analysis was also used to estimate the 
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overall eff ect of dosing approach (standard, bodyweight-based dosing and genotype-
based dosing) on renal function. All tests were two-tailed and statistical signifi cance was 
defi ned as a p-value <0.05. Statistical analyses were performed using IBM SPSS version 
20 (SPSS Inc., Chicago, IL).
RESULTS
Patients
Between November 10, 2010 (fi rst patient, fi rst visit) and September 30, 2013 (last pa-
tient, fi rst visit) 571 patients were screened of whom 254 were eligible for participation 
(Figure 1). Fourteen patients did not wish to participate. Two-hundred-forty patients were 
included and randomized. After inclusion, one patient was not transplanted and did not 
receive Tac. In two cases, an inaccurate Tac starting dose was prescribed. These patients 
were considered to have protocol violations and were excluded from the analysis, result-
ing in a total of 237 patients for the intention-to-treat analysis. The characteristics of 
these patients are described in Table 1. The mean daily starting dose of Tac was 0.20 mg/
571 Screened 
254 Eligible patients 
Not included (n = 317) 
Deceased donor kidney transplantation (n = 179) 
AB0-incompatible kidney transplantation (n = 25) 
HLA-identical kidney transplantation (no basiliximab) (n = 28) 
Use of immunosuppressive drugs other than prednisolone (n = 34) 
No DNA available (n = 23) 
Use of interacting drugs (n = 17) 
Participation in other clinical trial (n = 2) 
Non-renal transplantation (n = 5)  
Re-transplanted and already participated in trial (n = 4) 
 
No informed consent (n = 14) 
  
  
119 Intention to treat Population  
115 Completed 3 months  
follow-up 
 
Death (n = 1) 
Graft loss (n = 3) 
  
  
118 Intention to treat Population 
116 Completed 3 months  
follow-up 
 
Lost to follow-up (n = 1) 
Graft loss (n = 1) 
  
  
240 Randomized  
Excluded 
Protocol violation (n =1) 
  
  
120 Standard-dose group 120 Genotype-based group 
 
Excluded 
Not transplanted (n =1) 
Protocol violation (n =1) 
  
  
figure 1. Trial fl owchart. All patients who underwent transplantation and received at least one dose 
of the study drug Tac were included in the intention-to-treat population.
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kg in the standard-dose group (SDG) and 0.19 mg/kg in the genotype-based group (GBG). 
One-hundred-fifteen (96.6%) patients in the SDG and 116 (98.3%) in the GBG group 
completed the 3-month follow-up period.
The minor allele frequency was 15.2% (Supplementary Table 2). The observed CYP3A5 
genotype distribution was in accordance with the Hardy-Weinberg equilibrium (χ2 = 
Table 1. Baseline characteristics.
Standard-dose group
(n = 119)
Genotype-based group
(n = 118)
p
Gender recipient
Male / Female 73 (61.3%) / 46 (38.7%) 75 (63.6%) / 43 (36.4%) 0.73
Age of recipient (years) 57 (19 – 79) 55 (19 – 79) 0.55
Ethnicity 0.89
Caucasian 93 (78.2%) 93 (78.8%)
Asian 13 (10.9%) 10 (8.5%)
Black 11 (9.2%) 12 (10.2%)
Other 2 (1.7%) 3 (2.5%)
Bodyweight (kg) 75.7 (37.6 – 132.0) 81.2 (43.6 – 123.1) 0.21
Length (cm) 173.0 (145.0 – 203.0) 174.0 (151.0 – 196.0) 0.77
BMI (kg/m2) 25.5 (17.2 – 37.8) 26.2 (18.1 – 42.2) 0.21
Primary kidney disease
Diabetic nephropathy 21 (17.6%) 23 (19.5%)
Polycystic kidney disease 17 (14.3%) 18 (15.3%)
Glomerulonephritis 16 (13.3%) 27 (22.6%)
Hypertensive nephropathy 16 (13.3%) 13 (11.0%)
Reflux disease / Chronic pyelonephritis 7 (5.8%) 6 (5.0%)
Other 6 (5.0%) 4 (3.2%)
Unknown 36 (30.3%) 27 (22.9%)
Number of kidney transplantation 0.46
1st 111 (93.3%) 107 (90.7%)
2nd 7 (5.9%) 9 (7.6%)
3rd 1 (0.8%) 2 (1.7%)
RRT* prior to kidney transplantation 0.55
Hemodialysis 46 (38.7%) 44 (37.3%)
Peritoneal dialysis 20 (16.8%) 24 (20.3%)
Pre-emptive 53 (44.5%) 49 (41.5%)
Donor type
Living-Related / Living-Unrelated 48 (40.3%) / 71 (59.7%) 47 (39.8%) / 71 (60.2%) 0.94
PRA%§ (<15% / ≥15%) 111 (93.3%) / 8 (6.7%) 109 (92.4%) / 8 (6.8%) 0.97
Peak PRA% (<15% / ≥15%) 100 (84.%) / 19 (16.0%) 93 (78.8%) / 24 (20.3%) 0.37
*RRT = Renal replacement therapy; §PRA = Panel reactive antibodies
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3.17; p = 0.075) and is comparable to the reported17 genotype distribution of a largely 
Caucasian population (Supplementary Table 3).
Efficacy
Primary endpoint
For 203 (85.7%) patients (99 patients in the SDG and 104 patients in the GBG) a Tac 
C0 was available on day 3 after transplantation. Most of the missing C0 at day 3 were 
samples that had to be collected on a Sunday. Given the predicted 20% drop-out rate, 
these samples provided sufficient statistical power to study the primary endpoint.
On day 3 after transplantation, the median Tac C0 was 13.3 ng/mL (2.6 – 30.0 ng/mL) in 
the SDG vs. 11.6 ng/mL (4.1 – 30.0 ng/mL) in the GBG (p = 0.047; Table 2). At this time 
point, 37 patients (37.4%; 95%-CI 28.5 – 47.0%) in the SDG and 37 patients (35.6%; 
Table 2. Tacrolimus dose, pre-dose concentration and dose-corrected pre-dose concentration ac-
cording to the treatment group.
Whole group Standard-dose group n Genotype-based group n
Tacrolimus dose (mg/day)
Day 3 14.0 (7.0 – 32.0) 15.0 (8.0 – 26.0) 119 13.0 (7.0 – 32.0) 117
Day 7 12.5 (0.0 – 32.0) 12.0 (0.0 – 26.0) 119 13.0 (4.0 – 32.0) 117
Day 10 12.0 (0.0 – 36.0) 11.0 (0.0 – 26.0) 117 12.0 (3.0 – 36.0) 117
Day 14 11.0 (0.0 – 36.0) 10.0 (1.0 – 30.0) 117 12.0 (0.0 – 36.0) 116
Day 30 9.0 (2.0 – 34.0) 8.0 (2.0 – 22.0) 115 10.0 (3.0 – 34.0) 118
Day 60 6.0 (0.0 – 34.0) 6.0 (0.0 – 18.0) 114 6.0 (0.0 – 34.0) 117
Day 90 5.5 (0.0 – 34.0) 5.0 (0.0 – 16.0) 114 6.0 (0.0 – 34.0) 116
Tacrolimus C0 (ng/mL)
Day 3 12.2 (2.6 – 30.0) 13.3 (2.6 – 30.0) 99 11.6 (4.1– 30.0) 104
Day 7 12.5 (5.0 – 30.0) 12.7 (5.4 – 30.0) 96 11.9 (5.0 – 30.0) 96
Day 10 11.8 (4.3 – 23.9) 12.1 (5.9 – 22·7) 79 11.5 (4.3 – 23.9) 89
Day 14 11.0 (5.1 – 19.9) 11.1 (5.1 – 19.9) 44 10.6 (5.6 – 18.3) 41
Day 30 9.6 (2.9 – 30.0) 9.3 (2.9 – 30.0) 104 10.3 (3.6 – 23.2) 114
Day 60 8.2 (3.3 – 20.3) 8.6 (3.3 – 20.3) 110 8.1 (3.8 – 19.7) 109
Day 90 7.6 (2.7 – 16.8) 7.5 (2.7 – 16.7) 103 7.9 (3.4 – 16.8) 110
Tacrolimus C0/dose (ng/mL per mg/kg)
Day 3 67.8 (13.8 – 195.3) 64·6 (13.8 – 162.0) 97 72.0 (23.4 – 195.3) 104
Day 7 74.9 (20.2 – 355.6) 76.0 (23.5 – 355.6) 93 72.8 (20.2 – 275.6) 96
Day 10 75.6 (22.4 – 678.3) 80.9 (31.6 – 678.3) 77 74.5 (22.4 – 467.0) 88
Day 14 79.6 (10.8 – 531.6) 82.9 (10.8 – 531.6) 41 74.3 (15.8 – 255.9) 41
Day 30 84.6 (16.5 – 647.5) 90.5 (19.1 – 647.5) 101 79.5 (16.5 – 390.6) 113
Day 60 106.7 (14.4 – 439.2) 109.8 (25.7 – 439.2) 106 100.2 (14.4 – 415.7) 106
Day 90 114.2 (19.6 – 775.0) 114.7 (19.6 – 775.0) 100 113.3 (22.6 – 444.0) 109
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95%-CI 27.0 – 45.0%) in the GBG were within the target Tac C0 range (p = 0.79; Figure 2). 
The proportion of patients with a sub-therapeutic (i.e. <10 ng/mL) or a supra-therapeutic 
(i.e. >15 ng/mL) Tac C0 in the two groups was also not significantly different (Figure 2).
Secondary pharmacokinetic endpoints
Supplementary Figure 1 depicts the average of all Tac C0 obtained during the first and 
second week after transplantation. The median of the average of week 1 Tac C0 in the SDG 
was 13.1 ng/mL (5.3 – 30.0 ) vs. 12.8 ng/mL (5.2 – 30.0) in the GBG (p = 0.036), whereas 
the median of the average of week 2 Tac C0 in the SDG was 12.5 ng/mL (6.7 – 20.3) vs. 
11.6 ng/mL (5.1 – 22.7) in the GBG (p = 0.010).
 
figure 2. Boxplots depicting the predose Tac concentrations (C0) on day 3 after transplantation in 
the standard-dose and genotype-based groups. The boxes depict the median and the 25th and 75th 
percentiles. The whiskers depict the 5th and 95th percentiles. The dots represent the outliers and the 
asterisks represent the extreme outliers (more than three times the IQR). The shaded area repre-
sents the target Tac C0 range (10 - 15 ng/mL).
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There was no significant difference in the median time needed to achieve the target Tac 
C0 between the SDG and GBG: 6 days (3 – 17) vs. 6 days (3 – 28; p = 0.72; Figure 3), nor 
was there a significant difference in the number of daily dose modifications needed to 
reach the target Tac C0: 156 (SDG) vs. 129 (GBG); p = 0.30 (Supplementary Figure 2).
No significant between-group difference was found in the frequency of being markedly 
underexposed during the first month after transplantation. During this time period, 12 
patients (10.3%; 95%-CI 6.0 – 17.1%) in the SDG and 13 patients (11.1%; 95%-CI 6.6 
– 18.1%) in the GBG had one or more Tac C0 <5.0 ng/mL (p = 0.83). Likewise, the number 
of patients experiencing marked Tac overexposure was comparable between the SDG 
and GBG: 38 patients (32.5%; 95%-CI 24.7 – 41.4%) in the SDG and 28 (23.9%; 95%-CI 
17.1 – 32.4%) patients in the GBG (p = 0.15).
Post-hoc pharmacokinetic analyses
To investigate whether CYP3A5 expressers do require a higher Tac dose to achieve target 
concentrations compared with CYP3A5 non-expressers, the whole study population was 
analysed. On day 3 after transplantation, CYP3A5 expressers (n = 48) had a 36.3% higher 
Tac dose requirement (C0/D) compared with non-expressers (n = 153): 49.1 ng/mL per 
mg/kg (13.8 – 150.9) vs. 77.1 ng/mL per mg/kg (25.8 – 195.3); p < 0.001 (Supplementary 
Table 4). The difference in Tac C0/D between CYP3A5 expressers and non-expressers 
persisted throughout the 3-month follow-up period (Supplementary Table 4 and Supple-
mentary Figure 3). Repeated measurements analysis confirmed that the overall Tac C0/D 
 
figure 3. Time to achieve the target Tac C 0 range (10.0 – 15.0 ng/mL).
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was significantly lower in CYP3A5 expressers than in non-expressers, indicating a higher 
dose requirement of the former group (p <0.001).
Tac exposure on day 3 of the patients in the SDG and GBG was analysed according 
to their CYP3A5 genotype (Figure 4A). The median Tac C0 in patients homozygous for 
CYP3A5*1 was not statistically significantly different between patients in the SDG and 
GBG: median 6.8 ng/mL (4.6 – 10.6 ng/mL) vs. 9.4 ng/mL (8.1 – 25.7 ng/mL); p = 0.40 
(Figure 4A and Supplementary Table 5). Heterozygous CYP3A5*1 carriers in the SDG had 
a significantly lower Tac C0 compared with their counterparts in the GBG: median 10.4 
ng/mL (2.6 – 30.0) vs. 14.7 ng/mL (6.5 – 30.0); p = 0.032. Among CYP3A5 non-expressers 
(those with the CYP3A5*3/*3 genotype), Tac C0 was significantly higher in the SDG than 
in the GBG: 14.5 ng/mL (5.5 – 30.0) vs. 11.6 ng/mL (4.1 – 30.0); p < 0.001 (Supplementary 
Table 5; Figure 4A).
When the proportion of patients within the target Tac C0 range on day 3 after trans-
plantation was analysed according to CYP3A5 genotype (expressers and non-expressers), 
no significant differences were found between the SDG and GBG. Among the CYP3A5 
expressers, 39.1% (95%-CI 22.2 – 59.2%) of the patients in the SDG (n = 23) and 26.9% 
(95%-CI 13.7 – 46.1%) of the patients in the GBG (n = 26) were within the target Tac C0 
range (p = 0.36). A comparable situation was found among the CYP3A5 non-expressers: 
36.8% (95%-CI 26.9 – 48.1%) of the patients in the SDG (n = 76) and 38.5% (95%-CI 
28.4 – 49.6%) of the patients in the GBG (n = 78) were within the target Tac C0 range (p 
= 0.84; Figure 4B).
However, on day 3 after transplantation, a trend towards more frequent sub-therapeutic 
Tac exposure was observed among CYP3A5 expressers in the SDG compared with CYP3A5 
expressers in the GBG. The reverse was observed for CYP3A5 non-expressers who were 
significantly less frequently below the target Tac C0 in the SDG compared with the GBG 
(Figure 4B).
Safety
In total, 728 AEs occurred in the SDG and 750 in the GBG (p = 0.56; Tables 3 and 4). 
Of these, 148 and 167 were judged to be serious (p = 0.40). One patient in the SDG 
died from bacterial peritonitis. Overall kidney allograft survival (including death with a 
functioning transplant) was 96.6% in the SDG and 99.2% in the GBG (p = 0.370). Kidney 
allograft survival censored for death was 97.5% in the SDG and 99.2% in the GBG (p = 
0.62). Three patients in the SDG and one in the GBG lost their graft as a result of vascular 
complications.
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figure 4. Boxplots depicting the predose Tac concentrations (C0) on day 3 after transplantation in 
the standard-dose and genotype-based groups categorized by CYP3A5 genotype (4A) and by CY-
P3A5 expressers and non-expressers (4B).
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The overall incidence of BPAR was 10.5% (n = 25). The BPAR rate was comparable be-
tween the SDG and GBG: 10.1% (n = 12) vs. 11·0% (n = 13); p = 0.82. Also, the severity 
and sub-type of BPAR was not different between both treatment groups (Table 3). The 
rate of presumed acute rejection was not significantly different: SDG 4.2% (n = 5) vs. GBG 
5.1% (n = 6); p = 1.00.
The incidence of DGF was comparable between the two groups (Table 4). At month 3 
after transplantation, renal function was similar in the SDG and GBG: median eGFR 47 
(20 – 60) vs. 50 mL/min per 1.73 m2 (18 – 60), respectively (p = 0.80). There was no 
difference in renal function recovery or the amount of proteinuria between the SDG and 
GBG (Supplementary Figure 4 and Supplementary Table 6).
There were no significant between-group differences in the incidence of all other AEs, 
including PTDM (p = 0.49), acute Tac-associated nephrotoxicity, and neurotoxicity (Table 
4). Tac was tolerated well, and only three patients (all in the GBG) discontinued Tac. Tac 
was discontinued because of neurotoxicity (n = 2) and thrombotic microangiopathy (n = 
1).
Table 3. Incidence of rejection according to the treatment group.
Rejection type Whole group
(n = 237)
Standard-dose group
(n = 119)
Genotype-based group
(n = 118)
Borderline 5 (2.1%) 3 (2.5%) 2 (1.7%)
Type 1
1A 0 (0.0%) 0 (0.0%) 0 (0.0%)
1B 1 (0.4%) 1 (0.8%) 0 (0.0%)
Type 2
2A 9 (3.8%) 4 (3.4%) 5 (4.2%)
2B 7 (3.0%) 3 (2.5%) 4 (3.4%)
Type 3 1 (0.4%) 1 (0.8%) 0 (0.0%)
ABMR* 0 (0.0%) 0 (0.0%) 0 (0.0%)
Mixed ACR§ and AMBR 7 (3.0%) 3 (2.5%) 4 (3.4%)
Total BPAR† 25 (10.5%) 12 (10.1%) 13 (11.0%)
*ABMR = antibody mediated rejection; §ACR = acute cellular rejection; †Biopsy-proven acute rejec-
tion excluding borderline cases
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Table 4. Adverse events
Event Standard-dose 
group
(n = 119)
Genotype-based 
group
(n=118)
p
Blood or lymphatic system 35 46 0.31
 Leucopenia 17 19
 Anemia 14 22
 Thrombocytopenia 2 4
 Other 2 1
Bleeding and thrombotic events 65 57 0.41
 Major bleeding 28 21
 Minor bleeding 28 33
 Thrombosis 9 3
Cancer 2 3 0.68
 Prostate (Adenocarcinoma) 0 2
 Skin (Basal cell carcinoma) 2 1
Cardiac 50 52 1.00
 Acute coronary syndrome / myocardial ischemia 3 4
 Cardiac decompensation / volume overload 36 39
 Other 11 9
Gastro-intestinal 62 49 0.18
 Diarrhea 26 17
 Other gastro-intestinal disorder 36 32
Infection
Opportunistic Infection* 26 24 0.81
 BKV 6 8
 CMV 5 3
 EBV 1 1
 HSV 3 3
 VZV 0 1
 Fungal 11 8
Other infection 108 102 0.61
 Urinary tract infection 77 73
 Upper respiratory tract infection 12 11
 Pneumonia 3 2
 Gastro-intestinal infection 5 7
 Other 11 9
Locomotor system disorder 11 9 0.78
Metabolism or nutrition 137 143 0.94
 Post-transplant diabetes mellitus 22 28
 Hypo-/hyperglycemic dysregulation 29 23
 Calcium disorder (hypo-/ hypercalcaemia) 13 19
 Potassium disorder (hypo-/ hyperkalaemia) 19 15
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DISCUSSION
In this study, adaptation of the Tac starting dose based on an individual’s CYP3A5 geno-
type did not lead to a higher percentage of patients reaching the desired Tac C0 range on 
day 3 after kidney transplantation, as compared to a standard, bodyweight-based dosing 
approach. In addition, CYP3A5 genotype-based Tac dosing did not result in a lower num-
ber of Tac dose modifications, a shorter time to achieve the Tac target C0, or improved 
clinical outcome.
This study confirms that CYP3A5 expressers require a significantly higher Tac dose to 
reach the same target exposure compared with non-expressers.9,10 Using a standard, 
bodyweight-based dosing approach, the first median Tac C0 of CYP3A5 expressers was 
Table 4. Adverse events (continued)
Event Standard-dose 
group
(n = 119)
Genotype-based 
group
(n=118)
p
 Hypophosphataemia 23 23
 Other electrolyte abnormality 7 7
 Liver enzyme abnormality 24 28
Nervous system 38 45 0.58
 CVA/TIA§ 0 3
 Tremor 26 26
 Headache 7 8
 Other 5 8
Skin-related disorders 8 12 0.54
Surgical or procedural complication 22 31 0.31
 Acute tubular necrosis 8 15
 Delayed graft function 5 6
 Renal infarction 4 2
 Other 5 8
Tacrolimus-induced nephrotoxicity 35 30 0.53
Urological complication 42 58 0.16
 Hydronephrosis 21 25
 Urinary leakage 6 8
 Other 15 25
Wound-related problem 16 11 0.40
 Wound infection 8 5
 Other 8 6
Other 49 57 0.59
* BKV = BK virus; CMV = Cytomegalovirus; EBV = Epstein-Barr virus; HSV = Herpes simplex virus; VZV 
= Varicella zoster virus; § CVA = Cerebrovascular accident; TIA = Transient ischemic attack
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lower than that of non-expressers. With CYP3A5 genotype-based dosing, the proportion 
of patients with sub-therapeutic Tac exposure tended to decrease among CYP3A5 ex-
pressers, whereas it increased significantly among CYP3A5 non-expressers. The reverse 
was observed with regard to supra-therapeutic Tac exposure (Figure 4B). As a result, the 
CYP3A5 genotype-based adjustment of the Tac starting dose did not change the overall 
proportion of patients within the target Tac C0 range.
In a randomized-controlled study which included 280 RTRs, Thervet et al. demonstrated 
that CYP3A5-based adaptation of the Tac starting dose does increase the proportion of 
patients on target compared with a standard, bodyweight-based dosing approach. Three 
days after the start of Tac treatment, significantly more RTRs were within the target Tac 
C0 range if Tac was individualized according to CYP3A5 genotype as compared with stan-
dard Tac dosing (43.2% vs. 29.1%, respectively; p = 0.03).18 In addition, CYP3A5-based 
Tac dosing was associated with fewer dose modifications and a shorter time to reach the 
target C0. However, and in line with the present findings, CYP3A5 genotype-based Tac 
dosing did not improve clinical outcomes.18
It is unknown why the CYP3A5-based Tac dosing approach of Thervet et al. was beneficial 
in terms of early Tac exposure whereas this was not the case in the present study. In 
both studies, the same Tac starting doses were prescribed and the number of included 
patients is comparable. However, in contrast to the current study, in which Tac was started 
directly after transplantation, the initiation of Tac treatment was delayed until day seven 
after transplantation in the French trial, in which recipients of a deceased donor kidney 
were also included. Possibly, the between-patient variability in Tac concentrations in the 
few first days after transplantation was higher than the variability after a week. Early 
post-operative changes in gastro-intestinal motility and glucocorticoid dose may be re-
sponsible for this phenomenon and may have diluted the pharmacogenetic effect.19,20 
Furthermore, during the first week, 82% of the patients in the French study received 
induction therapy with anti-thymocyte globulin and all patients received a higher than 
standard dose of MMF.18 When such a potent immunosuppressive regimen is used in 
an immunologically low-risk transplant population, a delay in reaching the target Tac 
exposure may not significantly influence rejection risk.
It may be too early to conclude that the idea of personalising the Tac starting dose on an 
individual’s genotype should be abandoned. CYP3A5 genotype is currently the strongest 
known genetic predictor of Tac dose requirement. However, it does not explain all vari-
ability.21,22 In both the present and the French trial,18 only about 40% of patients in the 
CYP3A5 genotype-based dosing group were on target at first steady state. Other genetic 
variants may explain the residual variability in Tac dose requirement. Recently, several 
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other such variants including CYP3A4*22, CYP3A4*26, and P450 oxidoreductase *28 were 
found to be associated with Tac dose requirement.7, 23-25 Also, genetic variants in CYP3A5 
other than CYP3A5*3, such as the rare CYP3A5*6 SNP, which was not determined in this 
study, may explain some of the inter-individual differences in Tac exposure.17 Additional 
variability in Tac exposure may have resulted from variation in the exact timing of Tac 
intake and C0 sampling. Although this is a shortcoming of the present study, we feel that 
this is the way TDM is performed in everyday clinical practice in many transplant centers.
Rather than basing the Tac starting dose on bodyweight and CYP3A5 genotype, using a 
dosing algorithm which includes demographic and clinical factors plus multiple genetic 
variants may optimize early Tac exposure.26 The concept of using such an algorithm is 
appealing but these algorithms are complicated (possibly limiting their widespread 
clinical use). Furthermore, the first validation experiments were not very successful27 and 
their performance has not been tested prospectively in clinical trials. An alternative and 
more simple approach, could be to adjust the starting dose only in selected patients. 
Post-hoc analyses demonstrated that CYP3A5 expressers tended to be less frequently 
below the target C0 range if they received a higher Tac starting dose than standard. If one 
chooses not to prescribe a reduced dose to CYP3A5 non-expressers, sub-therapeutic Tac 
exposure in a population as a whole may be reduced. Such a strategy may be especially 
relevant for patients of African descent who are more often CYP3A5 expressers com-
pared to Caucasians.28 However, avoiding early sub-therapeutic exposure may come at 
the expense of more Tac toxicity.29
Perhaps the “trial and error” approach we routinely use for Tac dosing is not so bad. 
Physicians have become highly experienced in TDM and as shown in this and in previous 
studies, the majority of patients reach the target Tac exposure within 10 days.30 The out-
come of this study is in line with the recommendations of the Royal Dutch Association for 
the Advancement of Pharmacy which states that although an interaction exists between 
CYP3A5 genotype and Tac metabolism, no action is advised because with TDM doses are 
effectively adjusted.31 Other guidelines suggest that CYP3A5 genotyping cannot replace 
TDM, as other factors (i.e. demographic factors and drug-drug interactions) also influence 
Tac dose requirement.32
Our study has weaknesses. First, Tac concentrations were determined with immunoas-
says which, with the now more widespread availability of more sensitive techniques such 
as mass-spectrometry (MS), are no longer considered the gold standard. The main reason 
to use immunological assays was that MS was not used in our centre for the routine 
determination of Tac at the start of the trial. However, most studies that previously 
demonstrated an association between CYP3A5 genotype and Tac pharmacokinetics, were 
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performed using these same immunoassays and many transplant centres worldwide still 
rely on them. Second, out of necessity, two types of immunoassays were used to measure 
Tac C0. Although this may have added to residual variability in Tac exposure, there was no 
difference in the primary endpoint between the SDG and the GBG when the analysis was 
adjusted for assay type (data not shown). Third, the targeted Tac C0 range may nowadays 
be considered relatively high.33 Nonetheless, we feel that it was not excessive34, the 
more so given the fact that no induction therapy with T-cell depleting antibodies was 
prescribed. Furthermore, the optimal Tac exposure early after transplantation remains 
a matter for debate.35 Finally, in the French trial,18 the same Tac C0 range was aimed for. 
Because we were aware of this trial, which was ongoing at the time when the present 
study was planned, and to allow for comparison, it was decided to target the same Tac C0 
range, which was also the standard in our centre at that time. Fourth, and as stated above, 
one may argue that the a priori chances of finding a benefit of a CYP3A5 genotype-based 
Tac dosing approach will be highest among CYP3A5*1 carriers. In Western Europe, the 
majority of RTRs is of Caucasian descent and if we would have only included patients car-
rying the minor CYP3A5*1 allele, this study would have been relevant for about 15% of 
our transplant population. Fifth and final, although a gene-dose effect has been observed 
for CYP3A5 genotype and Tac dose requirement, both CYP3A5*1 carriers and CYP3A5*1 
homozygotes received the same Tac dose. It was anticipated that the actual number of 
patients with the CYP3A5*1/*1 genotype would be limited and therefore it was decided 
to use a Tac dosing strategy similar to that of the French trial.18
In conclusion, basing the Tac starting dose on an individual’s CYP3A5 genotype does 
not lead to earlier achievement of the target Tac C0 range or superior clinical outcome 
as compared with standard, bodyweight-based dosing after kidney transplantation in 
a low immunological risk population. Therefore, routinely genotyping renal transplant 
candidates for CYP3A5 cannot be recommended.
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Supplementary Table 1. Drugs interacting with tacrolimus. Patients using any of these drugs at the 
time of transplantation were not included in the study.
Drug Clinical effect
Antibiotics
Clarithromycin Increased exposure
Doxycyclin Increased exposure
Erythromycin Increased exposure
Rifampin Reduced exposure
Antiepileptics
Carbamazepine Reduced exposure
Phenobarbital Reduced exposure
Phenytoin Reduced exposure
Antihypertensive and antiarrhythmic agents
Amiodarone Increased exposure
Diltiazem Increased exposure
Verapamil Increased exposure
Antimycotic drugs
Fluconazole Increased exposure
Itraconazole Increased exposure
Ketoconazole Increased exposure
Other
HIV protease inhibitors Increased exposure
Theophylline Increased exposure
Supplementary Table 2. Frequencies of the three CYP3A5 genotypes in the whole population.
Genotype Whole population
(n = 237)
Standard-dose group (n 
= 119)
Genotype-based group 
(n = 118)
CYP3A5 *1/*1 9 (3.8%) 4 (3.4%) 5 (4.2%)
CYP3A5 *1/*3 54 (22.8%) 27 (22.7%) 27 (22.9%)
CYP3A5 *3/*3 174 (73.4%) 88 (73.9%) 86 (72.9%)
Supplementary Table 3. Frequencies of the three CYP3A5 genotypes in the population according 
to ethnic group.
Ethnicity CYP3A5*1/*1 CYP3A5*1/*3 CYP3A5*3/*3
Caucasian (n = 186) 2 (1.1%) 30 (16.1%) 154 (82.8%)
Asian (n = 23) 2 (8.7%) 12 (52.2%) 9 (39.1%)
Black (n = 23) 5 (21.7%) 11 (47.8%) 7 (30.4%)
Other (n = 5) 1 (20.0%) 4 (80.0%)
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Supplementary Table 4. Pharmacokinetic data of Tac according to CYP3A5 genotype (data of the 
standard-dose and genotype-based dose groups combined).
CYP3A5 expressers
(*1/*1 & *1/*3)
n CYP3A5 non-expressers 
(*3/*3)
n p
Tacrolimus dose (mg/day)
Day 3 19.0 (8.0 – 32.0) 62 13.0 (7.0 – 26.0) 174 <0.001
Day 7 18.0 (0.0 – 32.0) 62 12.0 (0.0 – 24.0) 174 <0.001
Day 10 16.0 (1.0 – 36.0) 60 11.0 (0.0 – 22.0) 174 <0.001
Day 14 15.0 (1.0 – 36.0) 60 10.0 (0.0 – 24.0) 173 <0.001
Day 30 12.0 (2.0 – 34.0) 60 8.0 (2.0 – 24.0) 173 0.001
Day 60 12.0 (1.0 – 34.0) 58 6.0 (0.0 – 18.0) 173 <0.001
Day 90 10.0 (0.0 – 34.0) 57 5.0 (0.0 – 18.0) 173 <0.001
Tacrolimus C0 (ng/mL)
Day 3 11.2 (2.6 – 30.0) 49 12.8 (4.1 – 30.0) 154 0.205
Day 7 12.2 (7.4 – 22.7) 48 12.5 (5.0 – 30.0) 114 0.829
Day 10 11.7 (5.9 – 18.4) 39 11.8 (4.3 – 23.9) 129 0.615
Day 14 10.0 (5.1 – 15.2) 21 11.4 (5.2 – 19.9) 64 0.040
Day 30 9.4 (2.9 – 15.8) 59 9.6 (3.6 – 30.0) 159 0.373
Day 60 8.6 (3.8 – 20.3) 54 8.0 (3.3 – 14.6) 165 0.116
Day 90 8.0 (3.0 – 12.3) 54 7.6 (2.7 – 16.8) 159 0.609
Tacrolimus C0/dose (ng/mL per mg/kg)
Day 3 49.1 (13.8 – 150.9) 48 77.1 (25.8 – 195.3) 153 <0.001
Day 7 50.7 (20.2 – 355.6) 48 82.1 (31.2 – 354.0) 141 <0.001
Day 10 55.4 (22.9 – 678.3) 39 82.7 (22.4 – 467.0) 126 <0.001
Day 14 48.2 (10.8 – 143.2) 21 93.9 (34.6 – 531.6) 61 <0.001
Day 30 56.2 (16.5 – 647.5) 59 93.4 (19.7 – 502.9) 155 <0.001
Day 60 58.5 (14.4 – 185.4) 51 119.0 (21.3 – 439.2) 161 <0.001
Day 90 54.5 (25.8 – 221.9) 52 132.5 (19.6 – 775.0) 157 <0.001
Supplementary Table 5. Pharmacokinetic data of Tac on day 3 after transplantation according to 
treatment group.
Standard-dose
group
n Genotype-based group n p
Tac dose (mg/day)
All Patients 15.0 (8.0 – 26.0) 119 13.0 (7.0 – 32.0) 117 0.02
CYP3A5 *3/*3 15.0 (8.0 – 26.0) 88 12.0 (7.0 – 26.0) 86 < 0.01
CYP3A5 *1/*3 14.0 (10.0 – 20.0) 27 24.0 (8.0 – 32.0) 27 < 0.01
CYP3A5 *1/*1 14.0 (12.0 – 16.0) 4 20.0 (18.0 – 26.0) 4 0.03
CYP3A5 *1/*1 & *1/*3 14.0 (10.0 – 20.0) 31 24.0 (8.0 – 32.0) 31 < 0.01
Tac C0 at (ng/mL)
All Patients 13.3 (2.6 – 30.0) 99 11.6 (4.1 – 30.0) 104 0.047
CYP3A5 *3/*3 14.5 (5.5 – 30.0) 76 11.6 (4.1 – 30.0) 78 < 0.01
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Supplementary Table 6. Renal function of the patients (excluding values measured at the time of 
DGF) according to treatment group.
Standard-dose group n Genotype-based group n
Serum creatinine (µmol/L)
Day 3 139 (59 - 702) 113 135 (4 - 975) 111
Day 7 132 (66 - 683) 112 137 (64 - 812) 111
Day 10 135 (53 - 501) 98 137 (56 - 458) 93
Day 14 149 (60 - 486) 51 131 (52 - 557) 55
Day 30 121 (58 - 223) 117 127 (52 - 329) 116
Day 60 126 (58 - 313) 116 127 (42 - 363) 116
Day 90 126 (38 - 226) 115 122 (58 - 315) 115
eGfR (mL/min per 1·73 m2)
Day 3 44 (7 - 60) 113 44 (5 - 60) 111
Day 7 46 (7 - 60) 112 44 (6 - 60) 111
Day 10 46 (10 - 60) 98 44 (11 - 60) 93
Day 14 40 (10 - 60) 51 48 (10 - 60) 55
Day 30 50 (20 - 60) 117 48 (14 - 60) 116
Day 60 48 (13 - 60) 116 49 (15 - 60) 116
Day 90 47 (20 - 60) 115 50 (18 - 60) 115
Protein/creatinine (mg/mmol)
Day 3 87.0 (20.3 – 515.4) 76 80.0 (3.1 – 1984.0) 67
Day 7 53.4 (10.3 – 2752.7) 106 58.3 (13.4 – 878.6) 100
Day 10 43.3 (9.2 – 448.5) 57 43.7 (12.7 – 562.5) 67
Day 14 33.4 (7.7 – 1868.0) 46 32.9 (7.1 – 1371.0) 47
Day 30 18.0 (3.3 – 1535.0) 107 24.0 (3.0 – 542.1) 106
Day 60 16.7 (3.8 – 982.3) 105 19.4 (4.9 – 429.6) 105
Day 90 16.4 (3.6 – 1094.0) 107 15.4 (4.7 – 354.3) 104
Supplementary Table 5. Pharmacokinetic data of Tac on day 3 after transplantation according to 
treatment group. (continued)
Standard-dose
group
n Genotype-based group n p
CYP3A5 *1/*3 10.4 (2.6 – 30.0) 19 14.7 (6.5 – 30.0) 23 0.03
CYP3A5 *1/*1 6.8 (4.6 – 10.6) 4 9.4 (8.1 – 25.7) 3 0.40
CYP3A5 *1/*1 & *1/*3 10.3 (2.6 – 30.0) 23 14.7 (6.5 – 30.0) 26 0.01
Tac C0/Dose (ng/mL per mg/kg)
All Patients 64.6 (13.8 – 162.0) 97 72.0 (23.4 – 195.0) 104 0.91
CYP3A5 *3/*3 72.3 (26.0 – 162.0) 75 80.1 (25.8 – 195.3) 78 0.97
CYP3A5 *1/*3 51.5 (13.8 – 150.9) 18 50.9 (23.4 – 100.8) 23 0.90
CYP3A5 *1/*1 34.5 (22.2 – 54.0) 4 30.4 (26.6 – 86.5) 3 0.63
CYP3A5 *1/*1 & *1/*3 48.6 (13.8 – 150.9) 22 50.0 (23.4 – 100.8) 26 0.80
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Supplementary figure 1. Average of all Tac C0 obtained in the first week (1) after transplantation 
and the average of Tac C0 obtained in the second week (2) after transplantation. The boxes depict 
the median and the 25th and 75th percentile. The whiskers depict the 5th and 95th percentiles. The 
dots represent the outliers.
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Supplementary figure 2. The number of dose modifications needed to achieve the target Tac C0 in 
the standard-dose group and genotype-based group.
 
Supplementary figure 3. Tac dose requirement (C0/D) according to CYP3A5 genotype. The open 
circles represent the CYP3A5 expressers, whereas the closed circles represent the CYP3A5 non-
expressers. Values are depicted as medians. The error bars represent the corresponding 95% con-
fidence intervals.
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Supplementary figure 4. Boxplots describing the distribution of estimated GFR after transplanta-
tion (days: 3, 7, 10, 14, 30, 60, and 90). The dark grey boxes represent the standard-dose group 
(including patients with DGF) whereas the light grey boxes represent the genotype-based group 
(including patients with DGF). The boxes depict the median and the 25th and 75th percentile. The 
whiskers depict the 5th and 95th percentiles.
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ABSTRACT
Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ transplan-
tation. Finding the optimal balance between effective Tac concentrations and toxicity 
is a challenge and requires therapeutic drug monitoring. In addition to the well-known 
inter-patient variability, the clinical use of Tac is also complicated by considerable intra-
patient variability (IPV) in Tac exposure. Tac IPV is defined as the amount of fluctuation 
of whole-blood concentrations over a certain period of time during which the Tac dose 
remains unchanged. A high IPV in Tac exposure has recently been recognised as a strong 
risk factor for acute rejection and poor long-term kidney transplantation outcome. In 
addition to non-adherence, several other factors determine the magnitude of the IPV in 
Tac exposure. Quantification of IPV is easy and can be easily incorporated into everyday 
clinical practice as a tool for optimizing transplantation outcomes.
Keywords: Intra-patient variability, kidney, pharmacokinetics, tacrolimus, transplantation
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1. INTRODUCTION
Since tacrolimus (Tac) was first introduced into the clinic in the early 1990s, the drug has 
evolved from an experimental immunosuppressive agent to become the backbone of 
modern immunosuppressive therapy after renal transplantation.1 With Tac-based immu-
nosuppression, the incidence of early acute rejection has decreased and 1-year patient 
and kidney transplant survival have improved considerably. Unfortunately, long-term 
transplantation outcomes have not improved to a similar degree and many transplanted 
patients will at some point in their lives suffer from graft failure or premature death.2
The causes of long-term kidney allograft loss are multifactorial. About half of successfully 
transplanted kidneys will fail because of diverse causes such as chronic rejection, late 
acute rejection, recurrent primary kidney disease, BK virus infection, or nephrotoxicity 
related to the chronic use of the calcineurin inhibitors (CNIs) Tac and cyclosporine A 
(CsA).3 The other half of all graft losses occurs because the recipient dies with a function-
ing kidney transplant, which is most often caused by cardiovascular disease, malignancy, 
or infection.4,5
The potent immunosuppression provided by Tac and its specific side effects (e.g. the in-
duction of diabetes mellitus, hypertension, dyslipidaemia, and nephrotoxicity) undoubt-
edly contribute to the limited long-term patient and kidney allograft survival. However, 
attempts to replace Tac with other, equally effective but less toxic immunosuppressive 
agents, have had limited success. For the next decade or so Tac will remain the first choice 
immunosuppressive agent, and therefore optimization of Tac-based immunosuppressive 
therapy is of utmost importance.
Recently, it has become clear that intra-patient variability (IPV) in Tac exposure is a (bio)
marker for long-term kidney transplantation outcome.6 In this review article, the phe-
nomenon of intra-patient variability in Tac pharmacokinetics is explained, the evidence 
that it predicts long-term transplantation outcome is summarized, and suggestions to 
use it as a tool for optimizing transplantation results are provided.
2. CLINICAL PHARMACOKINETICS Of TACROLIMUS
Tac pharmacokinetics is characterized by poor bioavailability, which averages 25% 
(ranging from 5 to 90%).7 Peak concentrations are usually obtained within 2 hr after oral 
administration. Tac distributes extensively into tissue and into the cellular fraction of 
blood. Erythrocytes have a high concentration of the Tac receptor FK-binding protein-12 
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and this explains why whole-blood Tac concentrations are 15 (range 4 to 114) times 
higher than those in plasma.7 More than 90% of the Tac plasma fraction is protein-bound. 
The drug is mainly excreted in bile (>90%) after biotransformation to at least 15 metabo-
lites by the polymorphically-expressed cytochrome P450 (CYP) 3A4 and 3A5 enzymes. 
Metabolism largely occurs in the liver but considerable pre-systemic biotransformation 
takes place in the wall of the intestine. Less than 5% of Tac is eliminated by the kidneys 
and <1% is eliminated renally as unchanged drug.7
A large variability exists in the pharmacokinetics of Tac between individual patients. 
Demographic factors and drug-drug interactions are well-known causes of this inter-
individual variability in Tac disposition.8 In addition, variation in the genes encoding the 
metabolizing enzymes CYP3A5 and CYP3A4, and possibly, the drug transporter ABCB1 
(previously known as P-glycoprotein; P-gp) and other proteins, explain between-patient 
differences in Tac pharmacokinetics.9,10 Another cause of Tac pharmacokinetic variabil-
ity, which is rarely considered, is circadian rhythm. Several studies have demonstrated 
that the disposition of Tac is influenced by the time of administration. The Tac Cmax and 
AUC after a morning dose is significantly higher than that after an evening dose.11 Such 
chronopharmacokinetic changes in Tac exposure may also relate to pharmacodynamic 
changes, as a lower night-time AUC was found to correspond with the occurrence of 
acute rejection.12
Tac is considered a critical dose drug. A too low exposure to Tac may result in under-
immunosuppression and acute rejection, whereas overexposure puts patients at risk 
for toxicity, which may occur at (whole-blood) concentrations that are considered 
therapeutic. The high inter-individual variability in its pharmacokinetics, the existence 
of a concentration-effect relationship, and its narrow therapeutic range have made that 
therapeutic drug monitoring (TDM) is routinely performed for Tac in most transplant 
centres throughout the world.13
3. INTRA-PATIENT VARIABILITy
In addition to being highly variable inter-individually (i.e. between patients), Tac phar-
macokinetics can also be variable within individual patients. This so-called intra-patient 
variability (IPV) in Tac exposure (hereafter referred to as “Tac IPV”) is defined as the 
fluctuation in Tac blood concentrations within an individual over a certain period of time 
during which the Tac dose is left unchanged.
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The large Tac IPV is apparent in everyday clinical practice. Some patients will have a 
stable Tac exposure that lies within the therapeutic range, whereas others will have 
highly fluctuating Tac concentrations, often exceeding or falling below the therapeutic 
range, despite a stable dose and for no apparent reason (Figure 1). It seems reason-
able to assume that patients in the latter category are at risk for inferior transplantation 
outcomes.
The variance (σ2) is a commonly used parameter for the quantification of Tac IPV.14,15 
Statistical variance gives a measure of how the data distributes around the mean. Con-
ceptually, it is the expected square difference between an observation and the mean 
value (denoted as μ). The true variance is not observed, but can be estimated in a data set 
using the sample variance for an individual patient as described in formula 1 (Table 1).
 
figure 1. Intra-patient variability in Tac exposure (Tac IPV).
An example from clinical practice to illustrate within-patient variability in whole blood Tac C0. Pa-
tient A has a low Tac IPV, whereas patient B has a high Tac IPV. The Tac C0 of these two patients were 
measured at regular visits to the outpatient clinic more than one year after transplantation. The 
target Tac C0 we aim for one year after transplantation is 4-8 ng/mL (represented by the horizontal 
lines). The various measures of Tac IPV are given below and were calculated using the formulas 
from Table 1. The dose-corrected Tac C 0 has a SD of 0.38 and that of patient B of 2.88. Based on the 
findings of Sapir-Pichhadze et al., the risk that patient B will develop late acute rejection, transplant 
glomerulopathy, or lose his graft is about twice as high as compared with patient A (hazard ratio 1.84 
(95% confidence interval 1.04, 3.25)).14
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The coefficient of variation (CV) is another useful term for the quantification of the 
IPV.15-20 The CV is a statistical measure for assessment of the degree of variation, which 
represents the ratio of the standard deviation (σ) to the μ (formula 2; Table 1). The σ is the 
square root of the variance (σ2). In other words, the CV represents the ratio of the square 
root of the σ2 to the mean. In a data set, the CV can be estimated using formula 3 (Table 
1).
For skewed data, it is often possible to make the distribution of the data normal using a 
(natural) logarithmic transformation. In this case, an adjusted estimator for CV must be 
used16 as described in formula 4 (Table 1). The CV interprets the relative magnitude of 
the standard deviation. In other words a high/low standard deviation does not automati-
cally mean more/less variable data.
Other investigators have used other statistical measures to calculate Tac IPV, namely the 
mean absolute deviation (MAD) (formula 5; Table 1).21 The main difference between MAD 
and CV is that in the computation of CV, the sum of the squares is taken first and then 
the square root is taken over the total (= within variance), whereas in the computation 
of MAD, the square root of each separate term is taken first and then the sum of these 
Table 1. Formulas for the calculation of Tac IPV.
Parameter formula
1 Variance
1
2 Coefficient of variation (CV%)
3 Coefficient of variation (CV%)
4 Coefficient of variation (CV%)
2 
5 Mean absolute deviation (MAD%)
3 
1   is the average of all available samples (in the case of Tac IPV, the average of all Tac C0 measured 
in time period j),  is an individual data point (a single Tac C0 measurement) and n is the number 
of all available data point (the total number of all available Tac C0 during time period j).
2  is the estimated within-subject variance of the natural log-transformed values.
3  Abs (…) denotes the absolute value function, so that the quantity ) is always a non-
negative value. The obtained Tac C0 has to be corrected to the corresponding daily Tac dose (C0/D).
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separate terms is taken. The advantage of the MAD is that it less susceptible to outliers, 
because MAD uses the absolute deviations from the mean, whereas CV uses the squared 
deviations from the mean.
An important consideration when calculating Tac IPV is the choice of the time period 
over which Tac concentrations and Tac dosages are collected. In the early phase after 
transplantation, Tac pharmacokinetics will be subject to variability due to changes in 
co-medication, including antibiotics and glucocorticoids. Furthermore, during hospi-
talisation, Tac exposure may change as a result of e.g. the inability to ingest the drug or 
changes in bioavailability.22 As this inter-occasion variability in Tac exposure may over-
estimate the true day-to-day variability, in many studies, only Tac concentration mea-
surements obtained during the “stable” phase after transplantation (i.e. from 6 months 
post-transplantation onwards) were included and data from periods of hospitalisation 
were not considered.
One has to bear the above-mentioned considerations in mind when interpreting the 
reported magnitude of Tac IPV. A wide range of Tac IPV has been reported in literature 
with some individuals having a Tac IPV of <5%, and others having a variability of >50% 
(Figure 2). On average, Tac IPV is between 15 and 30%.15-21
 
figure 2. Intra-patient variability in Tac exposure.
Distribution (by 5% intervals) of Tac IPV (i.e. MAD, formula 5) in a cohort of 238 stable renal trans-
plant recipients. Adapted from Shuker et al.83 with permission.
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4. DETERMINANTS Of INTRA-PATIENT VARIABILITy
Several factors can influence Tac pharmacokinetics and contribute to Tac IPV. In this 
paragraph these determinants are discussed.
4.1 Type of Tac analytical assay
Worldwide, several different analytical methods to measure Tac are currently in use. 
Important differences between these techniques may influence Tac IPV. The main disad-
vantage of immunological methods is cross-reactivity between Tac and its metabolites, 
which may cause an overestimation of the measured Tac concentration with unaccept-
able biases. Furthermore, some immunoassays -especially those of the first generation- 
have insufficient sensitivity to reliably measure Tac in the lower concentration range and 
suffer from a considerable degree of imprecision (CV% of 18 at lower Tac concentrations 
(<5.0 ng/mL)).23-25
Although better immunoassays are now available, analytical assays based on high-
performance liquid chromatography-linked tandem mass spectrometry (HPLC-MS/MS) 
are more sensitive, selective, and have a higher degree of precision.26-30 The last decade 
has seen a gradual shift from immunoassays to HPLC-MS/MS-based Tac concentration 
measurements and this may add to Tac IPV. However, the latter technique is at the mo-
ment not generally available and operational.
4.2 food
The oral absorption of Tac depends on the fat content of the consumed food and on 
the time of ingestion. Bekersky et al. investigated the influence of a high- versus a 
low-fat meal, relative to the fasting state, on the rate and extent of Tac absorption.31 
The concomitant ingestion of food significantly reduced Tac bioavailability and slowed 
absorption as compared with the fasted state but did not influence its half-life time.
In other studies, the effect of the timing of a meal on the rate and extent of Tac absorption 
was investigated. Ingestion of Tac in the fasting state was associated with a significantly 
higher bioavailability compared with concomitant or delayed (1 – 1½ hr after breakfast) 
ingestion of Tac.32,33
Food that influences the activity of CYP3A and/or ABCB1 can alter the blood concentra-
tion of Tac. Grapefruit (Citrus paradisi) interacts with a number of drugs, including CNIs.34,35 
Grapefruit juice inhibits the activity of CYP3A and ABCB1, and also down-regulates 
CYP3A4 protein expression in the intestinal wall, causing increased Tac exposure.36
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Egashira et al. reported a renal transplant recipient in whom Tac blood concentrations 
more than doubled after consumption of pomelo (Citrus maxima or Citrus grandis).37 Like 
grapefruit juice, pomelo contains furanocoumarins which are associated with inhibition 
of CYP3A activity. This observation prompted Egashira and colleagues to investigate the 
effect of pomelo on the pharmacokinetics of Tac in rats. The clinically-observed interac-
tion between pomelo and Tac was confirmed in this animal experiment.38 The exposure 
to Tac was about twice as high in rats pre-treated with 100% pomelo juice compared 
with animals pre-treated with water. In addition, turmeric (curcuma longa) and ginger 
(zingiber officinale) were found to have a comparable effect on Tac pharmacokinetics. 
Turmeric changes both the function and expression of ABCB1 and CYP3A4, whereas 
ginger reportedly changes the activity of this same enzyme and efflux transporter.39,40
4.3 Diarrhea
Several investigators reported that diarrhoeal illness leads to increased Tac levels.41-46 
Maes et al. demonstrated in 26 renal transplant recipients that severe diarrhea (more 
than 3 loose stools daily) caused a significant (100%) increase in Tac pre-dose concentra-
tions. This rise in Tac concentrations necessitated a Tac dose reduction of 30% to obtain 
pre-diarrhea Tac exposure.47 However, less severe diarrhea does not lead to increased 
Tac exposure.48 Lemahieu et al. demonstrated that the increase in Tac concentrations 
in patients with diarrhea can be attributed to an increased oral bioavailability. This was 
the result of reduced intestinal ABCB1 activity which was possibly caused by mucosal 
injury.49,50 A shortened intestinal transit time leading to a higher Tac delivery to the il-
eum, where CYP3A4 expression is lower than in the proximal intestine, could be another 
explanation for the increased Tac absorption seen during episodes of severe diarrhea.51
4.4 Drug-drug interactions
A drug may alter how the body absorbs, distributes, metabolises, or excretes another 
drug. For Tac, many such drug-drug interactions have been described.8,52 Most of the 
described drug interactions with Tac are caused by inhibition or induction of the in-
testinal and hepatic CYP3A system. Well-known interacting drugs are glucocorticoids, 
calcium-channel blockers, ritonavir, azole antifungals, rifampin, and several anti-epileptic 
drugs.53-55 In addition, non-prescription (over-the-counter) drugs and herbal preparations 
may also interact with Tac. St John’s wort (Hypericum perforatum) is one of the most com-
monly used herbal medicines for the treatment of depression, anxious states, and sleep 
disorders. Several studies have demonstrated that St John’s wort may induce hepatic and 
intestinal CYP3A4 and intestinal ABCB1, whereas the herb does not appear to influence 
CYP3A5 expression.56-58 Mai et al. showed that St John’s wort decreases the bioavail-
ability of Tac.59 Treatment with 600 mg/day of St John’s wort extract for 14 days reduced 
the Tac dose-corrected AUC0-12 by 57.8%. To maintain therapeutic Tac concentrations, 
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dose adjustments from a median of 4.5 mg/day at baseline to 8.0 mg/day under St John’s 
wort treatment were required.59
4.5 Genetic factors
The inter-patient variability in Tac exposure is in part explained by genetic differences 
between individuals. The CYP3A5*3 allele, which causes a loss a functional CYP3A5 
protein, has been repeatedly and consistently associated with Tac exposure.10,60 Patients 
who express CYP3A5 (those with the CYP3A5*1/*3 or CYP3A5*1/*1 genotype) need 
an approximately 50% higher dose to reach target concentrations as compared with 
CYP3A5 non-expressers (those with the CYP3A5*3/*3 genotype).10,60,61 Recently, other 
genetic variants were associated with Tac dose requirement.62,63
Whether CYP3A5 genotype also affects variations in Tac exposure within an individual 
over time has been the subject of several recent investigations. In a Korean bioequiva-
lence study conducted in healthy volunteers, CYP3A5 non-expressers had a 52% and 
41% higher IPV in Tac Cmax and AUC0-last (AUC from time zero to time of the last measur-
able concentration), respectively as compared with CYP3A5 expressers.64 The authors 
postulated that Tac metabolism in CYP3A5 non-expressers is fully dependent on the 
activity of CYP3A4. Because CYP3A4 is very much prone to inhibition/induction, CYP3A5 
non-expressers might have greater Tac pharmacokinetic fluctuations.
Conversely, three studies, conducted in 249, 209, and 118 stable renal transplant recipi-
ents, demonstrated no significant association between Tac IPV and CYP3A5 genotype.65-67 
Although the reasons for these conflicting results are not clear, it may relate to sample 
size (n = 29 in the study of Yong et al.), the populations studied (patients versus volun-
teers), and the fact that in the volunteer study, two single doses of two different Tac 
formulations were administered in a cross-over design.
4.6 Non-adherence
Adherence to the immunosuppressive drug regimen after renal transplantation is poor 
and an important risk factor for poor long-term outcomes.68 Obviously, non-compliance 
with the prescribed immunosuppressive regimen determines variability in Tac exposure. 
When patients do not take their medication on certain occasions or “bolus” themselves 
before visiting the outpatient clinic to make up for missing dosages, Tac concentrations 
will fluctuate.15 For an in-depth review of issues pertaining to non-adherence, the reader 
is referred to the article by Shemesh et al. in this edition of Transplantation Reviews.
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4.7 Generic Tac substitution
Several generic, twice-daily Tac formulations are now available. Substitution of the 
innovator drug for generic Tac may increase Tac IPV in several ways. First, although 
manufacturers are required to demonstrate bioequivalence of their generic drug with 
the innovator drug, there is no requirement to demonstrate bioequivalence with the 
other generic formulations.69 Still, the general belief is that all generics can be used 
interchangeably. In daily practice, prescribing physicians are not always informed when a 
pharmacist substitutes the brand name drug for a generic preparation. When one generic 
formulation is substituted for another, it is even less likely that the transplant physician 
will be notified. Limited data suggest that on average, switching from one formulation 
to another will result in comparable Tac exposure. However, this may not always be the 
case on an individual basis and monitoring Tac concentrations after switching is rec-
ommended.70 Perhaps more importantly, patients may inadvertently make medication 
errors after being switched. There is no requirement for generic formulations to have the 
same shape and color as the brand formulation. From personal experience we know that 
some patients do not realize this is the same drug, and take different Tac formulations at 
the same time causing over-exposure. We have also seen patients that out of confusion 
decided not to take the drug at all putting them at risk for rejection. Finally, successively 
prescribing different generic formulations may negatively affect drug adherence, another 
important contributor to high IPV.70
5. INTRA-PATIENT VARIABILITy AND RENAL TRANSPLANTATION 
OUTCOME
Kahan et al. were the first to demonstrate that a high intra-individual variability in CsA 
exposure increases the risk of developing chronic rejection after kidney transplanta-
tion.71.72 In a cohort of 204 adult renal transplant recipients treated with the oil-based 
CsA formulation (plus prednisolone), serial pharmacokinetic profiles for CsA were de-
termined. The incidence of chronic rejection over a period of 5 years was 24% among 
patients with a low variability in CsA exposure versus 40% in the highly variable cohort. 
Healthcare-associated costs were higher among patients with a high intra-individual 
variability of CsA exposure.71
Stoves and Newstead found that among 103 renal transplant recipients, younger age and 
a highly variable CsA exposure (determined using CsA C0) while on the micro-emulsion 
formulation (Neoral®) predisposed these patients to the development of chronic allograft 
nephropathy.73 The ROC analysis identified a CV cut-off of 20-24% to predict chronic 
allograft nephropathy.73 Other authors have reported worse kidney allograft survival, 
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poorer renal transplant function, and higher acute rejection rates among patients with a 
high intra-patient variability of CsA exposure as compared with patients with less vari-
ability.74-76
The first evidence that a high IPV in the clearance of Tac also negatively affects long-term 
kidney transplantation outcome, was provided by Borra et al.21 In this study, the Tac IPV of 
297 renal transplant recipients treated with Tac and mycophenolate mofetil (MMF) was 
calculated and based on Tac whole-blood C0 that were measured at the outpatient clinic 
between month 6 and 12 after transplantation. Tac IPV was then related to “graft failure”, 
a composite endpoint of graft loss, histologically-proven chronic allograft nephropathy, 
or doubling of serum creatinine in the period between month 12 after transplantation 
and last follow-up.21
After a mean follow-up of 1849 ± 585 days, 34 of the 297 patients reached the graft 
failure endpoint. The mean Tac IPV was 17.0%. Based on the mean, the group was then 
divided into a group with a low Tac IPV (n = 148 with a mean Tac IPV of 9.6%) and a group 
with a high Tac IPV (n = 149 with a mean Tac IPV of 24.2%). In the group of patients with 
graft failure, there were significantly more patients with a high IPV (24/34 or 71%) than 
a low IPV (10/34 or 29%). Among patients who did not reach the primary endpoint, there 
was no difference in the proportion of patients with a high or low Tac IPV (47.5% versus 
52.5%, respectively). Tac concentrations were not different between cases and controls 
and the incidence of acute rejection in the first post-transplant year did not differ be-
tween patients with a high or low Tac IPV. Finally, a multivariate Cox regression analysis 
demonstrated that Tac IPV was a predictor of poor outcome, together with recipient age 
and the occurrence of an acute rejection episode in the first post-transplant year. The 
influence of a high Tac IPV on graft survival was comparable to that of acute rejection.21
Ro and colleagues reported that a high Tac IPV was associated with more acute rejection 
after kidney transplantation among 249 adult, Korean patients.65 Only a few patients lost 
their grafts and therefore no meaningful analysis of the effect of Tac IPV on long-term 
transplantation outcome could be performed. Sapir-Pichhadze et al. have performed a 
rigorous statistical analysis of Tac IPV in relation to kidney transplantation outcome.14 
In 356 adult, Canadian renal transplant recipients, a higher Tac IPV was associated 
with worse long-term outcome (a composite endpoint of late (i.e. occurring after year 
1) allograft rejection, transplant glomerulopathy, graft loss, or death with a functioning 
transplant). Furthermore, a dose-response relationship between the height of Tac IPV and 
the relative hazard of adverse kidney transplant outcomes was observed.14
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Comparable observations have been made in children. In a group of 144 older (>8 years) 
pediatric solid organ transplant recipients who had either received a kidney, heart, lung, 
or liver transplant, a high variability in Tac predose concentrations (assessed by the 
standard deviation) was an independent risk factor for late allograft rejection and graft 
loss. A threshold of clinical significance was a standard deviation of the Tac concentration 
>2. Each 1-point increase above this cut-off was associated with a hazard of 1.58 for graft 
loss.77 Hsiau et al. reported a higher risk of histologically-confirmed kidney transplant 
rejection among children with a high Tac IPV as compared to children with a low Tac IPV.15 
ROC analysis demonstrated that a Tac CV% of more than 41% was associated with an 
increased risk of allograft rejection with an odds ratio of 9.7.15 In a study which included 
69 Dutch children with a kidney transplant, a high Tac IPV (assessed by the CV) was again 
associated with a higher risk of late rejection but did not significantly correlate with loss 
of renal function, although this may have been due to the small sample size.20
6. INTERVENTIONS AIMED AT REDUCING INTRA-PATIENT 
VARIABILITy
There is considerable evidence that patients with highly fluctuating Tac concentrations 
are at increased risk for poor kidney transplantation outcomes and this calls for interven-
tions. Once a patient is identified as having a high Tac IPV (using the proper analytical and 
statistical methods), physicians should ask about dietary habits, the use of interacting 
and over-the-counter drugs, possible substitution by generic formulations, and changes 
in bowel movement. Patients should be instructed to take their Tac in a consistent man-
ner, both regarding to the meal content (if possible) and timing of ingestion relative to 
consumption of meals. The use of interacting substances should be addressed, and any 
intestinal illness should be treated.
Improving non-adherence to the immunosuppressive drug regimen may be the most im-
portant intervention to reduce Tac IPV and improve long-term transplantation outcomes. 
Several strategies to do so are available.78-80 These will not be discussed further here as 
this topic is covered in-depth by Shemesh et al. in this edition of Transplantation Reviews.
Finally, switching from the standard, immediate release Tac formulation to a modified-
release, once-daily Tac formulation (Tac-OD) should be considered. Advagraf® (Astellas 
Pharmaceutical Company) has been approved for the prevention of rejection after kidney 
and liver transplantation.81 For this formulation, it was demonstrated by Kuypers et al. 
that the use of Tac-OD does lead to better adherence as compared with the standard, 
twice-daily Tac formulation.82
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The effect of conversion to Tac-OD on Tac IPV has been the subject of several studies. In a 
cohort of 129 Taiwanese, stable renal transplant recipients, conversion to Tac-OD led to a 
significantly lower IPV of Tac C0 (decreasing from 14.0 to 8.5%).18 Stifft et al. observed a 
lowering of Tac IPV in AUC0-24 by 3.2% after conversion to Tac-OD in a prospective study 
including 40 renal transplant patients.16 However, several other investigators did not find 
a reduction of Tac IPV after conversion from immediate-release Tac to Tac-OD.17,19,83 No 
data regarding Tac IPV of a novel, extended-release OD tacrolimus formulation (Tac-LCPT) 
is available.84
7. CONCLUSIONS
A high Tac IPV is a risk factor for poor long-term outcomes of kidney transplantation. 
Incorporating algorithms that calculate Tac IPV into electronic patient files may aid 
clinicians to rapidly recognize patients at risk for inferior transplantation results. Once 
patients with highly fluctuating Tac concentrations are identified, education with regard 
to the effects of food and over-the-counter medication on Tac exposure should be at-
tempted. When non-adherence is suspected, interventions aimed at improving drug 
compliance and possibly, switching to a Tac-OD formulation should be considered. Tac 
IPV is a cheap and widely available predictor for transplantation outcome that can be 
easily incorporated into everyday clinical practice. This is an opportunity that the trans-
plant community should not miss.
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ABSTRACT
Tacrolimus is a critical dose drug with a considerable intra-patient variability (IPV) in its 
pharmacokinetics. We investigated whether a high IPV in tacrolimus exposure is associat-
ed with adverse long-term renal transplantation outcomes. Tacrolimus IPV was calculated 
from pre-dose concentrations measured between 6 and 12 months post-transplantation 
of 808 renal transplant recipients (RTRs) transplanted between 2000 and 2010. One 
hundred eighty-eight (23.3%) patients reached the composite end-point consisting of 
graft loss, late biopsy-proven rejection, transplant glomerulopathy, or doubling of serum 
creatinine concentration between month 12 and last follow-up. The cumulative incidence 
of the composite endpoint was significantly higher in patients with high IPV than in pa-
tients with low IPV (hazard ratio 1.41, 95%-CI: 1.06 – 1.89; p = 0.019). After adjustment 
for several factors the higher incidence of the composite endpoint for RTRs with a high 
IPV remained statistically significant (hazard ratio 1.42 (95%-CI: 1.06 – 1.90; p = 0.019). 
Younger recipient age at transplantation, previous transplantation, worse graft function 
(at month 6 post-transplantation) and low mean tacrolimus concentration at 1-year post-
transplantation were additional predictors for worse long-term transplant outcome. A 
high tacrolimus IPV is an independent risk factor for adverse kidney transplant outcomes 
that can be used as an easy monitoring tool to help identify high-risk RTRs.
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INTRODUCTION
Tacrolimus (Tac) is widely used as part of the immunosuppressive regimen for kidney 
transplantation. It is a critical-dose drug with a considerable intra-patient variability 
(IPV) in its pharmacokinetics, which is defined as the fluctuation in Tac concentrations 
within an individual patient over a certain period of time during which the Tac dose is 
unchanged.1,2 A high IPV in Tac exposure may be caused by behavioral factors, interact-
ing co-medication, food,1-5 and to a lesser extent, genetic factors.6-8 Whatever the cause, 
a high Tac IPV may result in a Tac exposure which is outside the therapeutic window. 
These patients may be at risk for under-exposure and rejection, or Tac toxicity in case of 
over-exposure.
Late allograft rejection and graft loss remain important problems in the field of solid 
organ transplantation. The first evidence for the clinical importance of Tac IPV was ob-
tained by Borra et al.9 In this study, it was demonstrated that a high Tac IPV was associ-
ated with reduced kidney transplant survival. In a Korean study, it was shown that renal 
transplant recipients (RTRs) with a high Tac IPV had a significantly higher risk to develop 
a biopsy-proven acute rejection (BPAR) than patients with a low Tac IPV (hazard ratio, 
2.66; 95%-CI: 1.39 – 5.06; p = 0.003).10 Recently, Sapir-Pichhadze et al., in a study which 
included 356 adult RTRs, observed that a higher Tac IPV was associated with more late 
allograft rejection, transplant glomerulopathy, graft loss and death with a functioning 
transplant.11 In pediatric kidney transplantation, a high Tac IPV has also been associated 
with increased late rejection and graft loss.12-14
A limitation of the above-mentioned studies was their limited sample size and the 
relatively short follow-up period. The small number of events may have hampered the 
multivariate analyses of the obtained data. This prompted us to substantially enlarge our 
original study population9 and extend the duration of clinical follow-up to evaluate in 
this extended population whether a high Tac IPV is associated with a composite endpoint 
consisting of late acute rejection, transplant glomerulopathy, graft loss or doubling of 
serum creatinine.
SUBJECTS AND METHODS
Patients and setting
This was a retrospective cohort study. The study cohort included RTRs who were trans-
planted and followed at the Erasmus MC, University Medical Centre Rotterdam, the 
Netherlands, between January 2000 and December 2010. Adult (age >18 years) RTRs 
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were included if they were treated with Tac and mycophenolate mofetil (MMF) in the 
period between 6 and 12 months after kidney transplantation, survived the first post-
transplant year and had an estimated glomerular filtration rate (eGFR) of ≥ 25 mL/min at 
month 12 after transplantation. Patients who were treated between month 6 and 12 with 
an immunosuppressive regimen which did not consist of Tac plus MMF or who received 
a multi-organ transplant were not included. Usage of low-dose prednisolone, which is 
given in our center in the first three post-operative months as a component of the routine 
immunosuppressive regimen, was not an exclusion condition.
Tac concentrations were determined in whole blood by several kinds of immunoassays. 
Details on the sensitivity and reproducibility of the EMIT assay in our laboratory have been 
published previously.15 Proficiency samples were obtained from the United Kingdom Qual-
ity Assessment Scheme (Dr. Holt, St George’s Hospital Medical School, London, UK). The 
laboratory successfully participates in international proficiency testing schemes. The target 
Tac C0 between 6 and 12 months post-transplantation was between 4-10 ng/mL.
Endpoints
Because we hypothesized that a high IPV in Tac exposure could result in frequent under-
immunosuppression, the outcome of interest was a composite endpoint named “event” 
which consisted of graft failure [defined as re-transplantation, (re)start of dialysis or an 
eGFR ≤ 15 mL/min], late BPAR (i.e. occurring after month 12), histologically-confirmed 
transplant glomerulopathy, or doubling of serum creatinine concentration in the period 
between month 12 after transplantation and last follow-up, taken the serum creatinine 
concentration at month 12 as a reference. Biopsies were performed for cause only. Patients 
who died with a functioning graft and who did not have signs of transplant glomerulopathy 
or acute rejection were considered not to have reached the endpoint and were censored.
Intra-patient variability and outcome variables
The variable of interest was the IPV of Tac. For its calculation, at least 3 pre-dose Tac 
concentrations (C 0) for an individual patient had to be available. A median of 5 (range: 3 
– 11) Tac C0 measurements were used to calculate Tac IPV. Since RTRs are not on a stable 
Tac dose in the first phase after transplantation and because they often use interacting 
drugs [such as for example, antibiotics and (pulse) glucocorticoids] in this period, only 
data on Tac exposure measured at outpatient clinic visits in the period of 6-12 months 
post-transplantation were collected. Tac concentration measurements obtained during 
hospitalization were not considered. As not all patients received a constant drug dose 
between months 6-12, the obtained C0 were corrected for the corresponding daily Tac 
dose (C0/D). The IPV in Tac exposure (from now on referred to as “Tac IPV”) between 
months 6 and 12 post-transplantation was calculated as:
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where  is the mean C0/D of all available samples in the period of month 6-12 after 
transplantation;  is an individual value of C0/D measured in the period mentioned; 
and T is the number of all available values for an individual patient.
Statistical analysis
The distribution of baseline characteristics is reported using summary statistics and 
frequency tables for continuous and categorical variables, respectively. The sample was 
divided into groups by a dichotomized version of Tac IPV, using the median as threshold. 
The probability to have reached the composite endpoint as a function of the time since 
year one after transplantation was calculated using the Kaplan-Meier method, and com-
pared between groups using the log-rank test.
Univariable and multivariable Cox regression analyses were performed to study the as-
sociation between Tac IPV, other clinical variables and the composite endpoint. The time 
origin for the survival analysis was one year post-transplantation. Besides Tac IPV (coded 
as a dichotomous variable), the Cox regression analyses included the following covari-
ates: recipient age at transplantation, recipient gender, recipient ethnicity, primary kidney 
disease, panel reactive antibody level, donor type (living or deceased donor), transplant 
number (1 vs. > 1), number of HLA-mismatches, transplant year, delayed graft function, 
eGFR at 6-months post-transplant, acute rejection in the first year, and the mean of the 
average Tac concentrations measured for an individual patient in the period between 6 
and 12 months after transplantation. The covariates in the multivariable Cox regression 
model were selected from these variables using a backward elimination method with a 
threshold for removal of p = 0.20. We assessed the proportional hazard assumption by 
testing for an interaction between time and covariates in a multivariable Cox-regression 
with time-dependent covariates.
To test our hypothesis that high Tac IPV could put the patients who are usually exposed 
to low Tac concentrations at higher risk to lose their graft than patients who are usually 
at optimal Tac exposure, effect modification was tested by including the interaction term 
of IPV and Tac concentration as a covariate in the multivariable Cox regression model. 
This interaction term was tested in a model that included the main effects of IPV and Tac 
concentration as covariates (irrespective of the associated p-values), as well as covari-
ates that were selected using backward elimination.
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Finally, we considered the possibility of differential effects of Tac IPV in the first 2 years 
of follow-up (i.e. between 12 and 36 months after transplantation) versus the remaining 
follow-up period, by adding a time-dependent covariate to the Cox-regression and testing 
its significance. This covariate was defined as the Tac IPV (which was measured between 
6 and 12 months after transplantation) between 12 and 36 months after transplantation, 
and as 0 after 36 months.
Patients with missing data for one or more covariates were dropped from the multivari-
able Cox regression. Statistical analyses were performed using IBM SPSS Statistics 20 
(SPSS Inc., Chicago, IL). All tests were two-sided and a p-value < 0.05 was considered 
statistically significant.
RESULTS
Between January 2000 and December 2010, a total of 1232 adult patients were trans-
planted and started on Tac/MMF-based immunosuppression. A total of 424 patients were 
excluded from the present analysis, leaving a final study cohort of 808 patients. The 
characteristics of these patients are presented in Table 1. The reasons for not including 
the 424 patients were the following: death within the first year after transplantation (n 
= 31); graft failure within first year after transplantation (n = 70); GFR below 25 mL/min 
at month 12 after transplantation (n = 50); multi-organ transplant (n = 4); no treatment 
with tacrolimus and MMF (n = 179); less than 3 Tac C0 measurements available (n = 31); 
insufficient data available (n = 59).
The median follow-up was 1993 days (5.5 years) with a range of 23-5130 days (0.06 
-14.1 years) beyond the first year after transplantation. A total of 188 events (23.3%) 
were documented during 4823 person-years at risk: 68 cases of graft loss, 69 cases 
of late BPAR, 39 cases of transplant glomerulopathy, and 12 cases of doubled serum 
creatinine.
At 12 months after transplantation, the median Tac dose was 4.2 mg/day (0.10 – 28.0 
mg/day). Among patients who did not reach the composite end point the median Tac 
dose was 4.2 mg/day (1.0 – 28.0), whereas this was 4.4 mg/day (0.10 – 22.7) among 
patients who reached the composite end point. The corresponding median Tac C0 was 
7.2 ng/mL (1.8 – 16.5). The median Tac C0 was 7.4 ng/mL (1.8 – 16.5) and 6.9 ng/mL (2.3 
– 15.5) in patients who didn’t reach and patients who reached the composite endpoint, 
respectively.
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Table 1. Characteristics of renal transplant recipients.
Number of patients
(n = 808)
Summary measure
Gender recipient
Male / Female 521 / 287 64.5% / 35.5%
Age of recipient (years) 808 51 (18- 77)
Ethnicity
Caucasian 618 76.5%
Asian 84 10.4%
Black 61 7.5%
Other 45 5.6%
Primary kidney disease
Diabetic nephropathy 98 12.1%
Polycystic kidney disease 105 13.0%
Glomerulonephritis 202 25.0%
Hypertensive nephropathy 175 21.7%
Reflux disease / Chronic pyelonephritis pylonephritis 68 8.4%
Other 91 11.3%
Unknown 69 8.5%
Number of kidney transplantation
1st 662 81.9%
2nd 117 14.5%
≥3rd 29 3.6%
Donor type
Living / Deceased 519 / 289 64.2% / 35.8%
Delayed graft function
Yes / No 148 / 658 18.3% / 81.4%
Acute rejection in the first post-transplant year
Yes / No 165 / 643 20.4% / 79.6%
PRA%§ 803 0.0 (0.0 – 96.0)
Peak PRA% 804 4.0 (0.0 – 100.0)
HLA mismatches 807 3 (0 – 6)
Transplant year
2000 - 2005 328 40.6%
2006 - 2010 480 59.4%
Serum creatinine (μmol/L) at 6 months 808 125 (43 – 273)
eGFR* (mL/min/1.73 m2) at 6 months 808 50 (21 – 90)
Tac C0** (ng/mL) 808 7.2 (1.8 – 16.5)
§PRA = Panel reactive antibodies; *eGFR = estimated glomerular filtration rate; **Mean of the aver-
age Tac concentrations measured in the period between 6 and 12 months after transplantation. 
The summary measure for non-normally distributed variables is the median (range). For binary or 
categorical variables, the summer measure is the proportion.
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The median Tac IPV was 16.2% [range (1.1% – 76.0%); Figure 1]. Dividing patients 
into two groups based on their variability, using the median as cut-off, resulted in 404 
patients in the low-variability group, with a mean variability of 11.0% [median = 11.6% 
, range (1.1% - 16.1%)] and 404 patients with high variability, with a mean IPV of 25.1% 
[median = 22.6%, range (16.2% – 76.0%)].
To visualize the association between Tac IPV and the composite endpoint, a Kaplan-Meier 
curve was constructed for patients with low and high Tac IPV (Figure 2). Kaplan-Meier 
analysis demonstrated a cumulative incidence of the composite endpoint of 41.8% by 
14-years post-transplant for the composite end-point in patients with low Tac IPV com-
pared with 49.5% in patients with high Tac IPV. As shown in Figure 2, long term transplant 
outcomes were significantly worse in patients with high Tac IPV (p = 0.018).
 
figure 1. Distribution of Tac IPV in the studied cohort (n = 808). The mean Tac IPV was 18.1% (± 9.7); 
the median (shown by dotted line) Tac IPV was 16.2% (1.1% - 76.0%).
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Survival analysis
To determine whether the Tac IPV is a predictor for poor transplant outcome, univariable 
and multivariable Cox regression analyses were performed. In the univariable analyses, 
significance was found for six covariates, including Tac IPV (Table 2). Univariable analyses 
showed a 41.3% (hazard ratio of 1.413, 95%-CI: 1.059 – 1.886; p = 0.019) increase in 
the risk for the composite end-point for patients with high Tac IPV compared to those 
with low Tac IPV.
Only four patients (0.5%) were dropped from the multivariable Cox regression because 
of missing covariate data. The multivariable Cox regression analysis confirmed that high 
Tac IPV was associated with poor kidney transplant outcome (hazard ratio of 1.42, 95%-
CI: 1.059 – 1.903; p = 0.019. Table 3). Also using Tac IPV as a continuous variable the 
multivariable Cox regression analysis demonstrated a 1.4% increase in the hazard for 
composite end-points for every one-unit (1%) increase in Tac IPV (hazard ratio of 1.014, 
95%-CI: 1.000 – 1.028; p = 0.043). Allowing for differential effects of Tac IPV during the 
first 2 years of follow-up yielded an estimated hazard ratio of 2.03 during the first 2 years 
of follow-up and 1.20 during the remaining follow-up period. However the difference 
between these two hazard ratios was not statistically significant (p = 0.10).
 
figure 2. Kaplan-Meier survival curves for patients with low (< 16.2%) and high (≥ 16.2%) Tac IPV. 
These groups were compared using the log-rank test.
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Recipient age at transplantation, eGFR at 6-months post-transplantation, transplant num-
ber and the average Tac C0 measured in the period between 6-12 post-transplantation 
were also found to be independent predictors for transplant outcome (Table 3). The 
proportional hazards assumption was not violated, suggesting that the hazard ratios 
were constant with time.
Based on the mean Tac C0 at 12-months after transplantation (baseline), the patients were 
divided into four groups using the quartiles of mean Tac C0 as cut-off values. The interac-
tion term of Tac C0 subgroup and Tac IPV was added to the multivariable Cox proportional 
hazards model to determine the statistical significance of the resulting interaction term. 
Table 2. Univariable Cox proportional hazards analyses for the influence of clinical variables on the 
outcome of graft failure censored for death.
Hazard ratio (95%-CI) p-value
eGFR at 6-months (mL/min) 0.988 (0.979 – 0.998) 0.016
Recipient age at transplantation (year) 0.982 (0.972 – 0.992) < 0.001
Mean Tac concentration (ng/mL) 0.890 (0.819 – 0.967) 0.006
Transplant number (1st) 1.296 (1.073 – 1.565) 0.007
Tac IPV% (low vs. high) 1.413 (1.059 – 1.886) 0.019
Tac IPV% (continuous variable) 1.015 (1.001 – 1.028) 0.030
Acute rejection in the first year 1.425 (1.021 – 1.989) 0.037
Peak PRA(%) 1.005 (1.000 – 1.010) 0.052
PRA(%) 1.005 (0.997 – 1.013) 0.196
Ethnicity 0.452
Caucasian Reference
Asian 1.285 (0.826 – 1.999) 0.266
Black 1.327 (0.791 – 2.228) 0.284
Other 0.831 (0.424 – 1.631) 0.591
Primary kidney disease 0.138
Diabetic nephropathy Reference
Polycystic kidney disease 0.710 (0.381 – 1.323) 0.281
Glomerulonephritis 0.923 (0.550 – 1.550) 0.762
Hypertensive nephropathy 0.892 (0.519 – 1.535) 0.681
Reflux disease / Chronic pyelonephritis 1.544 (0.861 – 2.767) 0.145
Other 0.799 (0.432 – 1.478) 0.475
Unknown 0.692 (0.331 – 1.445) 0.327
HLA mismatch (none) 1.058 (0.967 – 1.157) 0.217
Transplant year (per year) 1.018 (0.965 – 1.074) 0.518
Recipient gender (male) 0.927 (0.686 – 1.252) 0.620
Delayed graft function (no) 0.923 (0.631 – 1.350) 0.679
Donor type (living) 1.045 (0.778 – 1.404) 0.770
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Dividing patients into groups using the quartiles of the mean Tac C0 at 12-months post-
transplantation as cut-offs resulted in four groups with Tac C0 as follows: group 1 with 
Tac C0 ≤ 6.2 ng/mL; group 2: 6.2 ng/mL < Tac C0 ≤ 7.2 ng/mL; group 3: 7.2 ng/mL < Tac 
C0 ≤ 8.2 ng/mL; and group 4 with Tac C0 > 8.2 ng/mL. There was no significant (p = 0.59) 
modification of the association between Tac IPV and the primary composite end-point 
by patients in the four Tac C0 groups. This was also the case when effect modification 
was tested by including the interaction term of IPV and Tac concentration (coded as a 
continuous variable) as a covariate in the multivariable Cox regression model (p = 0.35).
The estimated hazard ratios as a function of Tac IPV and mean Tac concentrations are 
shown in Figure 3 (A and B). This figure shows (based on the results of the multivari-
able model) the influence of Tac IPV and Tac C0, respectively as continuous variables on 
the risk of developing the composite endpoint. It is clear that the risk of reaching the 
composite endpoint (graft failure, late BPAR, transplant glomerulopathy or doubling of 
serum creatinine concentration) censored for death increases with increasing Tac IPV and 
decreasing Tac concentrations.
DISCUSSION
This study demonstrates that a high Tac IPV is associated with inferior long-term outcomes 
after kidney transplantation. Patients with a high Tac IPV had a 1.4 times higher risk of 
reaching the composite endpoint of graft failure, late BPAR, transplant glomerulopathy, 
or doubling of serum creatinine concentration. The multivariate analysis showed that the 
effect of Tac IPV was independent of other known risk factors for poor outcome, such as 
lower recipient age,16 number of transplantations and impaired renal allograft function.17
Table 3. Results of the multivariable Cox regression analysis. Impact of Tac intra-patient variability 
on the composite endpoint (graft failure, late biopsy-proven acute rejection, transplant glomeru-
lopathy or doubling of serum creatinine concentration) censored for death.
Hazard ratio (95%-CI) p-value
Recipient age at transplantation (year) 0.980 (0.970 – 0.991) < 0.001
eGFR at 6-months (mL/min) 0.985 (0.976 – 0.995) 0.002
Tac IPV% (high) 1.420 (1.059 – 1.903) 0.019
Transplant number (>1) 1.505 (1.066 – 2.125) 0.020
Mean Tac concentration (ng/mL) 0.913 (0.839 – 0.994) 0.036
HLA mismatch (none) 1.087 (0.989 – 1.194) 0.084
DGF 0.736 (0.473 – 1.146) 0.175
Donor type (deceased) 0.791 (0.555 – 1.127) 0.194
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This study was an extension of the previously published study of Borra et al., and has an 
almost 3-fold larger study population and a 2-fold longer follow-up period. The present 
findings are in line with our previous findings, although the association between Tac IPV 
and long-term graft failure as reported previously9 was stronger than the association 
observed here. In the study of Borra et al., patients with a high Tac IPV had a 3-fold higher 
risk for developing the composite end-point, whereas it was 1.4-fold higher in the pres-
ent study.
The smaller effect size observed here can be explained by the fact that in the present 
study, the composite end-point was modified and differed from that used by Borra et al. 
In the latter study, “biopsy-proven chronic allograft nephropathy (CAN)” was included 
in the composite endpoint in addition to graft loss, and doubling of serum creatinine 
concentration. CAN may be caused by several clinical entities including among others, 
calcineurin inhibitor nephrotoxicity, (antibody-mediated) rejection and chronic pyelone-
phritis.18 Because the definition of the histopathology of CAN has changed through the 
years and the histopathologic picture of CAN is not specific, the item “biopsy-proven 
CAN” was changed into the more specific diagnoses late BPAR and transplant glomeru-
lopathy in the present study. Moreover, a longer follow-up in the present study could be 
another reason for the smaller effect size we found. This study provides some indication 
that the effect of Tac IPV on the risk of developing the composite endpoint decreases 
with time. As has been mentioned previously, patients with high Tac IPV had a 2-fold 
higher risk than patients with low Tac IPV to develop an event in the first two years of 
follow-up, whereas this risk was only 1.20-fold higher during the remaining follow-up 
 
figure 3. Calculated hazard ratios of the composite endpoint with increasing Tac IPV (A) and de-
creasing Tac predose concentrations (B). Example: a patient with a high Tac IPV (25%) and low Tac 
predose concentration (4.0 ng/mL) has a higher risk (1.32 * 1.33 = 1.76) to reach the composite 
endpoint than a patient with the same Tac IPV but a higher Tac predose concentration (7.0 ng/mL; 
1.32 * 1.00 = 1.32).
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period. This finding suggests that the longer follow-up period in the present study may 
partially explain the smaller effect size we found.
Apart from Tac IPV, three other factors proved to be related to long-term kidney transplant 
failure in multivariate analysis: the recipient’s age at transplantation, graft function at 
six-months after transplantation, the transplant number and the mean of the average Tac 
concentrations measured between 6 and 12 months after transplantation. An advanced 
age of the recipient at the time of transplantation was found to be a protective factor. 
This may be explained by the lower immunological activity of elderly patients .16-19 It is 
also not surprising that graft function (eGFR) at baseline predicts the survival time of the 
graft.20 Salvadori et al. demonstrated in a multivariate analysis, that the effects of several 
highly relevant parameters from univariable analysis (such as acute rejection and delayed 
graft function) on 5-year GFR were fully explained by their influence on 1-year GFR. They 
showed that 1-year GFR was the most relevant predictor for 5-year allograft function.17 
They also demonstrated that immunological risk factor like previous transplantation has 
an ongoing effect on graft survival beyond year 1.17 In our study, a low mean of the 
average Tac C0 measured in the period between 6 and 12 months after transplantation 
was found to be another significant predictor for inferior long-term kidney transplanta-
tion outcomes. This finding is in line with the results presented by Naesens et al.21 They 
demonstrated in a multivariate analysis that low mean Tac exposure independently 
associated with higher increase in biopsy-proven chronicity scores [calculated as the 
sum of the four basic ‘chronic’ Banff qualifiers (chronic glomerular damage, interstitial 
fibrosis, tubular atrophy, and vascular intimal thickening)] between 3 and 12 months 
after transplantation. Recently, in the DeKAF study, a lower Tac exposure after month 3 
was also associated with increased risk of acute rejection.22 The association between the 
Tac IPV and poor kidney transplantation outcome was not significantly modified within 
four patients subgroups based on their mean Tac C0 . Contrary to previous reports9,23 that 
suggested that an episode of acute rejection is one of major factors for inferior graft 
outcome, our multivariate analysis did not confirm that. The reason probably is that the 
population we studied is a selection that survived at least one year after transplantation 
with acceptable renal function. Recently, a multivariate analysis performed in 739 liv-
ing donor recipients found steroid-resistant acute rejection, but not any acute rejection 
episode, to be significantly associated with death-censored graft loss.24 Unfortunately, in 
this retrospective analysis we were unable to distinguish between several types of acute 
rejection. The major reason for this is that this was a retrospective study and that in the 
period between year 2000 and year 2010 the Banff classification for kidney transplant 
rejection was frequently changed.
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This multivariable analysis in a large patient population with long follow-up underlines 
the importance of IPV as a predictor of long-term outcome after kidney transplantation. 
In our analysis, the median IPV value was used as a cut-off value. It remains unclear if 
there is a critical threshold for IPV above which the risk of graft loss increases. The cut-off 
values in the studies by Borra et al.9 and Ro et al.10 (14.9% and 18.0%, respectively) were 
close to the Tac IPV cut-off value of this study, namely 16.2%.
This study provides good evidence that high Tac IPV increases the risk of poor kidney 
transplantation outcome. Also the mean Tac concentration at month 12 after transplanta-
tion was a significant predictor of long term outcome after kidney transplantation. From 
Figure 3 (A and B) it can be suggested that in patients with a high Tac IPV (> 16.2%) 
it is judicious to strive for a Tac C0 of ≥ 7.0 ng/ml, to reduce the risk of poor kidney 
transplantation outcomes.
Calculation of Tac IPV is an easy and cheap monitoring tool that may help to identify 
high-risk patients during routine follow-up visits to the outpatient clinic. Incorporating 
algorithms that calculate IPV into electronic patient files may assist physicians to recog-
nize these patients. Once a patient is recognized as having a high IPV, physicians need 
to find out what is the underlying cause, and try to resolve the problem. It is interest-
ing to speculate on the potential causes of Tac IPV.5 Non-adherence to the therapy is 
considered an important cause of high variability25 and has been repeatedly associated 
with poor transplant outcome.26 Concomitant diet, over-the-counter medications and 
repetitive substitution of different (generic) Tac formulations may also contribute to Tac 
IPV. To avoid a high IPV in Tac exposure, patients should be instructed to take their Tac in 
a consistent manner, with respect to the meal content and timing of ingestion relative to 
consumption to meals. Moreover, the use of interacting substances should be addressed 
and substitution of the innovator drug for generic Tac or one generic formulation for 
another has to be avoided. Some investigators have reported improved adherence after 
switching from the twice-daily to the once-daily, modified-release Tac formulation .27 
Others also showed that Tac IPV decreased following a switch to a once-daily formula-
tion.28,29 This has however, not been a universal finding and at present it is unknown if 
switching to a once-daily Tac formulation will improve long-term kidney transplantation 
outcome.30
In conclusion, in the largest sample size studied so far, a high Tac IPV was found to be 
associated with adverse long-term renal transplant outcome. In patients with fluctuating 
tacrolimus concentrations despite a stable dose, physicians should discuss drug adher-
ence with the patient. To quantify the variability the IPV can be calculated but most likely 
there is not a critical threshold above which clinical outcome is impaired. In order to 
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collect more evidence, a prospective evaluation of the use of IPV monitoring to see if it 
can indeed improve outcomes is needed.
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ABSTRACT
We hypothesized that a high intra-patient variability (IPV) of tacrolimus (Tac) exposure 
after heart transplantation may be associated with progression of cardiac allograft vas-
culopathy (CAV) as a determinant of long-term survival of heart transplant recipients.
Eighty-six heart transplant recipients were included. Patients underwent coronary an-
giography at year 1 and 4 after transplantation and were divided according to low and 
high IPV of Tac exposure, with the median variability as cut-off. The primary outcome was 
the association between Tac IPV and the progression of CAV score between year 1 and 4. 
Secondary outcome was this association with acute cellular rejection.
There was no significant difference in the proportion of patients with high Tac IPV in the 
group with progression of CAV (n = 15) as compared with the group without CAV pro-
gression (n = 71) (60.0% versus 47.9% respectively, p = 0.57). There was no significant 
difference in the proportion of patients with high IPV between the group of 58 patients 
with one or more acute cellular rejection and the group of 28 patients without rejec-
tion (51.7% versus 46.4%, respectively, p = 0.82). A high IPV in Tac exposure was not 
associated with progression of CAV nor with acute cellular rejection in heart transplant 
recipients.
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INTRODUCTION
The immunosuppressive drug tacrolimus (Tac) has a narrow therapeutic range and its 
clinical use is complicated by a large inter-patient variability in its pharmacokinetics. 
The determinants for this inter-patient variability have been studied extensively, and 
include genetic factors, co-medication, and demographic variables.1-3 Because of this 
inter-patient variability, the Tac dose is routinely adjusted based on drug concentration 
measurements in blood in order to reach pre-defined target concentrations.
Tac also displays considerable variability in its pharmacokinetics within a single patient 
over time, so-called intra-patient variability (IPV). Certain patients who are treated with a 
stable drug dose will have stable exposure to Tac, but in others Tac concentrations may 
fluctuate considerably over time despite an unchanged dose. IPV in Tac exposure may be 
related to non-adherence but factors other than compliance may play a role. Food intake 
may be a relevant determinant,4 whereas genetic factors seem less important.5-7
Whatever the cause of the IPV in Tac pharmacokinetics may be, patients with a high 
variability have a Tac exposure more often outside the target range. Such patients may 
be at risk for under-immunosuppression and rejection, as well as overexposure and 
toxicity. In a previous study, we demonstrated that a high IPV in the exposure of Tac 
was associated with poor graft survival after kidney transplantation.8 Other investigators 
have reported that kidney transplantation outcomes are also worse in patients who have 
a high variability in the exposure of cyclosporine.9,10 Best et al.11 reported that a high IPV 
in cyclosporine exposure was associated with an increased risk for rejection early after 
heart-lung transplantation.
The impact of IPV in Tac exposure on graft vascular disease after heart transplantation 
has not been studied. Cardiac allograft vasculopathy (CAV) is an important problem that 
limits long-time survival after heart transplantion. CAV is characterized by proliferative 
thickening of the vascular intima and progressive narrowing of the vascular lumen. 
This process is related to both immunological and non-immunological mechanisms.12 
These mechanisms include a chronic allo-immune–mediated damage, as well as non-
immunological factors such as ischemia-reperfusion damage, donor age, hypertension, 
hyperlipidemia and CMV-infection. Cellular rejection early and late after heart transplan-
tation is an independent risk factor for the development of CAV.13,14 A variable exposure 
to Tac may lead to an increased frequency of cellular rejection and to the development of 
CAV. The aim of this study was to determine whether a high IPV in Tac exposure is associ-
ated with more rapid progression of cardiac allograft vasculopathy in heart transplant 
patients.
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PATIENTS AND METHODS
Study Population
The patients were adults who received a heart transplant at the Erasmus MC, University 
Medical Center Rotterdam, Rotterdam, the Netherlands, between 2000 and 2011. All 
patients received induction therapy with anti-thymocyte globulin (ATG) followed by a 
maintenance immunosuppressive regimen consisting initially of a calcineurin-inhibitor 
(cyclosporine or Tac), prednisolone and mycofenolate mofetil (MMF). The maintenance 
immunosuppression was thereafter changed according to the tolerance of the drugs and 
the occurrence of rejection.
Surveillance for rejection was performed by endomyocardial biopsies, weekly for the first 
6 weeks, biweekly for the next 3 months, then monthly and finally bimonthly until 1 year 
after transplantation. A surveillance endomyocardial biopsy was also performed 4 year 
after transplantation at the time of follow-up coronary angiography (CAG). Additional 
biopsies were performed when there was clinical suspicion of rejection. Surveillance 
for CAV was done routinely by performing CAG at 1 and 4 years after transplantation, 
according to the protocol at our institution. In few patients CAG was performed at a dif-
ferent time due to a clinical indication. As the aim of this study was to investigate the 
association between IPV in Tac exposure and the progression of CAV, only patients who 
had survived the first 18 months after transplantation were included. Furthermore, all 
patients had to use the twice daily oral Tac formulation (Prograf®, Astellas Pharma Inc.) 
between 6 and 18 months after transplantation.
Study Parameters
The primary outcome of this study was the development of CAV defined as progression 
of CAV score between the two predefined moments of angiographic follow-up, i.e. the 
1st and 4th year CAG. The extent of CAV was graded according to the 2010 ISHLT (The 
International Society for Heart & Lung Transplantation) Cardiac Allograft Vasculopathy 
nomenclature:15
- CAV0 indicates coronary vessels without detectable angiographic lesions.
- CAV1 (mild) indicates angiographic <50% stenosis of the left main coronary artery or 
<70% stenosis of a primary vessel or any branch stenosis <70% (including diffuse 
narrowing), in the absence of allograft dysfunction.
- CAV2: (moderate) angiographic <50% left main stenosis, a ≥ 70% stenosis in a single 
primary vessel or isolated ≥70% stenosis in branches of 2 systems, without allograft 
dysfunction.
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- CAV3: (severe) angiographic ≥ 50% stenosis of the left main coronary artery, or ≥ 70% 
lesions of two or more primary vessels, or ≥ 70% stenosis in branches of 3 systems, 
or when CAV1 or CAV2 are associated with allograft dysfunction.
Patients in whom the CAV score changed between the 1st and 4th year after transplanta-
tion were defined as patients with CAV progression. Patients in whom the CAV score 
remained constant were defined as patients without CAV progression.
As a secondary outcome we investigated the association between acute cellular rejection 
and IPV in Tac exposure. Acute cellular rejection was defined as a heart biopsy of at least 
grade 3A according to the 1990 ISHLT grading system (in the years 2000-2005) or at least 
grade 2R according to the 2004 ISHLT revised grading system (from 2006 until present).16 
Early acute rejection rates were calculated within the first year after transplantation and 
late acute rejection was defined as any rejection within the period of 1 year and 4 years 
after transplantation.
Tac predose concentrations (C0) were determined throughout the study period in whole-
blood by use of immunoassays [the Emit 2000 assay (Syva Company, Dade Behring Inc., 
Cupertino Calif.) and the ACMIA-Flex assay (Siemens HealthCare Diagnostics, Inc., Newark, 
DE)] on several analyzers [the IMX (Abbott laboratories, Ill), the Cobas Mira Plus analyzer 
(Roche Diagnostic Systems, Basel, Switzerland), the V-twin and Dimension XPand (both 
Siemens HealthCare Diagnostics, Inc, Newark, DE)]. Details on the sensitivity, reproduc-
ibility, and sensitivity of the Emit assay in our laboratory were published previously.17 
Proficiency samples were obtained from the International Proficiency Testing Scheme for 
Immunosuppressive Drugs (Professor Holt, Analytical Services International, St George’s 
University of London). The Tac predose concentration measurements were collected 
within the period of 18 months post-transplantation.
For the calculation of IPV in Tac exposure, at least 3 C0 had to be available for an individual 
patient. Because heart transplant patients are not on a stable Tac dose in the first phase 
after transplantation and because they often use interacting drugs in this period, only 
data on Tac exposure measured at outpatient clinic visits in the period of 6-18 months 
post-transplantation were collected. Tac concentration measurements obtained during 
hospitalization were not considered. Since not all patients received a constant drug dose 
between months 6 and 18, the obtained C0 were corrected for the corresponding daily 
Tac dose (C0/D). The IPV in Tac exposure was calculated using the following formula:
IPV %= {[|(Xmean –X1)| + |(Xmean –X2)| …+ |(Xmean -Xn)|] / n} / Xmean x 100
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Where Xmean is the mean Tac C0/D of all the available samples, X1 is the first available Tac 
C0/D sample, X2 is the second and so on.8
Statistical Analysis
The distribution of baseline characteristics is reported using summary statistics and 
frequency tables for continuous and categorical variables, respectively. Baseline charac-
teristics are compared with the Mann-Withney U test for continuous variables, and the 
chi-square test for categorical variables. The IPV was correlated with the CAV-grading and 
also with acute rejection using the chi-square test. Analyses were performed using IBM 
SPSS Statistics 20 (SPSS Inc., Chicago, IL). All tests were two-sided and a p-value < 0.05 
was considered statistically significant.
RESULTS
Between January 2000 and December 2010 a total of 177 patients aged >18 years were 
transplanted in our center. Of these, 33 died within the first four years after transplan-
tation, 8 did not undergo both angiographic evaluations (at the 1st and 4th year) due 
to co-morbidities, and 2 patients had severe CAV (CAV score 3) already at the 1st year 
angiography. These 43 patients were excluded from the analysis. Forty-eight patients 
used cyclosporine as the primary CNI during the selected time and were therefore 
excluded from the analysis. As a result a total of 86 patients using Tac and having a 
angiographic evaluation at the 1st and the 4th post-transplant year was available for the 
present analysis.
Development of CAV
Of the 86 patients, 15 patients had progression of their CAV score between the 1st and 
4th year. Baseline characteristics of the patients are shown in Table 1. There were no 
significant differences in the age of the recipient, the age of the donor, the ischemia time 
at transplantation, cholesterol levels, and the presence of hypertension and diabetes 
mellitus between patients with and those without CAV progression. There was a trend 
towards more CMV infection in the group of patients with progression of CAV (60.0% 
versus 16.9%; p = 0.10). Seventy-one patients had the same CAV score at the 1st year 
and 4th year CAG, and therefore did not have progression of CAV (Table 2). Systolic left 
ventricular function was normal in 14 patients with CAV and 70 patients without CAV. 
One patient in the CAV group and 1 patient in the group without CAV had an impaired 
systolic left ventricular function (Table 4).
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Table 1. Patient characteristics.
CAV progression
(n =15)
No CAV progression 
(n = 71)
P
Gender (% male) 66.7% 63.4% 1.00
Primary heart disease 0.97
Iscemic heart disease 6 (40.0%) 27 (38.0%)
Dilated cardiomyopathy 6 (40.0%) 32 (45.1%)
Hypertrophic cardiomyopathy 2 (13.3%) 7 (9.9%)
Congenital disease 1 (6.7%) 5 (7.0%)
Recipient age (year) 50 (30 – 61) 49 (24 – 65) 0.72
Donor age (year) 48 (31 – 63) 44 (16 – 64) 0.12
Ischemic time at transplantation (min.) 184 (88 – 260) 188 (88 – 295) 0.60
CMV infection 40.0% 16.9% 0.10
Hypertension 86.7% 70.4% 0.34
Diabetes Mellitus 33.3% 31.0% 1.00
Total Cholesterol (mmol/L)
at 1 year 4.9 (3.5 – 7.3) 5.0 (3.0 – 8.6) 0.85
at 4 year 4.9 (3.1 – 7.7) 5.2 (2.8 – 9.1) 0.46
Co-medication
Statin 100.0% 80.3% 0.12
Prednisolone 86.7% 87.3% 1.00
Mycophenolate mofetil 46.7% 53.5% 0.84
Everolimus 26.7% 9.9% 0.10
Sirolimus 0% 1.4% 1.00
* The summary measure for non-normally distributed variables is the median (range). For binary or 
categorical variables, the summer measure is the proportion.
Table 2. CAV score
CAV progression
(n = 15)
No CAV progression
(n = 71)
1 year CAV score
CAV0 12 (80.0%) 68 (95.8%)
CAV1 3 (20.0%) 2 (2.8%)
CAV2 0 1 (1.4%)
CAV3 0 0
4 year CAV score
CAV0 0 68 (95.8%)
CAV1 7 (46.7%) 2 (2.8%)
CAV2 4 (26.7%) 1 (1.4%)
CAV3 4 (26.7%) 0
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Intra-patient variability and CAV
The patients who developed CAV had an average of 10.8 ± 1.8 Tac concentration measure-
ments to calculate the IPV. This was comparable with the patients without CAV (10.7 ± 
2.4 Tac concentration measurements, p = 0.88). The median IPV in Tac pharmacokinetics 
was 17.7 %, but the variability range was distributed from 5.1% to more than 69.5%. 
There was no significant difference in the distribution of Tac IPV between patients with 
progression of CAV score and those without (Figure 1). The median Tac IPV in patients who 
developed CAV was 17.8% (9.6% -65.4%), whereas this was 17.5% (5.1% - 69.5%) in 
patients without CAV progression (p = 0.98). Using the 17.7% value as a cut-off, patients 
were divided into a low and high variability group. The 43 patients in the low IPV group had 
a median variability of 13.5% (range: 5.1% – 17.7%). The 43 patients in the high IPV group 
 
figure 1. Distribution of Tac intra-patient variability among patients with progression of CAV score 
and those without.
Table 3. Intra-patient Tac variability in tacrolimus exposure in patients without CAV progression and 
patients with CAV progression.
Intra-patient variability No CAV progression
(n = 71)
CAV progression
(n = 15)
P
Low 37 (52.1%) 6 (40.0%) 0.57
High 34 (47.9%) 9 (60.0%)
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had a median variability of 22.6% (range: 17.7% – 69.5%)%. Progression of CAV score was 
not correlated with the IPV. There was no significant difference in the proportion of patients 
with high IPV in the group with development of CAV as compared with the group without 
CAV (60.0% versus 47.9%, p = 0.57) as shown in Table 3.
Intra-patient variability and acute rejection
To test whether the IPV was correlated to the development of acute cellular rejection we 
divided the patients into those who had one or more rejection episodes in the first year 
after transplantation and compared them to patients who did not have any rejection in 
the first year after transplantation. A total of 58 patients experienced acute rejection 
episodes within the first year after transplantation, while 12 patients experienced a late 
rejection. Twenty-three patients had one rejection episode, whereas 22 had two, and 16 
had three or more rejection episodes. Most rejection episodes (n = 108) were treated 
with a course of intravenous methylprednisolone, 1 episode was treated with (rabbit-
ATG), and 17 were treated with an increased oral prednisone dose (Table 4).
Of the patients with a rejection, 48.3% (n = 28) had a low IPV and 51.7% (n = 30) had a 
high IPV of Tac exposure. When the variability of the patients who did not have a rejection 
(n = 28) were analyzed, comparable results were found: 53.6% (n = 15) had a low IPV and 
Table 4. Rejections
CAV progression
(n=15)
No CAV progression
(n = 71)
P
Early rejections ( < 1 year); n = 115
Moderate (3A or 2R) 27 85 0.04*
Severe (3B or 3R) 2 1
Late rejections (> 1 year); n = 13
Moderate (3A or 2R) 3 9 1.0
Severe (3B or 3R) 0 1
Number of patients with early rejection
1 2 (13.3%) 22 (31.0%) 0.06
>1 10 (66.7%) 24 (33.8%)
Number of patients with late rejection
1 1(6.7%) 10 (14.1%) 0.07
>1 1 (6.7%) 0
Left ventricular function
Normal 14 (93.3%) 70 (98.6%) 0.32
Impaired 1 (6.7%) 1 (1.4%)
Median number of episodes acute rejection among patients with progression of CAV score was 2.0 
(0 – 5), whereas the median number was 1 (0 – 6) in patients without progression of CAV (p = 0.04).
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46.4% (n = 13) a high IPV (p = 0.82), as shown in Table 5A. The distribution of the Tac IPV 
among patients who did develop an acute rejection was also not significantly different to 
the distribution of Tac IPV in patients who did not have an acute rejection (Figure 2). The 
median Tac IPV in patients with rejection was 17.8% (6.8% -65.4%), whereas this was 
17.6% (5.1% - 69.5%) in patients without rejection (p = 0.96).
 
figure 2. Distribution of Tac intra-patient variability among patients who did develop an acute rejec-
tion and those who did not.
Table 5A. Distribution of patients without rejections in the first year and patients with one or more 
rejections in the first year in the groups with low and high intra-patient variability of tacrolimus.
Intra-patient variability No rejection
(n = 28)
1 or more rejections
(n = 58)
P
Low 15 (53.6%) 28 (48.3%) 0.82
High 13 (46.4%) 30 (51.7%)
Table 5B. Distribution of patients without rejections in the first year and patients with three or more 
rejections in the first year in the groups with low and high intra-patient variability of tacrolimus.
Intra-patient variability No rejection
(n = 28)
3 or more rejections 
(n = 13)
P
Low 15 (53.6%) 5 (38.5%) 0.57
High 13 (46.4%) 8 (61.5%)
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We hypothesized that a high IPV might lead to multiple rejections. To test this hypothesis 
we compared the proportion of patients with high intra-patients Tac variability in the 
group with 3 or more rejections (n = 13 patients) and the group without any rejection 
(n = 28 patients). The null hypothesis was not rejected, as there were 61.5% (n = 8) 
and, respectively, 46.4% (n = 13) of patients with a high intra-patient Tac variability in 
the group with 3 or more rejections as compared with the group without any rejection, 
respectively (p = 0.57, Table 5B).
DISCUSSION
To the best of our knowledge this study is the first to investigate the IPV in Tac levels in 
adult heart transplant recipients. We show that the IPV in Tac exposure is not associated 
with progression of coronary allograft vascular disease within the first 4 years nor with 
acute rejection after heart transplantation. These data may be in contrast with the signifi-
cant association between IPV in Tac exposure and kidney allograft survival demonstrated 
in an earlier study performed by Borra et al.8
Development of CAV after heart transplantation is a complex process which is im-
munologically and non-immunologically mediated. The introduction of calcineurin 
inhibitors has not decreased the development of CAV.12 Mycophenolate mofetil has been 
shown to modestly reduce the intima thickness measured by intravascular ultrasound 
(IVUS) as compared to older immunosuppressive combinations using azathioprine.12 
In a randomized-controlled trial of 600 patients that evaluated everolimus versus aza-
thioprine in an immunosuppressive regimen including cyclosporine and corticosteroids, 
everolimus significantly reduced intima thickness measured by IVUS, although it did not 
improve graft survival and was associated with dyslipidemia and decreased renal func-
tion.18 It has been shown that CMV infection is an independent risk factor for CAV after 
transplantation, likely due to alteration of endothelial nitric-oxide synthase pathway.19 
ISHLT guidelines recommend a strict control of cardiovascular risk factors (hypertension, 
diabetes, hyperlipidemia, smoking and obesity), prophylaxis of CMV infection and the 
use of statins for the prevention of CAV.20
In our study, the group of patients with progression of CAV tended to have more CMV 
infections compared to the group of patients without progression of CAV, while there was 
no difference between the groups in terms of other atherosclerotic risk factors, the use 
of statins or immunosuppressive drugs. The design of the study allowed assessment of 
progression of CAV between 1 and 4 years post-transplantation excluding donor-related 
and surgery-related factors. Our hypothesis was that a high IPV in Tac exposure may 
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influence the development of CAV by lowering the chronic immunosuppressive exposure 
that allows a good transplant function. However, we found no association between a 
high intra-patient Tac variability and progression of CAV at 4 years. This suggests that 
other mechanisms unaffected by the calcineurin inhibitors influence development and 
progression of CAV.
Earlier studies have shown that there is a cumulative effect of acute rejection on de-
velopment of CAV and that also late acute rejections increase the risk of CAV.13,14 In our 
study there was a trend toward an increased number of patients with more than 1 acute 
rejections within the first post-transplant year and the progression of CAV after the first 
year. Contrary to our results, Pollock et al.21 have shown in a pediatric population, that 
a high variability in Tac levels in 144 solid organ transplantations (including 28 heart 
transplantations) is an independent risk factor for late graft rejection and graft loss. The 
difference with our study might be explained by the studied population, as the study of 
Pollock et al. was performed in a population with a median age of 13 year, and by the 
immunosuppressive treatment used in combination with Tac. Pollock et al. mentioned 
in their study that one of the contributing factors for the high IPV is the documented 
medication non-adherence. Ensuring adequate adherence in a pediatric population 
(especially adolescents) is more complicated compared to adults.22,23
As opposed to the deleterious effect of high intra-patient Tac variability for the graft 
survival found in the renal transplant recipients, we found no such effect on progression 
of CAV in heart transplant recipients. This may be explained by the compensation of the 
IPV of Tac exposure by a strong immunosuppressive regimen often consisting of three 
immunosuppressive drugs, including corticosteroids, in our heart transplant recipients. 
Although the number of patients with at least one rejection was high in both groups, 
the majority of rejections was moderate and was treated with a course of intravenous 
methylprednisolone, which may have compensated for the variability of Tac clearance. 
Furthermore, the large majority of the patients in both groups had preserved graft func-
tion, suggesting that rejections were well treated.
This study has several limitations. It is a retrospective study, and the time period that 
we have chosen for the analysis of Tac pharmacokinetics was between 6 and 18 months 
after transplantation. The early post-transplant period (< 6 months) is associated with in-
creased Tac exposure variability due to interaction with medications and more frequent 
hospital admission. A different period of measurement may lead to a different outcome. 
The number of investigated patients was low, and therefore our study may not have 
enough statistical power to identify the association between IPV and the progression of 
vascular disease. The evaluation of CAV was only made by the angiographic assessment, 
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and did not involve intravascular ultrasound (IVUS) or optical coherence tomography 
(OCT) for assessment of preclinical stages of coronary disease. Our results are limited to 
the period of 4 year after transplantation, and therefore cannot be extrapolated to more 
long-term graft function and survival.
CONCLUSION
A high IPV in Tac exposure was not associated with the development and progression of 
CAV nor to the development of acute cellular rejection. The use of a combination of two 
or three immunosuppressive drugs including corticosteroids after heart transplantation 
may protect against episodes of over –or underexposure to Tac. These findings suggest 
that the implications of a high IPV of Tac exposure may be organ-specific, and thus less 
important in heart transplant recipients.
162 Chapter 4.3
REfERENCES
 1. Hesselink DA, van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Zeier M, et al. CYP3A5 geno-
type is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant 
recipients. Pharmacogenet Genomics. 2008: 18: 339.
 2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ 
transplantation. Clin Pharmacokinet. 2004: 43: 623.
 3. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining 
variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant 
recipients. Ther Drug Monit. 2009: 31: 187.
 4. Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single 
oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001: 41: 289.
 5. Pashaee N, Bouamar R, Hesselink DA, Roodnat JI, van Schaik RH, Weimar W, et al. CYP3A5 genotype 
is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit. 2011: 33: 369.
 6. Spierings N, Holt DW, MacPhee IA. CYP3A5 genotype had no impact on intrapatient variability of 
tacrolimus clearance in renal transplant recipients. Ther Drug Monit. 2013: 35: 328.
 7. Yong Chung J, Jung Lee Y, Bok Jang S, Ahyoung Lim L, Soo Park M, Hwan Kim K. CYP3A5*3 genotype 
associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. 
Ther Drug Monit. 2010: 32: 67.
 8. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in 
the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. 
Nephrol Dial Transplant. 2010: 25: 2757.
 9. Kahan BD, Welsh M, Urbauer DL, Mosheim MB, Beusterien KM, Wood MR, et al. Low intraindividual 
variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J 
Am Soc Nephrol. 2000: 11: 1122.
 10. Waiser J, Slowinski T, Brinker-Paschke A, Budde K, Schreiber M, Bohler T, et al. Impact of the vari-
ability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant. 
2002: 17: 1310.
 11. Best NG, Trull AK, Tan KK, Hue KL, Spiegelhalter DJ, Gore SM, et al. Blood cyclosporin concentrations 
and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol. 
1992: 34: 513.
 12. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. 
Am J Transplant. 2006: 6: 1248.
 13. Brunner-La Rocca HP, Schneider J, Kunzli A, Turina M, Kiowski W. Cardiac allograft rejection late after 
transplantation is a risk factor for graft coronary artery disease. Transplantation. 1998: 65: 538.
 14. Stoica SC, Cafferty F, Pauriah M, Taylor CJ, Sharples LD, Wallwork J, et al. The cumulative effect of 
acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006: 
25: 420.
 15. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. 
International Society for Heart and Lung Transplantation working formulation of a standardized 
nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010: 29: 717.
 16. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 
1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejec-
tion. J Heart Lung Transplant. 2005: 24: 1710.
 Influence of tacrolimus intra-patient variability on heart allograft 163
4
 17. Hesse CJ, Baan CC, Balk AH, Metselaar HJ, Weimar W, van Gelder T. Evaluation of the new EMIT 
enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, 
heart, and liver transplant recipients. Transplant Proc. 2002: 34: 2988.
 18. Valantine HA. The role of viruses in cardiac allograft vasculopathy. Am J Transplant. 2004: 4: 169.
 19. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, et al. Everoli-
mus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N 
Engl J Med. 2003: 349: 847.
 20. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of 
Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung 
Transplant. 2010: 29: 914.
 21. Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, et al. Variability in tacro-
limus blood levels increases the risk of late rejection and graft loss after solid organ transplantation 
in older children. Pediatr Transplant. 2010: 14: 968.
 22. Griffin KJ, Elkin TD. Non-adherence in pediatric transplantation: a review of the existing literature. 
Pediatr Transplant. 2001: 5: 246.
 23. Shemesh E, Shneider BL, Emre S. Adherence to medical recommendations in pediatric transplant 
recipients: time for action. Pediatr Transplant. 2008: 12: 281.

4.4
Conversion from twice-daily to 
once-daily tacrolimus does not 
reduce intra-patient variability 
in tacrolimus exposure
Nauras Shuker, Minique Cadogan, 
Teun van Gelder, Joke I. Roodnat, 
Marcia M.L. Kho, Willem Weimar, 
Dennis A. Hesselink
Ther Drug Monit. 2015 Apr;37(2):262-9.
166 Chapter 4.4
ABSTRACT
Background: Intra-patient variability (IPV) in tacrolimus exposure is associated with renal 
allograft failure. The aim of this study was to investigate whether conversion from the 
twice-daily tacrolimus formulation (Tac-TD) to a once-daily formulation (Tac-OD) leads to 
a lower IPV in tacrolimus exposure.
Methods: Two-hundred-forty-seven stable renal transplant recipients were converted 
from Tac-TD to Tac-OD (Advagraf®) on a 1 mg:1 mg total daily dose basis. After conversion, 
patients were followed for 12 months and tacrolimus predose whole-blood concentra-
tions (C0), serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria 
were measured. These parameters were compared with those collected at all outpatient 
visits in the 12-month period (±3 months) before conversion (Tac-TD period). The IPV was 
calculated based on the dose-adjusted tacrolimus C0.
Results: The Tac-OD formulation provided an excellent graft survival (100%), a low acute 
rejection rate (0.8%), and good tolerability. Renal function remained stable: eGFR 48 
(16-90) mL/min vs. 46 (12-90) mL/min (p=0.15) before and after conversion, respectively. 
After conversion to Tac-OD, mean C0 was significantly lower, falling from 5.7 ± 1.5 ng/mL 
to 5.0 ±1.5 ng/mL, corresponding to a 12% reduction (p < 0.01). Both drugs had similar 
IPV (Tac-TD: 17.3 ±1.6% vs. Tac-OD: 16.4 ±1.6%; p =0.31).
Conclusions: Although conversion from Tac-TD to Tac-OD significantly reduces tacroli-
mus exposure as measured by C0, and appears safe, it does not reduce IPV in tacrolimus 
exposure.
Keywords: Intra-patient variability, modified-release, pharmacokinetics, tacrolimus.
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INTRODUCTION
Non-adherence to immunosuppressive drug treatment is associated with poor long-term 
transplantation outcome.1,2 Modified-release, oral dosage form of tacrolimus (Tac-OD; 
Advagraf®) provides a once-daily dosing alternative for the immediate-release (twice-
daily) Tac formulation (Tac-TD) and significantly improves adherence.3
The intra-patient variability (IPV) in a drug’s pharmacokinetics is the amount of fluctuation 
in drug concentrations within an individual over a certain period of time during which the 
dose is unchanged. A high IPV in the exposure to tacrolimus may put the patient at risk 
for toxicity (in case of overexposure) or for rejection if concentrations fall below the 
lower threshold of its narrow therapeutic window.4 In renal transplant recipients (RTRs) 
a high IPV in tacrolimus exposure is a risk factor for rejection and long-term treatment 
failure.5,6
Medication adherence may be an important determinant of IPV in drug exposure. 
Theoretically, the higher adherence to Tac-OD could lower IPV in tacrolimus exposure, 
and improve transplantation outcomes. Only a few studies, including limited patient 
numbers, have compared the IPV between Tac-TD and Tac-OD.7-11 This prompted us to 
investigate whether conversion from Tac-TD to Tac-OD results in a lower tacrolimus IPV 
in a larger cohort of stable RTRs.
PATIENTS AND METHODS
Study design
This was a single-center, nonrandomized, study to assess the safety of conversion from 
Tac-TD to Tac-OD after kidney transplantation. Patients were eligible for enrollment if 
they met the following inclusion criteria: 1) treatment with a Tac-TD-based immunosup-
pressive regimen; 2) a need for continued therapy with tacrolimus; 3) age ≥ 18 years; and 
4) a follow-up of ≥ 5 months after transplantation.
After inclusion, Tac-TD (Prograf®, Astellas Pharma, Leiden, the Netherlands) was con-
verted (t = 0) to Tac-OD (Advagraf®, Astellas Pharma; only morning dosing) on a 1:1 
(milligram:milligram) basis. During both study periods (pre-conversion and post-conver-
sion), tacrolimus doses were adjusted to achieve a predose whole-blood concentrations 
(C0) of 4-10 ng/mL. After conversion, patients were followed for 12 months with study 
assessments and laboratory sampling (tacrolimus C0 and renal function) at 3-monthly in-
tervals, or whenever deemed necessary by the attending physician. Variables of interest 
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were tolerability of Tac-OD, renal function, and serious adverse events (SAEs). Clinicians 
were allowed to monitor tacrolimus exposure and adjust the Tac-OD dose before the first 
scheduled study visit at month 3.
Within the frame of this study, we studied whether conversion from Tac-TD to Tac-OD 
influenced Tac IPV. We therefore collected all Tac C0 measured during visits to the outpa-
tient clinic from the time of conversion up until month 12 (±1 month) after conversion (t = 
12). To calculate Tac IPV during the use of Tac-TD, we collected the Tac C0 retrospectively 
from the year before conversion (t = -12 ±3 months).
As transplant recipients are not on a stable Tac dose in the first phase after transplanta-
tion, and because they often underwent interventions that may influence Tac exposure 
in this period (e.g. the use of interacting antibiotics or pulse corticosteroid therapy), only 
data on Tac exposure from month 5 (and onwards) post-transplantation were considered. 
Therefore, data on the Tac IPV were derived from patients at least 14 months after trans-
plantation. For the same reason, Tac C0 that were collected during hospital admission(s) 
were not included.
Ethics
The study was approved by the institutional review board. The conversion from Tac-TD 
to Tac-OD was considered to be in the realm of routine clinical care, and therefore, no 
formal medical ethical approval of this study was required. Nonetheless, all patients 
were asked if they objected to being switched to Tac-OD, and all gave written consent 
prior to conversion. For the study of the change in Tac IPV, data were used that were only 
obtained as part of routine patient care.
Intra-Patient Variability
The variable of interest was the Tac IPV. For its calculation, at least 3 Tac C0 measurements 
had to be available for both the Tac-TD and the Tac-OD phase. IPV was calculated as 
follows:5
IPV% = {[|(Xmean – X1)| + |(Xmean – X2)|… + |(Xmean – Xn)|]/n}/ Xmean x 100 1.
where Xmean is the mean Tac C0 of all available samples, X1 is the first available Tac con-
centration measurement, X2 is the second, and Xn is the nth available Tac C0. Using this 
formula the quantity (Xmean – Xn) is always expressed as a positive integer (absolute value). 
Because not all patients received a constant Tac dose throughout the study period, the 
obtained Tac C0 were corrected for the corresponding daily Tac dose (C0/D). The recipro-
cal of this ratio gives an apparent oral clearance.
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Patients were characterised as having a high or low IPV using the median variability of 
the IPV as the cutoff value.
Tacrolimus C0 were determined in whole-blood using the ACMIA-Flex immunoassay on a 
Dimension XPand (both Siemens HealthCare Diagnostics Inc., Newark, USA).
Statistical Analysis
The IPV was calculated using Microsoft Excel 2010. Statistical analyses were performed 
using Statistical Program of Social Sciences version 20 (SPSS Inc., Chicago, Ill., USA). Data 
distribution was assessed by visual inspection and the Kolmogorov-Smirnov test. As the 
distribution was mostly skewed, the log-transformed data were analyzed. Categorical 
variables are reported using frequency tables and percentages, and continuous variables 
are expressed as geometric means, unless stated otherwise.
Differences in IPV between the treatment periods were assessed using the paired t 
test. Differences in median values were tested by the Wilcoxon signed-rank test and 
distributions were tested by the Mann-Whitney U test. The relationship between various 
demographic, clinical, and laboratory variables with Tac IPV was assessed using univari-
ate analyses. Variables thet showed a statistically significant relation were then included 
in a multivariate regression analysis to investigate if they affected the relation between 
the formulation and IPV.
To quantify the effect of regression to the mean (RTM), the following formula was used:12, 13
RTM effect = σt(1 – ρ)C(z), −1≤ ρ ≤ 1 2.
where σt is the standard deviation (SD), ρ the correlation between two measures and,
C(z) = φ(z) / (1 − Φ(z))
where z = (c – population mean) / σt if the subjects are selected using a baseline mea-
surement greater than c, and z = (population mean – c) / σt if the subjects are selected 
using a baseline measurement less than c. The terms φ(z) and 1 – Φ(z) are, respectively, 
the probability density and the cumulative distribution functions of the standard normal 
distribution. The calculations were undertaken using the log-transformed data.
Statistical significance was defined as a two-tailed p-value <0.05. The post hoc power cal-
culation was performed using the program ‘G*power 3.1.9.2’ (Heinrich-Hein-University; 
Düsseldorf, Germany).
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RESULTS
Baseline characteristics and pharmacokinetic outcomes
Two hundred fifty one stable RTRs were enrolled between December 2009 and October 
2011 (Table 1 for characteristics). Of these, 247 were converted to Tac-OD. Three patients 
never took Tac-OD for unknown reasons, and 1 patient declined conversion after signing 
informed consent. Of these 247 patients, 227 completed the 12-month follow-up (Figure 
1). During follow-up, 2 patients died, 5 were lost to follow-up, and in 13 patients treat-
ment with Tac-OD was interrupted (in 8 cases because of side effects; in 4 for unknown 
reasons). These 12 patients were reconverted to Tac-TD. In 1 patient treatment with 
Tac-OD was interrupted because of recurrent glomerulonephritis requiring cyclophos-
phamide and high-dose glucocorticoid treatment.
Most patients (n = 211 or 85%) were converted from Tac-TD to Tac-OD on a 1:1 
(milligram:milligram) total daily dose basis. However, in 36 cases, it was decided to change 
the daily Tac dose at conversion and was therefore increased in 25 and decreased in 11 
patients. In 13 patients, the Tac dose was changed at the time of conversion because 
Tac C0 was outside the therapeutic range (4-10 ng/mL). In the remainder (n = 23), the 
clinicians changed the dose because they anticipated a decrease in Tac C0 or because of 
Tac toxicity (side effects).
Three months after conversion, 240 patients were still using Tac-OD. Their total daily 
Tac dose was comparable with that at the time of conversion: 4.0 ±1.8 vs. 4.1 ±1.7 mg/
day; P = 0.16. In the first three months after conversion, the daily Tac dose had been left 
unaltered in 149 but was increased in 51 and decreased in 40 patients based on Tac C0 
measurements.
Tac C0 decreased from 5.8 ng/mL at baseline to 5.1 ng/mL at month 3, corresponding 
to a 12% fall (P < 0.01). The dose-adjusted Tac C0 (C0/D) also decreased by 14% (P < 
0.01; Table 2). The analysis was repeated after exclusion of the 36 patients who were 
not converted on a 1:1 basis. Again, Tac C0 decreased significantly, decreasing from 5.7 
to 5.0 ng/ml or by 12% (P < 0.01). Tac C0/D decreased from 1.43 to 1.25 ng/mL per mg/
day (P < 0.01).
Clinical outcomes
Ninety-one SAEs occurred in 62 patients (25.1%). Patient survival was 99.2%. One patient 
died from liver insufficiency caused by hepatitis C virus-related cirrhosis. The second 
patient died of unknown cause while on holiday. Neither of these deaths was suspected 
to be related to the use of Tac-OD. One-year graft survival censored for death was 100%.
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Two patients experienced a biopsy-proven acute rejection. The first patient had a type 
1 acute cellular rejection occurring some 3½ years after transplantation and 8 months 
after conversion to Tac-OD, which was treated with methylprednisolone. The second pa-
tient experienced a type 1 acute cellular rejection occurring 3 months after conversion. 
Table 1. Patient demographics and baseline characteristics.
Number of subjects (%)
Gender:
Male / Female 175 (69.7%) / 76 (30.3%)
Age (years): 51 (18–80)*
Ethnicity:
Caucasian 183 (72.9%)
Black 28 (11.2%)
Asian 24 (9.6%)
Other 16 (6.4%)
Primary kidney disease:
Hypertensive nephropathy 35 (13.9%)
Polycystic kidney disease 26 (10.4%)
Diabetic nephropathy 25 (10.0%) 
Glomerulonephritis 52 (20.7%) 
Congenital / Reflux disease 14 (5.6%) 
Other 76 (30.3%) 
Unknown 23 (9.2%) 
Number of kidney transplantation:
1st / 2nd / 3rd or more 207 (82.5%) / 34 (13.5%) / 10 (4.0%) 
Donor type:
Living / Deceased 175 (69.7%) / 76 (30.3%) 
Number of HLA** mismatches:
0 11 (4.4%) 
1 23 (9.2%) 
2 54 (21.5%) 
≥3 157 (62.5%) 
Missing 6 (2.4%) 
Time from transplantation to conversion (months): 37 (5-312)*
Immunosuppression at baseline:
Tac-TD (monotherapy) 29 (11.6%) 
Tac-TD and MMF 193 (76.9%) 
Tac-TD and prednisone 13 (5.2%) 
Tac-TD, MMF and prednisone 8 (3.2%) 
Tac-TD and other immunosuppressive drugs 8 (3.2%) 
* median (range)
** Human leukocyte antigen
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This rejection may have been triggered by the conversion to Tac-OD as Tac exposure 
temporarily decreased to a nadir of 3.6 ng/mL.
Three patients developed nonmelanoma skin cancer. Two patients experienced recur-
rent primary kidney disease (1 case of IgA nephropathy and one of p-ANCA-associated 
 
figure 1. Flow chart.
Table 2. The pharmacokinetic parameters at conversion (t=0) and after conversion to Tac-OD. All 
values are expressed as geometric mean with standard deviation. The apparent oral clearance is 
calculated by taking the reciprocal of dose-corrected Tac C 0 (e.g., a Tac C0/dose of 1.4 ng/ml per mg/
day gives an apparent oral clearance of 0.50 L/min).
t = 0 Month 3 Month 6 Month 9 Month 12
Whole study population (n=247) n = 247 n = 240 n = 237 n = 234 n = 227
Tac dose (mg/day) 4.0 ±1.8 4.1 ±1.7 4.0 ±1.7 4.0 ±1.7 4.0 ±1.7
Tac C0 (ng/ml) 5.8 ±1.5 5.1 ±1.5 * 5.1 ±1.4 * 5.2 ±1.4 * 4.9 ±1.5 *
Tac C0/dose (ng/ml per mg/day) 1.46 ±1.88 1.26 ±1.85 * 1.27 ±1.74 * 1.31 ±1.73 * 1.24 ±1.81 *
Patients available for IPV analysis (n=167) t = 0 Month 3 Month 6 Month 9 Month 12
Tac dose (mg/day) 3.8 ±1.7 3.9 ±1.7 3.8 ±1.7 3.9 ±1.7 3.8 ±1.7
Tac C0 (ng/ml) 5.3 ±1.4 4.8 ±1.5 * 4.9 ±1.4 * 5.0 ±1.3 4.6 ±1.5 *
Tac C0/dose (ng/ml per mg/day) 1.39 ±1.92 1.25 ±1.80 * 1.27 ±1.70 * 1.33 ±1.72 1.23 ±1.84 *
*significant change (p < 0.05) comparing to the measurements at the conversion time point (t = 0).
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glomerulonephritis). Twenty-six SAEs were related to hospitalization for an infection. In 
56 cases, other reasons necessitated hospitalisation.
Fifty-seven nonsevere adverse events (AEs) occurred in 52 (21.1%) patients. The most 
frequently reported AEs included skin-related disorders (n = 10, 4.0%), and infections (n 
= 17, 6.9%), most of which were urinary tract infections (n = 10, 4.0%).
Renal function and proteinuria did not change during follow-up (Table 3). Renal function 
of the 12 patients who discontinued Tac-OD also remained stable (data not shown). Renal 
function of the patients (n = 114) who had a decrease in their Tac C0, also did not change 
after conversion: [(48 (16-90) mL/min at baseline versus 47 (15-90) mL/min at month 3 
after conversion; P = 0.13 versus 47 (12-90) mL/min at month 12 after conversion, P = 
0.82]. Apart from a small decrease in HDL-cholesterol, all other clinical and laboratory 
parameters were unaffected (Table 3).
Tac-OD was in general tolerated well, and only 8 patients discontinued Tac-OD because 
of side effects. The AEs that led to discontinuation of Tac-OD were mild and included rash 
(n = 2), gastrointestinal complaints (n = 2), headache (n = 1), myalgia (n = 1), insomnia (n 
= 1), and worsening of eczema (n = 2).
Table 3. Evolution of clinical and laboratory parameters in the 12 months after conversion from 
Tac-TD to Tac-OD.
Conversion Month 12 ± 1 p
Plasma creatinine (μmol/L) 132 (55-324) 134 (57-464) 0.38
eGFR (mL/min) 48 (16-90) 46 (12-90) 0.26
Proteinuria (g/L) 0.11 (0.02-3.42) 0.10 (0.01-6.88) 0.80
Protein/Creatinine (mg/mmol) 14.52 (4.00-551.60) 13.51 (3.97-1186.20) 0.57
Hemoglobin (mmol/L) 8.2 (4.9-11.0) 8.3 (5.1-11.4) 0.35
Fasting plasma glucose (mmol/L) 5.6 (3.9-26.7) 5.6 (3.8-22.2) 0.98
Triglycerides mmol/L 1.56 (0.46-6.88) 1.57 (0.45-6.76) 0.45
Total cholesterol (mmol/L) 4.6 (1.8-7.5) 4.5 (2.5-7.5) 0.41
HDL-cholesterol (mmol/L) 1.21 (0.33-4.86) 1.20 (0.63-3.44) 0.04
LDL-cholesterol (mmol/L) 2.65 (0.34-5.44) 2.70 (1.20-5.43) 0.59
Systolic blood pressure (mmHg) 135 (80-191) 139 (100-200) 0.65
Diastolic blood pressure (mmHg) 80 (50-110) 80 (58-104) 0.91
eGFR = estimated glomerular filtration rate; LDL = low density lipoprotein;
HDL = high density lipoprotein; Protein/Creatinine = urinary protein/urinary creatinine ratio
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Effect of conversion to Tac-OD on Tac IPV
To analyse the influence of Tac formulation on the IPV in Tac apparent oral clearance 
(hereafter referred to as Tac IPV), stricter inclusion criteria were applied. Eighty patients 
were excluded, leaving a total of 167 patients for the IPV analyses. In 9 cases, <3 samples 
were available after conversion because these patients were reconverted to Tac-TD. 
Seventy-one cases were excluded because the Tac-TD treatment phase was shorter than 
9 months.
As observed in the whole group, a significant drop in Tac C0 (9.5%) and in Tac C0/D (10%) 
occurred between conversion and month 3, despite a stable Tac daily dose (Table 2). The 
mean number of available samples per patient was 6.3 ±2.3 (Tac-TD period) and 5.8 ±2.5 
(Tac-OD phase), and was slightly higher before conversion (P = 0.02). In both phases, 
interpatient variability in IPV was considerable, with some individuals having a variability  
figure 2. Change of distribution (by 5% intervals) of Tac IPV before and after conversion from Tac-
TD to Tac-OD.
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of <5% and others >50%. The median IPV for Tac-TD was 17.9% (2.9-51.4%) and for 
Tac-OD 16.8% (4.2-64.1%), P = 0.25. Conversion to Tac-OD did not result in a change in 
geometric mean Tac IPV: 17.3% ±1.7% versus 16.4% ±1.6%, for the Tac-TD and Tac-OD 
phases, respectively, P = 0.31. The conversion also did not alter the distribution of the IPV 
(P = 0.12; Figure 2). When the 71 patients with a Tac-TD phase < 9 months were included, 
again Tac IVP did not change after conversion to Tac-OD: the median IPV for Tac-TD was 
16.9% (1.5%-56.1%) and for Tac-OD 16.5% (4.1%-68.5%), P = 0.71.
Patients were classified using the median Tac IPV before conversion (17.9%) as the cut-
off. This resulted in 83 patients being classified as having low variability (mean: 11.7% 
±1.4%), and 84 as having a high variability (mean: 25.6% ±1.3%). Using this same 
cut-off, after conversion, the number of patients in the low-variability group rose from 
83 to 93 (11.8% ±1.4%), whereas 74 patients ended up in the high-variability group 
(24.9% ±1.3%). Before conversion, patients with high IPV had a higher number of Tac 
dose changes in the 12±3 months observation period compared to patients with low IPV 
[median 0.5 (0-5) versus 0.0 (0-3), P = 0.02]. After conversion, there were no significant 
differences in the number of Tac-OD dose adjustments between the two groups: median 
1.0 (0-4) versus 0.0 (0-3) for the low and high-variability groups, respectively, P = 0.078.
This same analysis restricted to the group of 84 patients with high variability before 
conversion demonstrated a significant decrease in IPV after conversion: 25.6% ± 1.3% 
versus 17.1% ± 1.6% (P < 0.01, Figure 3B). This effect was even stronger when we in-
cluded only those patients with an IPV in the upper quartile: IPV decreased from 31.8% 
± 1.2% to 18.0% ± 1.6% in the Tac-OD phase (P < 0.01). The reverse was observed for 
the group of 83 patients who had a low Tac IPV before conversion: The IPV increased from 
11.7% ± 1.4% (Tac-TD) to 15.8% ± 1.6% (Tac-OD), P < 0.01 (Figure 3C).
Univariate analyses revealed that age, gender, time after transplantation, baseline cre-
atinine, and haemoglobin concentration had no influence on IPV. Unfortunately, CYP3A5 
genotype, which has been correlated with Tac dose requirement,14 was not available for 
this cohort. However, there was a direct proportional correlation between the number 
of samples and IPV, and between the number of dose changes and IPV. In a regression 
analysis, the effect of switching from Tac-TD to Tac-OD on the IPV remained statistically 
significant at the same level after adjustment for number of dose changes and the num-
ber of samples.
Subsequently, we investigated whether this observation was a treatment effect or 
whether it was caused by the RTM phenomenon. After conversion, patients with high 
variability in Tac exposure had a 0.1746 change (decrease) in IPV on the log scale, 
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corresponding to 8.5% on normal scale. Using equation 2 with σt = 0.1263, ρ = 0.05, 
population mean of 1.2386, c = 1.2538, φ = 0.40, and Φ = 0.47, the estimated RTM effect 
was 0.1726 (98% of the observed decrease). Hence, it can be concluded that there was 
no real change in the IPV after conversion.
DISCUSSION
This study demonstrates that converting stable RTRs from Tac-TD to Tac-OD is safe. Graft 
survival (censored for death) after conversion was 100% and only 2 patients died from 
causes unrelated to the Tac formulation conversion. Renal function, proteinuria, glucose 
levels, and blood pressure did not change after conversion. Although a considerable 
number of SAEs occurred, this is not unusual for RTRs who are immunocompromised and 
frequently have multiple comorbidities.
Tac-OD was tolerated well, treatment discontinuations due to AEs were infrequent, and 
drug-related side effects were mild. The nonrandomized design of this study is an obvi-
ous limitation, making a formal comparison regarding the safety of both formulations 
impossible. However, our findings are consistent with safety data of other conversion 
studies9,15-17 and the phase II and III trials.18
 
figure 3. The individual change of Tac IPV before and after conversion from Tac-TD to Tac-OD; A: All 
patients available for the IPV analysis (n = 167); B: Patients with high IPV before conversion (n = 84) 
and C: Patients with low IPV before conversion (n = 83).
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Industry-sponsored trials performed in both stable and de novo RTRs showed that conver-
sion from Tac-TD to Tac-OD on a 1:1 (milligram:milligram) daily dose basis yields compa-
rable drug exposure [measured as either the area-under the concentration vs. time-curve 
0-24 hr.  [AUC0-24] or C0].19 However, more recent reports demonstrate that conversion to 
Tac-OD is associated with considerably lower Tac exposure (of up to 15%), necessitating 
occasional dose changes.19-21 In line with the latter observations, significantly lower Tac 
C0 and Tac C0/D were observed after conversion in this study. These discrepancies in the 
changes in Tac exposure after conversion likely relate to differences in inclusion criteria 
of the various trials, which were stricter in the earlier trials. The present study was a “real 
world” conversion study, and only a few exclusion criteria applied.
Apart from 1 patient who suffered from acute rejection shortly after conversion, there 
were no other cases of rejection that contributed to low Tac exposure. It can be argued 
that the observed lowering of Tac exposure after conversion is not clinically relevant. 
Neverthless, to prevent the occasional case of marked overexposure or underexposure, 
at our center, we routinely measure Tac C0 1-2 weeks after conversion to Tac-OD.
This study shows that conversion from Tac-TD to Tac-OD does not result in a lower Tac 
IPV, confirming findings of Wehland et al.7 and van Hooff et al,11 which were conducted 
in smaller patient groups. Other investigators have observed a lowering of Tac IPV after 
conversion.8-10 An important limitation of the study of Wu et al. is the fact that the number 
of samples after conversion was larger than before conversion.9 By mathematical prin-
ciple, the estimation of IPV (or %CV) will become more precise if the number of samples 
increases.
In the study of Stifft et al, Tac IPV didn’t change after conversion when it was calculated 
using C0 but decreased when it was calculated using AUC0-24.10 In the study by Stifft et al, 
the decrease in Tac IPV, calculated using AUC0-24, was 3.2% which, although statistically 
significantly different, may be considered not to be clinically relevant. In the present 
study, we chose to evaluate Tac exposure using C0 only because of reports demonstrating 
a significant correlation between AUC0-24 and C0 for both Tac formulations8,10,22,23 and be-
cause Tac C0 is the therapeutic drug monitoring parameter that is used most frequently 
in clinical practice. A change in Tac IPV may thus have remained undetected. The present 
study did, however, have a power of almost 100% to detect a difference in IPV (data not 
shown).
In patients with a high Tac variability, conversion resulted in a significantly decreased 
IPV. This may have been caused by improved adherence as observed by Kuypers et al.3 
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We did not measure patient compliance directly. However, because the observed median 
IPV was not very high before conversion, we feel that the rate of medication adherence 
in the present, selected population may have been high, with little potential for further 
improvement by conversion to Tac-OD.
Alternatively, reported changes in IPV after conversion may not have been a true treat-
ment effect but rather the result of RTM. RTM is a statistical phenomenon that can make 
natural variation in repeated data look like a real change. This occurs when unusually 
large or small measurements tend to be followed by measurements that are closer to the 
mean.12,13 Indeed, about 98% of the decrease in IPV we observed was explained by RTM 
and therefore not the result of conversion per se. Whether the RTM phenomenon also 
affected the results of previous studies cannot be determined. However, the chance that 
this phenomenon occurs increases when a nonrandomized, controlled, or noncrossover 
design is followed.
In conclusion, conversion from the Tac-TD to the Tac-OD formulation on the same 
milligram-for-milligram daily dose basis significantly reduces Tac exposure but does not 
lower Tac IPV. Nonetheless, conversion to Tac-OD seems to be safe.
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GENERAL DISCUSSION
More than sixty years have elapsed since the first successful human kidney transplanta-
tion and this procedure has become the treatment of choice for patients with end-stage 
renal disease. Although the development of powerful and specific immunosuppressive 
drugs has contributed to the success of this therapy, several challenges remain. Patients 
still suffer from rejections and kidney allograft loss, while they are also at increased risk 
of severe infectious complications, cancer and other immunosuppressive drug-related 
toxicity. In this thesis we tried to find strategies to optimize the immunosuppressive 
therapy with tacrolimus (TAC) with the primary goal to improve the (long-term) outcomes 
of solid organ transplantation.
1. Concentration-effect relationship
In Chapter 2 we studied the relationship between the exposure to Tac and the efficacy 
of this drug. The use of Tac has resulted in a decrease in the incidence of acute rejection 
and improved early graft survival.1 The narrow therapeutic range of Tac concentrations, 
and the high inter-patient pharmacokinetic variability have resulted in the recommenda-
tion to perform TDM . Whole blood predose Tac concentrations (C0) have been found to 
correlate well with the area under the concentration-curve measurements (AUC), sug-
gesting that C0 are a good index of overall Tac exposure.2-5 Despite the fact that Tac has 
been a widely used immunosuppressive drug for almost 30 years, only a few prospective 
controlled trails have been conducted to establish the target Tac concentrations in rela-
tion to clinical outcome.6-8 Based on the results of these studies, a Tac C0 range of 5-15 
ng/mL was advised to achieve optimal efficacy with minimal toxicity in the first month 
post-transplantation. The relationship between Tac exposure and rejection in renal trans-
plantation has been evaluated in several other studies.4,9-11 The results of these studies 
are not consistent. Most transplant centers worldwide have nevertheless implemented 
TDM for Tac, disregarding the fact that only limited evidence is available for performing 
TDM and that the exact target C0 range is poorly defined.12
An important cause of late loss of kidney allografts is chronic allograft nephropathy. Since 
episodes of acute rejection, particularly if severe, are considered to be a major risk factor 
for chronic allograft nephropathy,13-15 avoiding episodes of acute rejection is an important 
objective to improve organ survival. This prompted us to investigate whether there is a 
correlation between the currently used Tac target C0 and the incidence of acute rejection 
in a large cohort (n = 1304) of kidney transplant recipients (Chapter 2.1). We did not find 
a correlation between the development of acute rejection in first month or first year after 
transplantation and the Tac C0. Over the years the target Tac concentrations substantially 
changed, with targets as high as 20 ng/mL in the early years, and with targets as low as 
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3-7 in the Symphony study.16 We stratified our data into two groups: patients with Tac C0 
< 5.0 ng/mL vs. patients with Tac C0 > 5.0 ng/mL and patients with Tac C0 < 10.0 ng/mL 
vs. patients with Tac C0 > 10.0 ng/mL. From this analysis we could not conclude that the 
target Tac C0 should be above 5 or 10 ng/mL to avoid renal transplant recipients from an 
acute rejection. Based on our results one could argue that the threshold for efficacy lies 
even below the currently used targets. This is in line with the results of a single-center 
study of 528 prospectively followed kidney transplant recipients, recently reported by 
Gaynor et al.17 They demonstrated that the hazard rate of developing a first acute rejec-
tion during the first 12 months after renal transplantation was significantly higher among 
patients having a lower Tac C0 measured prior to the time of rejection occurrence. Gaynor 
et al. reported a 18% lower acute rejection rate for every 1 ng/mL increase in Tac level 
(p = 0.0003). Use of the cut-off of < 4.0 vs. ≥ 4.0 ng/mL for Tac C0 yielded an even greater 
association with acute rejection rate, with an estimated hazard ratio of 6.33 (p < 0.0001). 
Based on these findings Gaynor et al. suggested a Tac C0 cutoff of 4.0 ng/mL as the lower 
limit of the therapeutic window.17
Contrary to our results Israni et al. did find an association between Tac C0 and incidence of 
acute rejection in the first 6-months post-transplant in a cohort of 1930 patients.18 Using 
a multivariate Cox proportional hazards model, they found that each 1 ng/mL decrease 
in Tac C0 was associated with a 7.2% increased risk of acute rejection [hazard ratio (HR) 
= 1.07, 95%-confidence interval (CI) (1.01, 1.14); p = 0.03] in the first 6 months18 One of 
the most important discrepancies between our study and Israni et al. is that we only had 
access to Tac concentrations drawn at predefined time points (days 3, 10, 14, and months 
1 and 6 after transplantation). These Tac concentrations might not be the last measured 
concentrations prior to the occurrence of the acute rejection, so we cannot exclude the 
possibility that a similar analysis with Tac C0 measured right before diagnosing acute 
rejection would show an association. In the study of Israni and colleagues clinical data 
were collected at the time of transplantation and regularly thereafter until allograft 
failure and maintained in a central database.
Despite the lack of a clear concentration-effect relationship, our study presented in 
chapter 2 does not led us to propose that TDM of Tac is useless. TDM of Tac remains a ma-
jor support to patient management, to assess unexpected pharmacogenetic influences 
on Tac pharmacokinetics. Without Tac TDM the large between-patient variability in Tac 
pharmacokinetics would be unrecorded putting some patients at risk for overexposure 
(C0 > 15 ng/mL) and consequently toxicities and other patients for underexposure (Tac 
< 4.0 ng/mL) which may lead to higher risk for acute rejection. Moreover, TDM of Tac is 
useful to assess compliance and in the detection of drug interactions.
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1.1. Intracellular tacrolimus concentrations
Due to the fact that the intracellular compartment of lymphocytes is the target site 
of Tac action, we think that whole blood concentrations can only serve as substitute 
markers, at least when considering its efficacy. Several small studies have evaluated the 
potential contribution of measuring Tac intracellular concentrations in peripheral blood 
mononuclear cells (PBMCs).19-22 All studies demonstrated a lack of correlation between 
intracellular Tac concentrations and whole blood concentrations, providing support 
for the assumption that the whole blood concentration rather serves as a global drug 
exposure marker, whereas intracellular drug monitoring may more precisely determine 
whether a patient’s immunosuppressant intake is sufficient. Capron at al. performed 
a study that included 96 kidney transplant recipients 6 (5.8%) of whom developed 
rejection during the first month after kidney transplantation.20 Rejection tended to be 
associated with lower Tac concentrations in PBMCs (p = 0.094).20 A later study, also 
performed by Capron at al. demonstrated in liver transplant recipients that clinical rejec-
tion established in 12 patients (10.8%) was characterized by a significantly lower mean 
Tac PBMC concentrations on days 5 and 7 after transplantation (p < 0.05).19 Lemaitre 
et al. explored the pharmacokinetics and pharmacodynamics of Tac in 10 de novo liver 
transplant recipients by measuring the calcineurin activity as well as whole blood and in-
tracellular Tac concentrations.22 There was one study participant suffering acute cellular 
rejection during the study period despite an adequate Tac whole blood concentrations. 
However, his intracellular Tac concentrations were four-fold lower compared to those 
of the mean study population.22 Tac intracellular concentrations displayed a greater 
variability between patients, and tended to be lower prior to acute rejection. However, 
despite these encouraging findings, more studies on intracellular Tac concentrations are 
required and the following questions need to be answered: Can a therapeutic range be 
defined, and could this kind of monitoring be relevant for both early post-transplant 
period and long-term examinations? Currently we are working on a prospective study 
to establish whether measurement of intracellular Tac concentrations in PBMC indeed 
better correlates with the incidence of acute rejection in the renal transplant recipients 
(n = 240) during the first year after transplantation.
1.2. Pharmacodynamic markers
Measurement of a drug’s pharmacodynamic effect may be a good way to perform TDM 
of Tac. Several studies have focused on pharmacodynamic markers, which may better 
reflect efficacy and safety taking into account the inter-patient variability in the immu-
nomodulatory effect of Tac rather than whole blood C0.23,24 Diverse methods have been 
evaluated and validated for the measurement of biomarkers such as lymphocyte prolif-
eration, T-cell surface antigen expression (CD25, CD26, CD71, CD54, CD95, and CD134), 
and intracellular cytokine synthesis (like IL-2) in stimulated whole blood from treated 
188 Chapter 5
transplant recipients.25 Tac inhibits the calcineurin pathway of activated T-lymphocytes 
resulting in decreased levels of dephosphorylated NFAT, less production of IL-2, and 
ultimately, inhibition of T-lymphocyte proliferation. Several studies demonstrated that 
the protein expression of IL-2 in cell samples can be used as a pharmacodynamic tool 
for TDM of Tac.23 However, this assay measures the effects of other immunosuppressive 
drugs, like steroids, as well, and is therefore not specific for Tac.24 Recently it was found 
that the amount of phosphorylation of the p38MAPK, a key factor in T-cell development 
and activation, is inversely correlated with Tac C0 of kidney transplant recipients. Further-
more, increased p38MAPK phosphorylation was associated with higher T-lymphocyte 
activation status, which was inhibited by Tac in a dose dependent way in vitro.26,27
In a pilot study (Chapter 2.2), conducted in 12 stable renal recipients, we evaluated the 
effect of the conversion from twice-daily to a once-daily Tac formulation on p38MAPK 
phosphorylation status. All of these patients participated in a non-randomized conver-
sion study, conducted in stable renal transplant recipients (n = 247) to evaluate the safety 
of the conversion from Tac twice-daily formulation to a once-daily formulation (Chapter 
4.4). In this conversion study and in other studies it has been shown that conversion from 
twice-daily to a once-daily Tac formulation on a 1:1 (milligram : milligram) daily dose 
basis is associated with significantly lower Tac exposure (of up to 15%).28-31 Because the 
incidence of acute rejection after conversion in our study was extremely low (0.8%) we 
think that observed decrease in Tac exposure after conversion is not clinically relevant. 
In order to generate additional proof for this statement we decided to investigate the 
effect of conversion on the pharmacodynamic effect of Tac in this pilot study (Chapter 
2.2). Despite the fact that in these 12 patients Tac C0 was not significantly decreased 
after conversion (6.0% reduction, p = 0.54), p38MAPK phosphorylation was significantly 
increased (11.8% increase; p = 0.034), demonstrating the high sensitivity of this assay. 
Since increased p38MAPK phosphorylation has been associated with more T-lymphocyte 
activation32 it may theoretically result in a higher risk of acute cellular rejection for renal 
transplant recipients.33 It would be interesting to determine the risk of rejection dur-
ing Tac therapy in renal transplant recipients with the help of phosphor-specific flow 
cytometry. If indeed this pharmacodynamic parameter appears to correlate well with the 
incidence of acute rejection, then in a subsequent clinical trial it could be tested whether 
this pharmacodynamic approach can be used to decide on dose adjustments during Tac 
therapy.
2. Individualization of tacrolimus starting dose
Obtaining adequate exposure to Tac as early after transplantation as possible is con-
sidered important to ensure maximum efficacy of the drug.16 With this in mind, it would 
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make sense to individualize the starting dose of Tac according to a patient’s phenotype 
(Chapter 3.1) or genotype (Chapter 3.2).
2.1. Phenotyping
In Chapter 3.1 we evaluated whether pre-transplant Tac dose requirement phenotyping 
is a feasible strategy for patients scheduled for a kidney transplantation to achieve in 
the early phase after transplantation therapeutic Tac concentrations. The primary goal 
of the study described in Chapter 3.1 was to investigate whether pre-transplant Tac 
dose requirements of patients scheduled to undergo living donor kidney transplanta-
tion correlate with post-transplant dose requirement. The first attempt to characterize 
the oral pharmacokinetics of Tac prior to transplantation to assess possible predictors 
for dose requirements after transplantation, was done by Boots et al.34 They performed 
a 3-hour AUC prior to transplantation in 71 renal transplant recipients. The Tac doses 
and the corresponding C0 (at 0.5, 1, 2, 3, 6, 13 and 26 weeks post-transplantation) were 
used to calculate the Tac dose necessary to achieve a C 0 of 10 ng/mL. The observed 
correlation between the 3-hour dose-normalized AUC and the Tac dose required to 
achieve 10 ng/mL after transplantation was however weak.34 Subsequently, Campbell 
et al. hypothesized that when the first post-operative Tac dose would be given accord-
ing to single pre-transplant whole blood concentration 2-hour (C2) after Tac dosing, the 
proportion of subjects achieving therapeutic Tac C0 (C0 ≥ 10 ng/mL) within 3 days of 
kidney transplantation would increase compared with these subjects treated with stan-
dard bodyweight-based Tac dose.35 They demonstrated in a cohort of 90 renal transplant 
recipients, of whom 84 were included in the intention to treat analysis (control group n 
= 43; intervention group n = 41), that the proportion of subjects achieving Tac C0 ≥ 10 
ng/mL within 3 days of kidney transplantation was not significantly different between a 
group of patients who received a standard, bodyweight-based Tac dose and a group in 
which post-transplant Tac dose was based on a C2; 82.9% control vs. 93.0% intervention 
group, p = 0.19.35 The findings demonstrated by Boots et al. and Campbell et al. are not in 
line with our results, presented in Chapter 3.1. We evaluated retrospectively the predic-
tive value of Tac dose requirements pre-transplantation on this same parameter post-
transplantation in a cohort of 57 AB0-incompotible (AB0i) kidney transplant recipients. 
This study demonstrated that Tac dose requirements (defined as the ratio of the Tac C 0, 
divided by the total daily Tac dose, D; C0/D) before transplantation correlate strongly with 
dose requirements early after transplantation explaining 63% of the variation in dose 
requirements on post-transplantation day 3: r2 = 0.633, p < 0.01. The choice to perform 
this study among AB0i kidney transplant recipients, was substantiated by the fact that 
in this population of kidney transplant recipients the treatment with immunosuppres-
sive therapy (Tac, mycophenolate meofetil, and prednisolone) is routinely started two 
weeks before transplantation date and TDM is performed during this time. Thus, these 
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patients are in steady-state at the time of surgery and the effects of glucocorticoids on 
Tac pharmacokinetic may not change much after transplantation. Whereas patients in 
previous studies34,35 were not in steady-state prior transplantation, and pre-transplant 
Tac pharmacokinetic (based on a single dose) in these patients was correlated and 
compared with Tac pharmacokinetic and Tac dose requirement determined at least after 
3 days post-transplantation (steady-state condition). Another possible explanation for 
the conflicting results between our study and studies by Boots and Campbell could be 
the concomitant use of glucocorticoids. Steroids increase the clearance of Tac, possibly 
due to induction of the cytochrome P450 enzyme system in the liver.36,37 This inducing 
effect of glucocorticoids on the metabolizing system may not have had post-operatively 
an important influence in our study as our patients had been treated with a stable and 
pharmacologically relevant prednisolone dose for two weeks before transplantation, 
whereas patients in Boots et al. and Campbell et al. did receive glucocorticoids only after 
transplant surgery.
The rationale behind pre-transplantation phenotyping is to shorten the time to reach 
target Tac exposure, and to avoid substantial over- and under-exposure to this drug. In 
Chapter 3.1 we have shown a strong correlation between pre- and post-transplant Tac 
dose requirement. Based on our data it would make sense to base the Tac starting dose 
on the pre-transplant dose requirement rather than use a standard bodyweight-based 
starting dose of Tac at the time of transplantation. With this strategy one may be able to 
prevent under-exposure and rejection, or Tac toxicity in case of over-exposure. However, 
the possible benefit of such a strategy to start immunosuppressive therapy before trans-
plantation has to be demonstrated in a prospective clinical study.
2.2. Genotyping
Several non-randomized, descriptive studies evaluated the association between the 
CYP3A5 6986A>G variant allele (rs776746, A=*1, G=*3) and Tac pharmacokinetics 
in transplant recipients. The available literature does provide evidence of a strong 
association between CYP3A5 genotype and Tac pharmacokinetics and dose require-
ment.38-46 Based on these findings, it was conceived that pre-transplantation genotyping 
for CYP3A5 and using this pharmacogenetic information to choose the starting dose 
of Tac, would be a promising option to personalize Tac therapy and this idea justified 
a prospective, randomized-controlled clinical trial. The first prospective randomized-
controlled study (Tactique study) which investigated whether a CYP3A5 genotype-based 
Tac dosing strategy is beneficial was conducted by Thervet et al.47 They demonstrated in 
280 renal transplant recipients that CYP3A5-based adaptation of the Tac starting dose 
increases the proportion of patients reaching the target Tac C0 as compared with a stan-
dard, bodyweight-based dosing approach. Furthermore, by a CYP3A5 genotype-based 
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approach, the time to reach the Tac target exposure range was shortened (8 versus 25 
days after the start of Tac in the genotype-based and standard-dose group, respectively). 
Nonetheless, a CYP3A5 genotype-based Tac dosing approach was not associated with a 
reduction of the incidence of acute rejection nor an improvement of any other clinical 
outcome.47 This may have resulted from the fact that in the study of Thervet et al. Tac 
was started as late as day 7 after transplantation. In the first post-transplant week, most 
patients received powerful immunosuppression with antithymocyte globulin and high-
dose mycophenolate which is not the standard in any transplant centers. In a recently 
published study this French investigation group have also demonstrated that the adapta-
tion of initial Tac dose according to CYP3A5 genotype does not lead to better long-term 
transplantation outcomes of the 236 kidney transplant recipients who participated in the 
Tactique study.48
Our randomized-controlled trial (Chapter 3.2) was specifically designed to prospectively 
investigate the added value of pre-transplant genotyping for CYP3A5 in kidney trans-
plantation. This study -conducted among 240 de novo renal transplant recipients- shows 
that a CYP3A5-based adaptation of Tac starting dose does not lead to a higher proportion 
of patients reaching the target Tac C 0 range on day 3 after kidney transplantation as 
compared to a standard, bodyweight-based dosing approach. In addition, CYP3A5 -based 
dosing of Tac was not associated with a shorter time to achieve the Tac target C 0 nor 
with improved clinical outcome. These findings demonstrate that a CYP3A5-genotype 
based approach to Tac treatment is not beneficial for kidney transplant recipients re-
ceiving standard, Tac-based, combination immunosuppressive therapy from the day of 
transplantation and in whom the Tac dose is adjusted by routine Tac blood concentration 
monitoring (TDM). This is in line with the available guidelines for pharmacogenetics and 
Tac dosing which suggest that CYP3A5 genotyping cannot replace TDM, as other demo-
graphic and clinical factors also have impact on Tac dose requirement.49,50
These two randomized-controlled trials should lead to the conclusion that the idea of 
personalizing the Tac dose on an individual’s genotype should be abandoned. Up until 
now, CYP3A5 is the strongest known genetic predictor of Tac dose requirement, however 
it does not explain all variability.51,52 In our study and in the study of Thervet, around 
40% of patients in the CYP3A5 genotype-based dosing group were within the target Tac 
C0 range at first steady state. Other genetic variants contribute to the residual variability 
in Tac dose requirement. Recently, several genetic variants have been found to be associ-
ated with Tac dose requirement. The CYP3A4*22 SNP (rs35599367; C>T) in intron 6 has 
an allele frequency of about 5% in Caucasians. The T-variant allele has been associated 
with reduced CYP3A4 mRNA expression and lower in vitro CYP3A4 enzyme activity.53 
Elens et al. have demonstrated that de novo kidney transplant recipients who carry 1 or 2 
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T alleles require significantly lower Tac doses to reach the target C0 than wild-type CC pa-
tients. This effect was independent of CYP3A5 genotype.54 These findings were confirmed 
by the same researchers in an independent cohort of kidney transplant recipients and 
a cohort of pediatric heart transplant recipients.55,56 Pallet et al. confirmed these results 
in a cohort of 186 kidney transplant recipients, in whom the CYP3A4*22 allelic variant 
was associated with a slower Tac metabolism and higher systemic exposure in the early 
post-transplant period. The patients carrying this gene variant may require 30% lower 
Tac doses than patients with the CYP3A4*1/*1 genotype.57 Therefore, multiple genotype-
based dosage adjustment taking into account CYP3A5 and CYP3A4 allelic variants might 
optimize initial Tac doses more accurately than if based on CYP3A5 alone.
Besides the polymorphisms in the genes expressing the Tac-metabolizing enzymes 
CYP3A4 and CYP3A5, several other polymorphisms have been shown to also affect Tac 
pharmacokinetics. Nicotinamide adenine dinucleotide phosphate (NADPH)-CYP oxidore-
ductase (POR) is a protein that functions as an electron donor for CYP mono-oxygenase 
enzymes (including CYP3A) and is therefore essential for CYP-mediated drug oxidation.58 
Actually, polymorphisms in the P450 oxidoreductase (POR) genes have been demon-
strated to modulate the activity of CYP3A enzymes. Several studies provide evidence 
that the POR*28 SNP (rs1057868; C>T) is associated with additional increases (25%) 
in Tac dose requirements in patients carrying a CYP3A5*1 allele. Moreover, patients 
expressing CYP3A5 and carrying the POR*28 T-variant allele also required a significantly 
longer time to reach the target Tac C0 and were more often underexposed in the early 
phase after transplantation.59,60
Polymorphisms in the gene expressing the drug transporter ABCB1 could also contribute 
to alterations in Tac pharmacokinetics. Due to the importance of ABCB1 in the absorption 
of Tac several SNPs in the ABCB1 gene have been extensively investigated in relation 
to Tac pharmacokinetics. The ABCB1 3435C>T (rs1045642), 1236C>T (rs1128503), and 
2677G>T/A (rs2032582) SNPs, which are in linkage disequilibrium, have received the 
most attention in this respect. Taken together, the results of these studies have been 
disappointing as they have demonstrated only a limited (if any) effect of ABCB1 SNPs on 
Tac disposition.44,61
Taken together, several SNPs in genes other than CYP3A5 have been associated with Tac 
dose requirement. Their impact, however, appears to be smaller than that of CYP3A5*3. 
If these additional genetic variants do indeed explain residual variability in Tac dose 
requirement, development of an accurate polygenic algorithm could be a good approach 
to help physicians to decide on an individual’s starting dose.62 By combining genetic 
information with demographic and clinical variables, which are found to be associated 
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with Tac dose requirements such as age, weight, days after transplantation, albumin, 
hemoglobin, the use of calcium channel blockers and corticosteroid use, predictive 
algorithms may be developed that will allow for more reliable dosing, thereby limiting 
early over- and under-exposure.62,63
3. Tacrolimus intra-patient variability
Strategies targeting adequate exposure to Tac as early after transplantation as possible 
are being pursued in the effort to improve short-term outcomes. However, adequate 
exposure to immunosuppressive drugs in maintenance treatment is crucial for long term 
graft survival. In Chapter 4 of this thesis we have studied a recently identified (bio)marker 
for long-term kidney transplantation outcome, namely the intra-patient variability (IPV) 
in Tac exposure. Borra et al. was the first to provide evidence that high IPV in Tac expo-
sure is associated with poor graft survival after kidney transplantation.64 Subsequently, 
several investigators have confirmed the finding of Borra et al. both in adults65-67 and in 
pediatric68-70 renal graft recipients. All these studies were limited by a relatively small 
number of events and short follow-up period. This prompted as to enlarge our original 
study population (Borra et al.) and extend the duration of the follow-up to evaluate 
the impact of high IPV in Tac exposure on a composite endpoint consisting of late cute 
rejection, transplant glomerulopathy, graft loss (censored for death) or doubling of serum 
creatinine (Chapter 4.2). Using multivariate analysis we have now confirmed in a cohort 
of 808 renal transplant recipients that IPV in Tac exposure is an independent risk factor 
for inferior long-term outcomes after kidney transplantation. Patents with high IPV had a 
1.4 times higher risk of reaching the composite endpoint (hazard ratio 1.42, 95%-CI: 1.06 
– 1.90; p = 0.019). Moreover, we have shown that the risk of developing the composite 
endpoint increases with increasing Tac IPV and decreasing Tac C0 (Chapter 4.2; Figure 3). 
Hence, it has been suggested that in patients with high IPV (>16.2%) it is judicious to 
strive for higher Tac C0 (> 7.0 ng/mL), to reduce the risk of poor kidney transplantation 
outcomes. Incorporating algorithms that calculate IPV in Tac exposure into electronic 
patient records may assist physicians to recognize patients with high intra-patient Tac 
variability. Based on the available data, a prospective evaluation of the use of Tac IPV 
monitoring to investigate whether it can indeed improve outcomes could be suggested.
The impact of IPV in Tac exposure on graft survival after heart transplantation had not 
been studied before. Cardiac allograft vasculopathy (CAV) is a problem that limits long-
time survival after heart transplantation. We decided to evaluate whether a high IPV 
in Tac exposure is associated with more rapid progression of CAV in heart transplant 
recipients (Chapter 4.3). In contrast to the renal transplant recipients, we failed to find 
a relationship between the IPV in Tac exposure and the risk on CAV. These findings sug-
gest that the implication of a high IPV of Tac exposure might be organ-specific, and thus 
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less important in heart transplant recipients. The discrepancy between renal and heart 
transplant recipients might be explained by the fact that Tac C0 (measured between 6 
-12 months after transplantation) in heart transplant recipients are substantially higher 
than in renal transplant recipients (11.0 ng/mL vs. 6.9 ng/mL, respectively). Due to the 
higher exposure fluctuations in exposure downwards may not reach levels associated 
with under-immunosuppression. Although the main immunosuppressive regimen in 
both populations consists of Tac, mycophenolate mofetil and prednisolone, the heart 
transplant recipients use the prednisolone for a longer period of time and they have 
more outpatient visits in the first year post-transplantation than renal transplant re-
cipients. Therefore, a progression in the disease and eventually non-compliance to the 
drug therapy might be noticed earlier. These differences may have contributed to the 
contrasting outcomes of the two studies. It is however, also possible that we have missed 
a positive correlation, as the population in the study with heart transplant recipients 
was quite smaller and the number of events was considerable lower than in the study 
with renal transplant recipients. This study in heart transplant patients may not have had 
sufficient statistical power to identify the association between the IPV in Tac exposure 
and the progression of CAV. Consequential studies with a higher number of investigated 
patients (higher number of events) and longer follow-up period, which would allow to 
conduct multivariable Cox-regression analysis, should be performed to clarify whether 
progression of CAV is associated with the IPV in Tac exposure among heart transplant 
recipients.
Several factors can influence Tac pharmacokinetics and contribute to Tac IPV.71 Obvi-
ously, IPV in Tac exposure may be related to non-adherence to the immunosuppressive 
drug regimen and non-adherence was found to be an important risk factor for poor long 
term outcomes.72 A meta-analysis showed that non-adherent renal graft recipients had 
a seven-fold increase in the risk for graft failure.72 Across a variety of therapeutic classes 
it has been proved that less frequent dosing regimens resulted in better medication 
adherence. To improve adherence in transplant recipients, a prolonged-release oral dos-
age form of Tac (Advagraf®, Astellas Pharma) has been developed to enable once daily 
dosing alternative with a similar safety profile as the widely used immediate-release 
(twice daily) formulation (Prograf®, Astellas Pharma). In a recently published study of 
Kuypers et al. it was shown that a once daily regimen of Tac was significantly superior to a 
twice daily regimen. This study demonstrated that 81.5% of the renal transplant patients 
randomized into the once daily group remained persistent with treatment during the 
follow up period of 6 months, whereas this percentage was about 72% in the twice daily 
group. Among patients who remained persistent with the regimen, 88.2% of the once 
daily group and 78.8% of twice daily group (p = 0.0009) took the prescribed number of 
daily doses.73 Theoretically, the improved adherence to Advagraf® could contribute to 
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a reduced intra-patient Tac exposure variability. Since there is a significant association 
between the IPV in Tac exposure and graft survival, we investigated (Chapter 4.4) whether 
Advagraf® exhibits a lower IPV in Tac exposure than Prograf®. In this non-randomized 
conversion study, conducted in a cohort of 247 stable renal transplant recipients it was 
shown that conversion from Tac twice-daily to Tac once-daily formulation on the same 
milligram-for-milligram daily dose basis does not result in a lower Tac IPV (calculated 
using C0). This finding is in line with findings provided by Wehland et al.74 and Hooff et 
al.75 which were also conducted in stable renal transplant recipients but in a smaller 
patient groups. However, other studies ( also in smaller populations) have demonstrated 
a reduction of Tac IPV after conversion from twice-daily to a once-daily formulation.76-78 
Alloway et al. demonstrated in a cohort of 67 stable kidney transplant recipients that IPV 
in Tac exposure (calculated using AUC0-24) significantly decreased after conversion to a 
once-daily Tac formulation in African-American patients (n = 12).76 However, no signifi-
cant decrease in Tac IPV was observed among Caucasians in this study. Owing to different 
dissolution properties, Advagraf® is typically released and absorbed further along the 
gastrointestinal tract, while Prograf® is characterized by an absorption more proximally, 
primarily in the proximal small intestine. It has been reported that the expression of 
CYP3A enzymes reduces progressively along the length of the gastrointestinal tract.79 
Consequently, the CYP3A status (activated or inhibited) may have less impact on the 
intra-patient Tac exposure variability by use of Advagraf® compared with Prograf®. Given 
that about 85% of Africans are CYP3A5 expressers, this information could explain the 
findings of Alloway et al. namely, the four-fold lower Tac IPV in African-American patients 
compared with Caucasians after conversion from twice-daily to once-daily Tac formula-
tion.76 Another factor contributing to lower variability in black patients may be the fact 
that CYP3A5 is more stably expressed, whereas CYP3A4 expression is more variable, and 
more influenced by environmental factors. The vast majority of our study population 
was Caucasian (73%) about 15% of whom were CYP3A5 expressers.80 Conversion from 
Prograf® to Advagraf® in a cohort of 129 Taiwanese stable renal graft recipients also led 
to a significant decrease in mean IPV of Tac C0: 14.0% ± 7.5% before conversion vs. 8.5% 
± 5.0% (p < 0.05).78
In the study of Stifft et al. the IPV in Tac exposure did not change after conversion from 
twice-daily to once-daily Tac formulation when it was calculated using C0. However, they 
did find a significant change in Tac IPV after conversion when it was calculated using 
AUC0-24.77 The IPV in Tac AUC0-24 decreased with 3.2% after conversion, which although 
statistically significantly different, may be considered not to be clinically relevant. In 
our study, we chose to evaluate the IPV in Tac exposure using C0 based on the reports 
demonstrating a significant correlation between AUC0-24 and C0  for both Tac formulations. 
Moreover, C0 is the TDM parameter that is used most frequently in clinical practice. An 
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important weakness of our study is that we did not measure patient compliance directly. 
However, because the observed median IPV in Tac C0 was not very high before conver-
sion (17.9%), we feel that the rate of medication adherence in the selected population 
may have been high, with a little potential for further improvement by conversion to Tac 
once-daily formulation.
4. Conclusions of this thesis
In this thesis several studies are reported with the aim to improve the use of Tac after 
solid organ transplantation. A striking first finding was the lack of an association between 
the Tac C0 and the incidence of acute rejection after kidney transplantation. This observa-
tion in our view does not imply that TDM of Tac can be abolished. We have shown that 
monitoring of pharmacodynamic markers such us monitoring of p38MAPK phosphoryla-
tion in T-lymphocytes by whole blood phospho-specific flow cytometry could be another 
alternative for TDM of Tac.
In this thesis we have shown that steady-state, pre-transplant Tac dose requirements 
strongly correlate with post-transplant dose requirements. Using information on pre-
transplant Tac dose requirement (Tac dose and concentration data), may be able to 
predict Tac exposure after transplantation and limit under- and over-suppression.
Adapting the starting Tac dose according to a patient’s CYP3A5 genotype does not lead to 
earlier achievement of the target Tac C0 range or superior clinical outcome as compared 
with standard, bodyweight-based dosing approach. Therefore, routinely genotyping 
renal transplant recipients for CYP3A5 cannot be recommended.
A high IPV in Tac exposure is associated with poor long-term kidney transplant outcome 
in kidney transplant recipients. However, a high IPV in Tac exposure was not found to be 
associated with the progression of CAV in heart transplant recipients.
Conversion from immediate-release (twice-daily) Tac formulation (Prograf®) to a 
modified-release (once-daily) Tac formulation (Advagraf®) on the same milligram-for-
milligram daily dose basis significantly reduces Tac exposure but does not lower IPV in 
Tac exposure.
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ALGEMENE DISCUSSIE
Zestig jaar geleden werd de eerste succesvolle niertransplantatie bij de mens uitge-
voerd. Inmiddels is niertransplantatie de voorkeurs behandeling voor patiënten met 
eindstadium nierfalen. De ontwikkelingen op het gebied van immunosuppressieve 
geneesmiddelen hebben de overleving na niertransplantatie sterk verbeterd, maar er 
zijn nog diverse uitdagingen. Nog steeds krijgen veel patiënten een afstoting en velen 
van hen krijgen een ernstige infectie, maligniteit of een andere bijwerking van de immu-
nosuppressieve therapie. Het onderzoek zoals beschreven in dit proefschrift had als doel 
om de behandeling met tacrolimus (Tac) verder te optimaliseren, waarbij de nadruk lag 
op het verminderen van de risico’s in de eerste fase na transplantatie en het verbeteren 
van de lange termijn uitkomsten.
1. Concentratie-effect relatie
In Hoofdstuk 2 is de relatie bestudeerd tussen de expositie aan Tac, uitgedrukt als de 
(volbloed) concentratie en de effectiviteit van het geneesmiddel. Het gebruik van Tac 
heeft geleid tot een belangrijke reductie van de incidentie van acute afstoting en het ge-
neesmiddel heeft de korte termijn resultaten duidelijk verbeterd.1 Tac is een zogenaamd 
“critical dose drug”, wat wil zeggen dat de effectieve (werkzame) concentraties dicht 
liggen bij de toxische concentraties. Deze nauwe therapeutische index, alsmede de grote 
inter-individuele variabiliteit van Tac concentraties bij een vergelijkbare dosering, heeft 
geleid tot het advies om dit geneesmiddel te doseren op geleide van bloedconcentraties. 
Dit principe staat bekend als “Therapeutic Drug Monitoring (TDM)”. Volbloed dalspiegels 
van Tac (C0) correleren vrij goed met de expositie gedurende een doseringsinterval -ge-
meten als “area under the concentration-versus-time curve” (AUC)-, hetgeen suggereert 
dat deze C0 een goede maat is voor TDM van Tac.2-5 Jammer genoeg zijn er maar een 
paar prospectieve, gecontroleerde studies verricht om de streefconcentratie van Tac vast 
te stellen.6-8 De resultaten van deze studies ondersteunen de momenteel geadviseerde 
streef Tac C0 van 5-15 ng/mL in de eerste maand na transplantatie. Diverse andere 
onderzoekers hebben getracht om de optimale Tac C0 range te definiëren, waarbij een 
goede verdraagbaarheid is gekoppeld aan een laag risico op afstoting.4,9-11 De resultaten 
van deze studies zijn niet eenduidig en worden vaak gehinderd door de retrospectieve 
studieopzet. De meeste transplantatiecentra in de wereld hebben TDM voor Tac in hun 
programma’s geïmplementeerd, ofschoon het bewijs dat dat nuttig is beperkt is en de 
streefconcentraties slecht gedefinieerd zijn.12
Een belangrijke oorzaak van laat verlies van transplantaten is het proces dat van oudsher 
bekend staat als “chronic allograft nephropathy”. Omdat het optreden van acute rejectie, 
en vooral van ernstige acute rejectie, gezien wordt als een belangrijke risicofactor voor 
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het krijgen van chronic allograft nephropathy,13-15 is het vermijden van dergelijke afsto-
tingen een belangrijk middel om de lange termijn transplantaatoverleving te verbeteren. 
Wij onderzochten daarom het verband tussen de hoogte van de Tac C0 en de incidentie 
van acute rejectie in een groot cohort (n = 1304) niertransplantaat ontvangers (Hoofdstuk 
2.1). Deze patiënten werden met de huidige standaard immunosuppressieve “cocktail” 
behandeld en de gerealiseerde Tac expositie was variabel en lag tussen de 2,5 en 29 ng/
mL. Ondanks het feit dat een zeer groot aantal patiënten onderzocht werd in deze ana-
lyse en er betrouwbare data uit grote klinische studies beschikbaar waren, konden we 
geen correlatie vinden tussen het optreden van acute rejectie in de eerste maand of in 
het eerste jaar na niertransplantatie en de hoogte van de Tac C0. In de afgelopen 20 jaar 
is de streefwaarde van de Tac concentratie substantieel veranderd, met streefwaarden 
van 20 ng/mL en hoger in de eerste jaren na introductie van Tac en streefwaarden tussen 
3 en 7 ng/mL in de Symphony studie.16 We hebben de beschikbare data onderverdeeld 
in twee groepen: patiënten met een Tac C0 < 5,0 ng/mL vs. patiënten met Tac C0 > 5,0 ng/
mL en de andere groep omvatte patiënten met een Tac C0 < 10,0 ng/mL vs. patiënten met 
Tac C0 > 10,0 ng/mL. Uit deze aanvullende analyse kunnen we niet concluderen dat de 
streefwaarde van de Tac C0 al dan niet boven 5 of 10 ng/mL moet zijn om acute rejectie 
na niertransplantatie te vermijden. Wij kunnen derhalve geen streefwaarde voor de Tac 
C0 definiëren. Gebaseerd op onze studieresultaten zou zelfs gesteld kunnen worden dat 
de drempel voor effectiviteit lager ligt dan de momenteel gangbare streefwaarde van 5 
tot 15 ng/mL. Onze conclusies zijn in overeenstemming met de resultaten van een re-
centelijk gepubliceerde studie, uitgevoerd door Gaynor et al.17 Zij rapporteerden op basis 
van een prospectief vervolg van 528 niertransplantatie patiënten, dat het risico op het 
ontwikkelen van een acute rejectie gedurende de eerste 12 maanden na transplantatie 
significant hoger was in patiënten met lagere Tac C0, gemeten voorafgaand aan het ont-
staan van acute rejectie. Deze studie heeft gedemonstreerd dat elke 1 ng/mL stijging in 
de Tac C0 het risico op een acute rejectie met 18% deed dalen (p =0,0003). Door gebruik 
te maken van een grenswaarde voor Tac C0 (< 4,0 vs. ≥ 4,0 ng/mL) werd een sterkere 
associatie met de incidentie van acute rejectie gevonden (hazard ratio (HR) = 6,33, p < 
0,0001). Op basis van deze bevindingen suggereren Gaynor et al. dat de onderste limiet 
van de Tac therapeutische range C0 4,0 ng/mL moet zijn.17
Israni et al. vonden ook in een cohort van 1930 patiënten een verband tussen de Tac C0 
en de incidentie van acute rejectie in de eerste 6-maanden na transplantatie.18 In een 
multivariaat analyse vonden zij dat elke 1 ng/mL afname van de Tac C0 in die periode het 
risico op afstoting met 7,2% deed stijgen [hazard ratio (HR) = 1,07, 95%-betrouwbaar-
heidsinterval (BI) (1,01, 1,14); p = 0,03].18 Een belangrijk verschil tussen onze studie en die 
van Israni et al. is dat wij alleen toegang hadden tot de Tac concentraties die afgenomen 
waren op een aantal vooraf gedefinieerde tijdspunten (dag 3, 10, 14, en maand 1 en 6 na 
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transplantatie). Deze Tac concentraties zijn veelal niet de laatst gemeten concentraties 
voorafgaande aan een afstoting. Daarom kunnen we de mogelijkheid niet uitsluiten dat 
een vergelijkbare analyse van onze data, met de Tac C0 gemeten net voor een afstoting, 
wel een significante relatie zou laten zien.
Onze studieresultaten moeten niet leiden tot de conclusie dat TDM voor Tac zinloos is. 
Aangezien Tac een geneesmiddel is met een grote inter-individuele farmacokinetische 
variabiliteit, blijft TDM voor dit geneesmiddel nodig. Na een standaarddosering Tac zul-
len verschillende individuen dus grote variaties in Tac expositie kunnen vertonen. Indien 
TDM niet wordt uitgevoerd, wordt deze grote inter-individuele variabiliteit niet gede-
tecteerd met als consequentie dat sommige patiënten bloot worden gesteld aan een te 
hoge Tac concentratie (C0 > 15,0 ng/mL) wat op zijn beurt de kans op toxiciteit verhoogt, 
terwijl andere patiënten juist een hogere kans zouden kunnen hebben op acute rejectie 
als gevolg van een te lage blootstelling (C0 < 4,0 ng/mL). Bovendien is TDM van belang 
bij het beoordelen van therapietrouw en het detecteren van geneesmiddelinteracties.
1.1. Intracellulaire tacrolimus concentraties
Tacrolimus remt de vermeerdering van lymfocyten en dit is het belangrijkste immuno-
suppressieve werkingsmechanisme van dit geneesmiddel. Het lijkt daarom logisch om 
de concentratie van Tac te bepalen in deze cellen en niet in het volbloed dat voor een 
groot gedeelte uit plasma, rode bloedcellen en bloedplaatjes bestaat. Een aantal kleine 
studies heeft de mogelijke meerwaarde van het meten van intracellulaire Tac concen-
traties in mononucleaire cellen uit het perifere bloed (“peripheral blood mononuclear 
cells”; PBMCs) onderzocht.19-22 Al deze studies toonden een slechte correlatie tussen 
de intracellulaire Tac concentratie en de volbloed concentratie, wat de veronderstelling 
ondersteunt dat de intracellulaire Tac concentratie een betere afspiegeling is van de 
mate waarin het immuunsysteem wordt onderdrukt. Capron et al. voerden een studie uit 
bij 96 niertransplantaat ontvangers waarvan er 6 een afstoting ontwikkelden in de eerste 
maand na transplantatie.20 Deze afstotingen waren geassocieerd met een lagere Tac 
concentratie in de PBMCs (p = 0.094).20 In een vervolgonderzoek van Capron et al. werd 
bij levertransplantaat ontvangers aangetoond dat de 12 patiënten met een afstoting een 
significant lagere concentratie Tac in PBMCs hadden op dag 5 en dag 7 na transplantatie 
in vergelijking met de patiënten die geen rejectie kregen (p < 0.05).19 Lemaitre et al. 
bestudeerden de farmacokinetiek en farmacodynamiek van Tac in 10 levertransplaat 
ontvangers door naast de volbloed en de intracellulaire Tac concentraties ook de calci-
neurine activiteit te meten.22 In dit onderzoek maakte één patiënt een acute cellulaire 
rejectie door ondanks een adequate Tac volbloed concentratie. Echter, de intracellulaire 
Tac concentraties van deze patiënt waren viervoudig lager dan die van de andere pati-
enten.22 De intracellulaire Tac concentraties kenden ook een grotere variabiliteit tussen 
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patiënten en leken lager voorafgaande aan het diagnosticeren van een acute rejectie. 
Ondanks deze bemoedigende bevindingen is het bewijs dat het meten van de intracel-
lulaire Tac concentraties nuttig is niet geleverd en is meer onderzoek nodig. Bovendien 
moet nog een therapeutisch venster voor deze intracellulaire concentraties worden 
gedefinieerd, zowel voor de vroege fase na transplantatie als voor de onderhoudsbe-
handeling. Onze onderzoeksgroep werkt tegenwoordig aan een prospectieve studie om 
in een studiepopulatie van 240 niertransplantatie patiënten te bepalen of intracellulaire 
Tac concentraties daadwerkelijk beter correleren met de incidentie van acute rejectie in 
het eerste jaar na transplantatie dan met de Tac concentratie in de volbloed.
1.2. Farmacodynamische markers
Het bepalen van het farmacodynamisch effect van een geneesmiddel is op theoretische 
gronden een veelbelovende manier om TDM uit te voeren. In diverse studies is gezocht 
naar farmacodynamische parameters die de inter-individuele variatie in de immunosup-
pressieve werking van Tac beter weergeven dan de volbloed C0.23-24 Diverse methoden 
zijn ontwikkeld en gevalideerd voor het meten van biomarkers zoals; lymfocyten prolife-
ratie, T-cel oppervlakte antigeen expressie (CD25, CD26, CD71, CD54, CD95 en CD134) 
en intracellulaire cytokine synthese (zoals IL-2) in gestimuleerd bloed van transplantatie 
patiënten.25 Zoals hierboven beschreven remt Tac de productie van IL-2, hetgeen resul-
teert in een vermindering van de proliferatie van T-lymfocyten. Verschillende studies 
hebben aangetoond dat de IL-2 eiwitexpressie gebruikt kan worden als een methode 
voor farmacodynamische TDM voor Tac.23 Echter, deze assay meet ook de effecten van 
andere immunosuppressieve geneesmiddelen zoals prednison en is dus niet specifiek 
voor Tac.24 Recent werd bij niertransplantaat ontvangers vastgesteld dat de mate van 
fosforylering van het “mitogen activated protein kinase” (p38MAPK), een belangrijke 
stap in de T-cel ontwikkeling en activatie, omgekeerd evenredig is gerelateerd aan de Tac 
C0. Ook bleek een hoge p38MAPK fosforylering geassocieerd te zijn met meer T-lymfocyt 
activatie.26,27 Hoofdstuk 2.2 beschrijft een pilot farmacodynamische studie. In een stu-
diepopulatie van 12 stabiele niertransplantaat ontvangers hebben we het effect van het 
omzetten van deze patiënten van tweemaal daags naar eenmaal daags Tac formulering 
op de p38MAPK fosforylering bestudeerd. Deze 12 patiënten hebben eerder deel geno-
men aan een niet-gerandomiseerde conversie studie ter evaluatie van de veiligheid van 
de omzetting van stabiele niertransplantaat ontvangers van tweemaal daags Tac formu-
lering naar een eenmaal daags formulering. In onze conversie studie bevestigden wij de 
eerder gedane observatie dat volgend op een 1:1 omzetting van tweemaal daags naar 
eenmaal daags Tac formulering, de Tac expositie significant daalt (tot 15% lager).28-31 
Dat deze verandering klinisch niet relevant is blijkt uit de extreem lage incidentie van 
rejectie rondom dergelijke omzettingen. In onze studie maakten 2 van de 247 patiënten 
(0.8%) rondom de omzetting een acute rejectie door en in één van die gevallen leek deze 
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direct gerelateerd te zijn aan een te lage Tac expositie. Om meer steun te krijgen voor de 
veronderstelling dat de 15% daling in Tac volbloed concentraties niet klinisch relevant 
is, besloten wij om deze farmacodynamische studie uit te voeren. Ofschoon de Tac C0 in 
deze 12 patiënten niet significant veranderde (p = 0.54), nam de p38MAPK fosforylering 
significant toe (11.8% toename; p = 0.034). Deze bevinding suggereert dat TDM van de 
farmacodynamiek van Tac gevoeliger is dan de klassieke farmacokinetische TDM middels 
volbloed concentraties. Aangezien een toegenomen p38MAPK fosforylering gekoppeld 
is aan meer activatie van T-lymfocyten32 zou dit dus theoretisch kunnen leiden tot rejec-
tie.33 Het zou interessant zijn om bij patiënten met een niertransplantaat het risico op 
afstoting te vervolgen middels fosfo-specifieke flowcytometrie van p38MAPK. Als deze 
farmacodynamische parameter inderdaad sterk geassocieerd blijkt te zijn met rejectie, 
dan zou in een prospectieve studie bestudeerd kunnen worden of het uitvoeren van TDM 
op basis van deze parameter de klinische uitkomst verbetert.
2. Individualiseren van tacrolimus startdosering
Zoals uitgelegd in paragraaf 1 is de optimale C0 range voor Tac niet onomstotelijk vast-
gesteld. Veel transplantatiecentra houden echter de waardes aan zoals beschreven in 
de bijsluiter door de producent van Tac (7 - 20 ng/mL). Daarnaast zijn er centra die een 
lagere Tac concentratie (5 - 15 ng/mL) nastreven welke vergelijkbaar is met de concen-
traties die in de Symphony studie zijn aanbevolen.16 Een andere vraag is hoe deze streef-
concentratie zo snel mogelijk is te bereiken. Het snel bereiken van een adequate Tac 
concentratie wordt gezien als een belangrijke factor in de preventie van rejectie.16 Het 
zou daarom goed zijn om bij initiatie van Tac behandeling te onderzoeken in hoeverre 
het fenotype (Hoofdstuk 3.1) of genotype (Hoofdstuk 3.2) van de patiënt kan helpen in 
het individualiseren van de startdosering.
2.1. Fenotyperen
In Hoofdstuk 3.1 is onderzocht of de dosisbehoefte voorafgaand aan transplantatie, 
voorspelt hoeveel Tac een patiënt nodig heeft na transplantatie. Een eerste studie met 
dezelfde vraagstelling werd uitgevoerd door Boots et al.34 Bij 71 niertransplantatie pa-
tiënten werd een 3-uurs AUC voorafgaand aan de niertransplantatie gemeten na een 
eenmalige proefdosis Tac. De Tac dosis en de corresponderende C0 (op 0,5; 1; 2; 3; 6; 13 
en 26 weken na transplantatie) werden gebruikt om de Tac dosis te berekenen die nodig 
zou zijn om een C0 van 10 ng/mL te bereiken. In dit onderzoek bleek de correlatie tussen 
de Tac dosisbehoefte voor en na transplantatie zwak.34 Campbell et al. onderzochten 
of het kiezen van een startdosering op basis van de volbloed concentratie 2 uur na Tac 
inname, de zogenaamde C2, na een eenmalige testdosis voorafgaand aan transplantatie 
resulteerde in een hoger percentage patiënten in het therapeutisch raam na transplan-
tatie (C0 ≥ 10 ng/mL).35 De controlegroep kreeg een Tac dosis gebaseerd op lichaamsge-
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wicht. In een groep van 84 patiënten (controle groep n = 43; interventie groep n = 41) 
konden zij geen voordeel aantonen van het gebruik van informatie verkregen tijdens 
de testdosis. De proportie patiënten met een Tac C0 ≥ 10 ng/mL binnen de eerste drie 
dagen na niertransplantatie was niet significant hoger in de interventie groep (82,9% in 
controle groep vs. 93,0% in interventie groep, p = 0,19).35 De belangrijkste tekortkoming 
van beide studies is het feit dat de farmacokinetische gegevens van Tac voorafgaand 
aan transplantatie werden bepaald na een eenmalige Tac toediening en dat deze na 
transplantatie gecorreleerd werden aan Tac farmacokinetiek in “steady-state” toestand.
In een groep van 57 AB0-incompatible (AB0i) niertransplantaat ontvangers hebben 
we retrospectief onderzocht of de Tac dosisbehoefte (uitgedrukt als de ratio van de 
Tac C 0 gedeeld door de Tac dosering; C0/D) vóór transplantatie de dosisbehoefte na 
transplantatie kan voorspellen. In ons onderzoek vonden wij dat de Tac dosisbehoefte 
vóór transplantatie sterk correleerde met de dosisbehoefte na transplantatie. Maar liefst 
63% van de variabiliteit in dosisbehoefte na transplantatie kon worden verklaard met 
de farmacokinetische gegevens verkregen voorafgaand aan transplantatie: r2 = 0,633; 
p < 0,01. Deze studie was juist in deze groep AB0i niertransplantatie ontvangers uitge-
voerd omdat bij hen de combinatie Tac, mycofenolaat mofetil en prednisolon al twee 
weken voorafgaand aan de transplantatie was gestart. Daarom waren de patiënten in 
ons onderzoek al in “steady-state” ten tijde van de operatie. Bovendien gebruikten de 
patiënten een stabiele dosis prednisolon. Glucocorticoïden verhogen de klaring van 
Tac, mogelijk door inductie van het cytochroom P450 enzym systeem in de lever.36,37 
In onze studie was gebruik van prednisolon dus geen storende variabele. In de eerder 
genoemde studies34,35 waren patiënten echter niet in stabiele toestand, werd vaak het 
advies gebaseerd op de effecten van een enkele dosering en was er pretransplantatie 
meestal geen co-medicatie met prednisolon.
Aangezien er een sterke correlatie bestaat tussen de Tac dosisbehoefte vóór en na trans-
plantatie, zouden patiënten die voor transplantatie al starten met Tac theoretisch gezien 
sneller een therapeutische concentratie bereiken dan patiënten die volgens het huidige 
protocol (start immunosuppressiva op de dag van transplantatie) worden behandeld. 
Echter, het mogelijke voordeel van het pre-emptief starten met immunosuppressiva the-
rapie vlak voor transplantatie zou nader onderzocht moeten worden in een prospectief 
gerandomiseerde studieopzet.
2.2. Genotyperen
Een belangrijke voorspellende factor voor de Tac dosisbehoefte van een individuele 
patiënt is het cytochroom P450 (CYP) 3A5 genotype. Het CYP3A5 enzym speelt een be-
langrijke rol in het metabolisme van Tac en sinds 1990 is bekend dat dit enzym polymorf 
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tot expressie komt. Verschillende studies hebben de associatie tussen aanwezigheid 
van het CYP3A5 6986A>G variant allel (rs776746, A=*1, G=*3) en de Tac farmacokine-
tiek in transplantatie patiënten onderzocht. Uit deze onderzoeken werd geconstateerd 
dat CYP3A5 non-expressers (CYP3A5*3/*3) een hogere dosis-gecorrigeerde dalspiegel 
en een hogere piekspiegel hebben (C0/D en Cmax), een hogere dosis-gecorrigeerde 
AUC en een kortere tijd tot het bereiken van de streefconcentratie. De onderhouds-
dosering is bij CYP3A5 non-expressers lager dan bij CYP3A5 expressers (CYP3A5*1/*3 
en CYP3A5*1/*1).38-46 Vanwege het sterke verband tussen het CYP3A5 genotype en 
de Tac dosisbehoefte is de gedachte ontstaan dat door genotyperen voor CYP3A5, 
voorafgaande aan de transplantatie, voor elk individu een passende startdosering kan 
worden gekozen. Dit zou wellicht tot het sneller bereiken van de streefconcentratie kun-
nen leiden en misschien ook tot betere uitkomsten van niertransplantatie. De eerste 
prospectieve gerandomiseerd-gecontroleerde studie die onderzocht of een op CYP3A5 
genotype-gebaseerde startdosering Tac inderdaad voordelen heeft, werd uitgevoerd in 
Frankrijk door Thervet et al.47 Zij toonden aan in hun onderzoek, waar 280 niertransplan-
tatie patiënten aan meededen, dat een op CYP3A5-gebaseerde aanpassing van de Tac 
startdosering leidt tot een toename van het percentage patiënten dat de C0 streefwaarde 
bereikt. Bovendien was, dankzij de CYP3A5 genotype gebaseerde behandeling, de tijd 
tot het bereiken van de streefwaarde korter dan in de groep die de standaard startdo-
sering kreeg (8 vs. 25 dagen na start van de behandeling). Echter waren de incidentie 
van acute afstoting of andere klinische uitkomsten vergelijkbaar in beide groepen.47 Dit 
werd mogelijk verklaard door het feit dat in de studie van Thervet et al. pas 7 dagen na 
de transplantatie gestart werd met Tac. In de eerste week na transplantatie werden de 
patiënten namelijk behandeld met krachtige immunosuppressie, zoals anti-thymocyten 
globuline en hoge doses mycofenolzuur, hetgeen in de meeste Nederlandse transplan-
tatie centra geen standaardbehandeling is. In een recente studie heeft deze Franse on-
derzoeksgroep aangetoond dat de aanpassing van de Tac startdosering op basis van het 
CYP3A5 individu genotype ook niet tot betere lange termijn transplantatie uitkomsten 
heeft geleid.48
Onze gerandomiseerde studie (Hoofdstuk 3.2) was ook specifiek ontworpen om de 
meerwaarde van het CYP3A5 genotyperen voorafgaand aan niertransplantatie te on-
derzoeken. Wij vonden dat een op CYP3A5-gebaseerde startdosering Tac niet leidt tot 
verhoging van het percentage patiënten dat de streefwaarde voor Tac C 0 op dag 3 na 
transplantatie bereikt. Evenmin was er een kortere tijd tot het bereiken van die streef-
waarden. De klinische uitkomsten waren niet beter dan het gangbare beleid van een al-
leen op lichaamsgewicht gebaseerde dosis. Beschikbare richtlijnen erkenden tot nu toe 
wel dat het CYP3A5 genotype een duidelijke invloed heeft op de Tac dosisbehoefte maar 
genotyperen werd niet geadviseerd, omdat voor Tac intensieve TDM wordt uitgevoerd en 
204 Chapter 5
eventuele verschillen in expositie zodoende snel kunnen worden gecorrigeerd. Op basis 
van onze resultaten is er geen reden die richtlijn te herzien.49,50
Ons eigen en het Franse onderzoek zijn niet het definitieve bewijs dat er geen toekomst 
is voor het genotyperen van niertransplantatie patiënten om de Tac dosis te individua-
liseren. Hoewel CYP3A5 de sterkste genetische voorspeller is voor de dosisbehoefte is 
er nog veel resterende (niet door genetisch polymorfisme verklaarde) variabiliteit.51,52 
Deze zogenaamde residuele variabiliteit bedroeg in onze studie en in die van Thervet, 
ongeveer 60%. Overige genetische variaties hebben waarschijnlijk ook bijgedragen aan 
de resterende variatie in dosisbehoefte. Het CYP3A4*22 polymorfisme (rs3559936; C>T) 
in intron 6 heeft een allel frequentie van ongeveer 5% in Kaukasiërs. Het T-variant al-
lel leidt tot verminderde CYP3A4 mRNA expressie en tot lagere in vitro CYP3A4 enzym 
activiteit.53 Elens et al. toonden aan dat patiënten die drager zijn van 1 of 2 T allelen 
significant minder Tac nodig hebben om de C0 te bereiken dan wild-type (CC) patiën-
ten. Dit effect was onafhankelijk van het CYP3A5 genotype.54 Dezelfde onderzoekers 
bevestigden deze bevinding in een tweede groep niertransplantaat ontvangers en ook 
in een groep kinderen met een harttransplantatie.55,56 Pallet et al. toonden ook aan dat 
het CYP3A4*22 polymorfisme is geassocieerd met de Tac dosisbehoefte van 186 nier-
transplantatie patiënten. Dragers van het CYP3A4*22 lijken een 30% lagere Tac dosis 
nodig te hebben dan patiënten met het CYP3A4*1/*1 genotype.57 Dat betekent dat een 
dosisadvies gebaseerd op CYP3A5 en CYP3A4*22 genotype wellicht accurater is dan 
wanneer dit uitsluitend op het CYP3A5 genotype wordt gebaseerd.
Naast de polymorfismen in de genen die coderen voor de metaboliserende enzymen 
CYP3A4 en CYP3A5, is voor een aantal andere polymorfismen ook aangetoond dat zij 
de Tac farmacokinetiek beïnvloeden. Nicotinamide adenine dinucleotide phosphate 
(NADPH)-CYP oxidoreductase (POR) is een eiwit dat als elektronen-donor fungeert voor 
CYP mono-oxygenase enzymen (waaronder CYP3A). POR is daarom van groot belang 
voor de CYP-gemedieerde geneesmiddel-oxidatie.58 Polymorfismen in het POR gen 
moduleren de activiteit van CYP3A enzymen. Verschillende studies hebben aangetoond 
dat het POR*28 polymorfisme (rs1057868; C>T) leidt tot een toename van de Tac do-
sisbehoefte (25%) in dragers van het CYP3A5*1 allel (zogenaamde CYP3A5 expressers). 
Patiënten die CYP3A5 tot expressie brengen en tegelijkertijd het POR*28 T-variant allel 
dragen hebben significant meer tijd nodig om de streefwaarde van Tac C0 te bereiken en 
bij hen komen vaker sub-therapeutische Tac concentraties voor in de eerste weken na 
transplantatie.59,60
Polymorfismen in het gen dat codeert voor het transporteiwit ABCB1 zouden ook kunnen 
bijdragen aan variabiliteit in de Tac farmacokinetiek. De effecten van dit polymorfisme 
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zijn met name op de absorptie van Tac uit de darm onderzocht. De ABCB1 3435C>T 
(rs1045642), 1236C>T (rs1128503), en 2677G>T/A (rs2032582) polymorfismen hebben 
hierbij de meeste aandacht gekregen. Echter, in grote lijnen gaven dergelijke studies een 
negatief resultaat en werd geen grote bijdrage gevonden van deze drie polymorfismen 
op de Tac kinetiek.44,61 Er lijkt momenteel dan ook geen plaats te zijn voor het genotype-
ren van patiënten voor ABCB1.
Samenvattend, naast de polymorfismen in de genen die coderen voor het CYP3A5 enzym 
werden verschillende andere polymorfismen in diverse genen geassocieerd met Tac 
farmacokinetiek. Op zijn best hebben deze genetische variaties slechts een gering effect 
op de Tac farmacokinetiek en vele malen kleiner dan dat van CYP3A5*3. Ondanks het feit 
dat de individuele bijdrage van deze polymorfismen gering is, zouden ze theoretisch wel 
in een doseringsalgoritme kunnen worden geïncorporeerd om zo de beste startdosering 
te berekenen.62 De voorspellende waarde van een dergelijk algoritme wordt wellicht 
groter indien genetische factoren worden gecombineerd met klinische en demografische 
variabelen, zoals leeftijd, plasma albumine en hemoglobine concentratie, lichaamsge-
wicht en co-medicatie (zoals b.v. calciumantagonisten of glucocorticoïden).62,63
3. Intra-patiënt variabiliteit
Het bereiken van adequate Tac concentraties in de vroege post-operatieve periode is 
vooral bedoeld om de korte termijn resultaten te verbeteren. Echter is het ook voor de 
onderhoudsbehandeling van belang dat de concentraties van de immunosuppressieve 
geneesmiddelen zo veel mogelijk binnen de streefwaarden blijven. In Hoofdstuk 4 wordt 
de betekenis van een recent geïdentificeerde parameter voor lange termijn uitkomsten 
beschreven, namelijk de intra-patiënt variabiliteit van de Tac expositie, hierna te noemen 
“IPV”. Grote schommelingen van de Tac concentraties binnen een individuele patiënt 
zorgen voor een toegenomen risico op periodes met onder- en over-immunosuppressie. 
Als gevolg daarvan kan de patiënt afstotingen respectievelijk toxiciteit ervaren. Borra et 
al. hebben aangetoond dat een hoge IPV in de Tac expositie geassocieerd is met slech-
tere transplantaatoverleving na niertransplantatie.64 Sinds de publicatie van deze studie 
hebben verschillende andere onderzoekers de relevantie van de IPV als voorspeller voor 
de lange termijn uitkomst bevestigd, zowel in volwassenen65-67 als in kinderen met een 
niertransplantaat.68-70 In de meeste van deze onderzoeken waren de aantallen patiënten 
en events beperkt en de follow-up kort. Om die reden besloten wij onze oorspronke-
lijke studie-populatie zoals beschreven door Borra et al. uit te breiden en hen langer te 
volgen. (Hoofdstuk 4.2). Met een multivariate analyse bevestigen we in een cohort van 
808 niertransplantatie patiënten dat IPV in Tac expositie een onafhankelijke risicofactor 
is voor een slechte transplantaat uitkomst. Patiënten met een hoge IPV hadden een 1,4 
keer hogere kans op het bereiken van het samengestelde primaire eindpunt (transplan-
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taatverlies, late acute rejectie, transplantaat glomerulopathie en verdubbeling van het 
serum creatinine): hazard ratio 1,41, 95%-CI: 1,06 – 1,89; p = 0,019). Mogelijk kan bij 
patiënten met een hoge IPV (>16.2%) een hogere Tac C0 (> 7.0 ng/mL) bescherming 
bieden tegen rejectie. Artsen zouden bij de behandeling van hun patiënten niet alleen 
aandacht voor de absolute blootstelling aan Tac moeten hebben, maar ook oog moeten 
hebben voor de schommelingen in de Tac concentraties. Deze IPV zou relatief eenvoudig 
in het elektronisch patiëntendossier kunnen worden gegenereerd.
De betekenis van de IPV voor de prognose na harttransplantatie was nog niet eerder 
bestudeerd. Chronische allograft vasculopathie (“CAV”) na harttransplantatie is een 
aandoening die vergelijkbaar is met chronische afstoting na niertransplantatie. Wij be-
studeerden daarom of de IPV in Tac expositie ook geassocieerd is met snellere progressie 
van CAV na harttransplantatie (Hoofdstuk 4.3). In tegenstelling tot de studie na niertrans-
plantatie vonden wij bij de harttransplantatie patiënten geen relatie tussen de IPV en 
(de progressie van) CAV, wat suggereert dat de impact van IPV mogelijk orgaanspecifiek 
is. Mogelijk kan dit verschil in uitkomst worden verklaard doordat de Tac C0 (gemeten 
tussen 6 -12 maanden na transplantatie) na harttransplantatie aanzienlijk hoger was 
dan bij niertransplantatie ontvangers (11,0 ng/mL vs. 6,9 ng/mL, respectievelijk). De 
schommelingen in de concentraties naar beneden zouden daardoor wellicht niet hebben 
geleid tot sub-therapeutische expositie, terwijl hogere spiegels die bij niertransplantatie 
leiden tot nefrotoxiciteit bij een harttransplantatie patiënt niet leiden tot schade aan 
het getransplanteerde hart. Een ander verschil tussen de twee onderzochte populaties 
is dat na harttransplantatie de behandeling met prednison langer wordt voortgezet en 
ook worden patiënten na harttransplantatie vaker op de polikliniek terug gezien. Door 
de meer frequente controles zou de ziekte progressie en eventuele therapieontrouw de 
behandelaars mogelijk ook eerder zijn opgevallen. Het is echter ook mogelijk dat we 
een positief verband hebben gemist doordat de populatie harttransplantatie patiënten 
te klein was en dit onderzoek te weinig statistisch onderscheidend vermogen had. Wij 
zouden dan ook willen adviseren om een soortgelijke studie te herhalen in een groter 
cohort.
Verschillende factoren kunnen de Tac farmacokinetiek beïnvloeden en bijdragen aan de 
IPV.71 Uiteraard kan de IPV groter zijn naarmate de patiënt minder therapietrouw is. Van 
therapieontrouw weten we dat het de kans op nierfalen na transplantatie zevenvoudig 
vergroot.72 Het minder vaak per dag doseren van een geneesmiddel lijkt de therapietrouw 
te bevorderen, zoals aangetoond voor diverse klassen van medicamenten. Voor trans-
plantatie patiënten is een Tac formulering met vertraagde afgifte ontwikkeld (Advagraf®, 
Astellas Pharma). In een Belgisch onderzoek bleek het eenmaal daagse Tac regime 
duidelijk superieur aan het twee maal daagse regime, aangezien 81,5% van de eenmaal-
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daagse groep therapietrouw bleef, tegen 72% van de twee maal daagse groep.73 De 
betere therapietrouw aan Advagraf® zou ook een gunstig effect op de IPV kunnen heb-
ben. In Hoofdstuk 4.4 beschrijven we een studie waarin we onderzochten of gebruik van 
Advagraf® inderdaad tot een lagere IPV leidt dan Prograft®. In deze niet-gerandomiseerde 
conversie-studie, uitgevoerd bij 247 stabiele niertransplantatie patiënten, vonden wij 
geen afname van de IPV (gebruik makend van herhaalde C0 metingen). Ook Wehland et 
al.74 en van Hooff et al.75 vonden geen afname van de IPV na conversie van Tac-Prograft® 
naar de eenmaal-daagse formulering. Echter, een aantal andere studies vond wel 
degelijk een verschil in IPV.76-78 Alloway et al. toonden aan dat in 67 niertransplantaat 
ontvangers de IPV in Tac expositie (gebruikmakend van AUC0-24) wel significant daalde 
na omzetting naar de eenmaal-daagse formulering.76 Dit werd enkel geobserveerd in de 
Afro-Amerikaanse patiënten (n = 12) en dus niet in de Kaukasische patiënten. Vanwege 
de vertraagde afgifte wordt Tac uit Advagraf® meer distaal in het darmkanaal vrijgegeven 
dan Prograft®. Omdat de expressie van CYP3A enzymen naar distaal in het darmkanaal 
afneemt,79 zouden wisselingen in CYP3A activiteit door bijvoorbeeld dieet invloeden 
wel eens minder van invloed kunnen zijn op de IPV van Advagraf®. Omdat 85% van de 
Afro-Amerikaanse patiënten CYP3A5 expresser is, zou dat de resultaten van Alloway et al. 
in de deze subgroep kunnen verklaren.76 Immers is CYP3A5 activiteit minder onderhevig 
aan invloeden van omgevingsfactoren, terwijl CYP3A4 expressie meer variabel is. In ons 
onderzoek was de meerderheid van de patiënten Kaukasisch (73%) en slechts 15% van 
hen was CYP3A5 expresser.80 Omzetting van Prograft® naar Advagraf® in 129 Taiwanese 
nierontvangers gaf ook een significante verlaging van de IPV van Tac C0: 14,0% ± 7,5% 
voor conversie vs. 8,5% ± 5,0% (p < 0,05) erna.78
In een mooi opgezet onderzoek toonden Stifft et al. aan dat de IPV van Tac expositie niet 
verandert door omzetting naar eenmaal-daags, indien berekend op basis van de C0. Ech-
ter bleek de IPV berekend op basis van een AUC0-24 wel significant te dalen.77 De IPV nam 
af met 3,2%, hetgeen weliswaar statistisch significant was, maar niet klinisch relevant. In 
ons eigen onderzoek werd alleen de C0 gemeten en we kunnen slechts speculeren over 
de mogelijke uitkomst indien we AUC0-24 hadden gemeten. C0 is in de dagelijkse praktijk 
de meest gebruikte parameter aan de hand waarvan de Tac dosering wordt aangepast. 
Verder werd in ons onderzoek de therapietrouw niet rechtstreeks gemeten. Omdat de 
mediane IPV in de Tac C0 niet erg hoog was voorafgaand aan de omzetting (17,9%), 
zou het kunnen zijn dat wij een groep hebben bestudeerd die al therapietrouw was, 
waardoor er nauwelijks meer ruimte was voor verbetering na introductie van de eenmaal 
daagse formulering.
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4. Conclusies van de dissertatie
In dit proefschrift beschrijven wij een aantal studies die bijdragen aan het optimalise-
ren van het voorschrijven van Tac aan patiënten die een orgaantransplantatie hebben 
ondergaan. Een eerste opvallende bevinding van ons onderzoek was het ontbreken van 
een associatie tussen de hoogte van de Tac C0 en het optreden van acute rejectie na 
niertransplantatie. Deze observatie impliceert ons inziens niet dat TDM voor Tac kan 
worden afgeschaft. Met TDM sporen we patiënten op die (ver) buiten het therapeutische 
venster liggen, en in die patiënten is het aanpassen van de dosis wel bijdragend. In een 
pilot studie hebben we aangetoond dat juist een farmacodynamische parameter, zoals 
p38MAPK fosforylering in T-lymfocyten middels flowcytometrie, het biologisch effect 
van Tac beter reflecteert en daarmee ook tot betere associaties met optreden van rejec-
tie leidt. Mogelijk kan een dergelijke bio-marker in de toekomst de voorschrijver helpen 
om de juiste dosering te kiezen.
Het nadeel van de momenteel toegepaste strategie van TDM voor Tac is dat dit een ‘trial 
and error’ benadering is, die geen voorspellende waarde heeft. Bij veel patiënten duurt 
het lang voordat de Tac streefconcentratie na transplantatie wordt bereikt en zolang de 
expositie te laag is loopt de patiënt een risico op afstoting. In dit proefschrift tonen wij 
aan dat de Tac dosisbehoefte voor transplantatie goed voorspelt welke dosis een patiënt 
na niertransplantatie nodig heeft. Informatie over de farmacokinetiek van Tac, verkregen 
voorgaand aan de transplantatie, zou derhalve kunnen worden gebruikt om een dosering 
te kiezen waarmee de patiënt aansluitend aan de transplantatie behandeld kan worden. 
Zo kan onder- en overbehandeling worden tegengegaan.
In een gerandomiseerde klinische studie hebben wij aangetoond dat CYP3A5 genotype 
gebaseerde aanpassing van de Tac startdosering niet leidt tot het eerder bereiken van 
de beoogde Tac C0 ten opzichte van het gangbare beleid van een op lichaamsgewicht-
gebaseerde Tac startdosering. Ook de klinische uitkomsten waren vergelijkbaar in beide 
groepen. Het implementeren van CYP3A5 genotypering voorafgaand aan niertransplan-
tatie wordt daarom niet aanbevolen.
In de studie met het tot dusverre grootste aantal patiënten stelden we vast dat een hoge 
intra-patiënt variabiliteit in Tac expositie een belangrijke en onafhankelijke risicofactor 
is voor een slechte transplantaat uitkomst na niertransplantatie. We bevelen artsen dan 
ook aan om de intra-patiënt variabiliteit in de dagelijkse zorg te meten en te gebruiken. 
De IPV in Tac expositie bleek echter geen vergelijkbaar effect te hebben op de prognose 
van harttransplantatie patiënten.
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Omdat therapietrouw een mogelijke determinant is van de IPV, onderzochten we of het 
omzetten van de tweemaal-daagse Tac formulering naar een eenmaal-daagse formule-
ring de IPV verlaagt. In onze studie zagen we weliswaar dat volgend op een 1:1 omzet-
ting de Tac concentraties daalden (reductie van 15%), maar dat de IPV in Tac expositie 
onveranderd bleef. Verlaging van de IPV is derhalve geen argument om patiënten te 
converteren naar het duurdere eenmaal-daagse Tac preparaat.
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voor al je hulp en statistische kennis. Judith Kal wil ik bedanken voor het opbouwen van 
de database voor de Mozaïek studie en het aanleveren van de juiste data. 
Mijn paranimfen Lamis en Rachida verdienen beiden een grote blijk van waardering. 
Beste Rachida, wij hebben de afgelopen jaren veel met elkaar samengewerkt en ik moet 
je zeggen dat ik ervan heb genoten! Jouw ambitie, doorzettingsvermogen en hoge stress-
grens zijn bewonderenswaardig. Toeval of niet; ik dank God nog steeds voor de dag dat ik 
jou tegenkwam en jij me enthousiast vertelde dat het Erasmus MC op zoek zou zijn naar 
een onderzoeker.  Naar aanleiding van onze toevallige ontmoeting, zijn wij niet veel later 
hechte collega’s geworden. Rachida bedankt voor alles!
Lieve Lamis, naast dat wij al 23 jaar zussen zijn, zijn wij de afgelopen jaren ook een soort 
van collega’s van elkaar geworden. De vele avonden die wij samen op een verlaten po-
likliniek en op kantoor hebben doorgebracht om data te verzamelen, zijn onvergetelijk. 
Ondanks het feit dat je een stuk jonger bent dan ik, moet ik eerlijk zeggen dat mijn leven 
zonder jouw steun en hulp een stuk moeilijker zou zijn. Ik bewonder jouw creativiteit 
en jouw capaciteit om bepaalde gedachten en ideeën op een aantrekkelijke manier te 
verwoorden en tot uiting te brengen. Deze eigenschappen zullen je enorm begunstigen 
in jouw verdere wetenschappelijke carrière. Jij hebt de juiste beslissing genomen om het 
wetenschappelijke pad te belopen en ik ben ervan overtuigd dat het succes altijd aan 
jouw kant zal staan. Jouw mooiste eigenschap is je bereidheid om iedereen om je heen 
een helpende hand te bieden. Bedankt voor de steun.
Mijn lieve studiemaatjes en sindsdien dikke vriendinnetjes: Talin, Karima, Heshu, Shalini 
en Elif wil ik vooral bedanken voor het vertrouwen dat ze in mij hebben. Wij zien elkaar 
weliswaar niet meer zo regelmatig, maar dat neemt niet weg dat wij er altijd voor elkaar 
zullen zijn. Ik wil jullie bedanken voor het bieden van een luisterend oor en voor de 
gezellige tijden die wij samen hebben meegemaakt. Owee als jullie mij niet komen 
bezoeken in Libanon, ik weet jullie te vinden! 
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Naar mijn idee doe ik het niet vaak genoeg: mijn familie bedanken. Graag zou ik van deze 
mogelijkheid gebruik willen maken en mijn waardering voor de belangrijkste mensen in 
mijn leven in woorden proberen uit te drukken. Papa, als jij er niet was geweest dan had 
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Tenslotte wil ik de man bedanken, waarmee ik de rest van mijn leven ga spenderen. Lieve 
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